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AAPH 2,2'-Azobis(2-amidinopropane) dihydrochloride 
ACR Acrolein 
ADH Alcoholdehydrogenase 
AGE Advanced glycoxidation end products 
AGER Advanced glycation end products specific receptor 
AKR Aldo-keto reductase 
ALDH Aldehydedehydrogenase 
ALE Advanced lipoxidation end products 
APCI Atmospheric pressure chemical ionization 
ARP Aldehyde reactive probe 
CEL Carboxy-ethyllysine 
CID Collision-induced dissociation 
CML Carboxy-methyllysine 
CYP Cytochromes P450 
DHN 1,4-dihydroxy-2-nonene 
DHP Di-hydropyridine adduct 
DNPH 2,4-Dinitrophenylhydrazine 
ECD Electron-capture dissociation 
ELISA Enzyme-linked immunosorbent assay 
ESI Electrospray ionization 
ETD Electron-transfer dissociation 
FDP N-(3-formyl-3,4-dehydro-piperidinyl) 
FITCR Fourier-transform ion cyclotron resonance 
GC Gas chromatography 
GO Glyoxal 
GSH Glutathion 
GST Glutathione S-transferase 
HCD Higher-energy collisional dissociation 
HHE 4-hydroxy-2-hexenal 
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HNE 4-hydroxy-(2)-nonenal 
HPLC High-performance liquid chromatography 
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HSA Human serum albumin 
HTPO N−2-(4 hydroxy-tetrahydro-pyrimidyl) ornitine (propane-arginine) 
iTRAQ Isobaric tags for relative and absolute quantitation 
LC Liquid chromatography 
MA Michael adduct 
MALDI Matrix-assisted laser desorption/ionization 
MDA Malondialdehyde 
MG Methylglyoxal 
MP Nε-(3-methylpyridinium) 
MRM Multiple reaction monitoring 
MS Mass spectrometry 
NADP Nicotinamide adenine dinucleotide phosphate 
NADPH Dihydronicotinamide-adenine dinucleotide phosphate 
nePTM Non-enzymatic post-translational modification 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NP N-propenal adduct 
NPO N-2-pyrimidyl-ornithine adduct 
nrf2 Nuclear factor erythroid 2-related factor 2 
PCO Protein carbonyl 
PP 2-pentyl-pyrrole 
PTM Post-translational modification 
PUFA Polyunsaturated fatty acid 
PVDF Polyvinylidene fluoride or polyvinylidene difluoride 
RAGE Receptor for advanced glycation end products 
RCS Reactive carbonyl species 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
SB Schiff’s base 
SILAC Stable Isotope Labeling by/with Amino acids in Cell culture 
SIM Selected ion monitoring 
SRM Selected reaction monitoring 
TMT Tandem Mass Tag 
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 Chapter I: Introduction 
The purpose of the PhD project was to characterize pro-inflammatory advanced glycation 
endproducts and advanced lipoxidation endproducts and their binding mechanisms with the 
receptor for advanced glycation endproducts. 
1.1 Oxidative stress 
Oxidative stress occurs when there is an imbalance between oxidants and anti-oxidants leading 
to the attack of biomolecules by free radicals. They can be either produced endogenously, during 
cellular metabolism, or can come from exogenous sources, such as the ingestion of oxidized 
foodstuffs or inhalation of air pollutants. Free radicals are highly reactive species with one or more 
unpaired electrons, seeking other electrons to form a stable molecule. Under normal 
circumstances free radicals are scavenged by anti-oxidants such as tocopherols and ascorbic 
acid, however, increased levels of free radicals, or decreased levels of defensive mechanisms 
can lead to the attack of different biomolecules like proteins, lipids and DNA. Oxidation of proteins, 
leading to post-translational modifications (PTMs), can have multiple repercussions, such as a 
conformational change, aggregation and crosslinking, or establishing new interactions with other 
biomolecules [1]. Lipid oxidation can produce a wide variety of end products which have been 
described in many different pathologies. End products include long- and short-chain oxidation 
products and a major class of break-down products, predominantly reactive carbonyl species 
(RCS). RCS are highly reactive and metabolized rapidly, either by phase I and II metabolism, or 
by reacting with nucleophilic residues on proteins. Besides proteins and lipids, oxidative damage 
can occur at nuclear level, where guanine is the most susceptible base pair to oxidation and has 
been linked to the progression of carcinogenesis [2]. 
Nucleophilic targets can also be attacked by a group of sugars that is already oxidized, reducing 
sugars with a free aldehyde group acting as a reducing agent. Reducing sugars can also adduct 
proteins at Lysine residues, causing the formation of Advanced Glycation End Products (AGEs). 
Proteins adducted by RCS coming from the lipid peroxidation pathway are called Advanced 
Lipoxidation End Products. Both groups of modified proteins are explained in the following 
paragraphs. 
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Figure 1: Overview of the different oxidation pathways of biomolecules. 
1.2 Advanced Glycation End Products 
Modification of amino side chains on proteins by free radicals are not the only PTMs originating 
from oxidative stress. Another class of compounds are advanced glycoxidation end products 
(AGEs), proteins covalently modified by reducing sugars or their oxidative degradation products. 
It is described by the Maillard reaction, which is a set of reactions starting with the condensation 
between the carbonyl group of a reducing sugar and a primary amino group present on amino 
acid side chains, for example lysine and arginine. Through dehydrations, cyclizations and Amadori 
rearrangements, a large variety of structures are generated, both oxidative degradation of the 
Amadori products and break-down products after fragmentation of ketoses producing α-
dicarbonyls [3]. The first include an adduct with a reducing sugar, specifically glucose or fructose, 
with lysine, and further oxidize into different products such as carboxy derivatives and cross-links. 
The latter involves the production of α-dicarbonyls, like glyoxal and methylglyoxal, that can further 
react with nucleophilic amino acids. 
Glyoxal is the smallest dialdehyde and is produced by sugar autoxidation pathways, lipid 
peroxidation pathways or via the Maillard reaction. Glyoxal can react with Arg, Lys and Cys 
residues to either form carboxy derivatives, imidazolone adducts, or cross-links.  
Another α-dicarbonyl is methylglyoxal, which can be produced via many different pathways from 
mostly sugars or lipids. Heating and prolonged storage of sugars and lipids can lead to the 
fragmentation into methylglyoxal, but also glycolytic processes, acetone metabolism, and 
ROS
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DNA Damage
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Formation of 
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Reducing sugars
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 metabolic pathways of threonine and glycine can lead to the production of methylglyoxal. Similar 
to glyoxal, methylglyoxal can react with Arg, Lys and Cys residues leading to the formation of the 
same set of adducts, carboxy derivatives, imidazolone adducts, or crosslinks, but also a pyrimidine 
adduct on Arg by adding a second methylglyoxal molecule to the imidazolone adduct. 
1.3 Advanced lipoxidation end products 
Advanced lipoxidation end products (ALEs) are macromolecules adducted by reactive carbonyl 
species (RCS), highly reactive molecules containing one or more carbonyl groups, arising from 
lipid peroxidation pathways or lipid metabolism. Three main classes coming from lipoxidation 
break-down and lipid metabolism are short chain RCS, oxidized truncated phospholipids and 
prostaglandin metabolites, however the main focus will be on short chain RCS. Short chain RCS 
can be subdivided in three groups; α,β-unsaturated aldehydes, di-aldehydes and keto-aldehydes, 
each of which can react with a nucleophilic target on proteins to form an ALE. 
Polyunsaturated fatty acids (PUFAs) are the major source of reactive carbonyl species. Free 
radicals, mainly hydroxyl and peroxynitrite, attack the allylic hydrogen in PUFAs, yielding a lipid 
radical, which then react with oxygen to produce a lipid peroxyl radical. This radical will abstract a 
hydrogen from another PUFA, continuing the lipid peroxidation cycle, and form a stable lipid 
peroxide which can generate α,β-unsaturated aldehydes like HNE and acrolein (ACR) and 
dialdehydes such as malondialdehyde (MDA). Glyoxal and methylglyoxal, described before, can 
also be produced upon lipid peroxidation. 
Defense mechanisms are in place to detoxify the production of RCS by a reaction with glutathione 
for example, or by reducing enzymes including alcohol dehydrogenase and aldo/keto reductase. 
The metabolic fate of HNE is described in chapter 3. However, when there is an excess of HNE, 
it can react with proteins, lipids and DNA. HNE is a lipid peroxidation break-down product of ω-6 
fatty acids with three reactive groups, an aldehyde, double bond and a hydroxy group. It is able to 
react with nucleophilic side chains on amino acids such as Lys, His and Cys to form a Michael 
adduct or a Schiff base. Other adducts include unsaturated cyclic forms and cross links due to the 
presence of an aldehyde and an electrophilic carbon. 
Acrolein shows the highest reactivity towards nucleophiles and is not only produced by lipid 
peroxidation, but also by metabolism of amino acids and polyamines and by exogenous sources 
like food.  A Michael adduct on cysteine is the main site of adduction of acrolein, followed by 
Michael adducts on histidine and lysine. Acrolein is also able to form a Schiff base on lysine which 
can react with another acrolein molecule to form a cyclized adduct. Similarly, two acrolein 
molecules can react through a Michael addition with lysine to form another cyclized adduct. 
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 Arginine can also be adducted by acrolein to form a propane adduct. Finally, acrolein adducts can 
react with other nucleophilic residues to form crosslinks. 
The most abundant di-aldehyde is malondialdehyde produced upon lipid peroxidation and mainly 
reacts with lysine to form a propenal adduct. It can further react to produce a crosslink, or a 
cyclized adduct. Furthermore, it can react with arginine to form a pyrimidine adduct. 
1.4 Biological significance of AGEs and ALEs 
AGEs/ALEs are pathogenic factors involved in many different diseases. The formation of 
AGEs/ALEs can have multiple mechanisms to exert its damaging activity. One of the outcomes is 
a conformational change of the protein, as shown by the aggregation of α-synuclein involved in 
Parkinson’s disease, due to the crosslinks formed by HNE [4]. Acrolein have been shown to modify 
the p50 subunit, a member of the NF-κB family of proteins, resulting in a differently regulated pro-
inflammatory response [5]. Whereas MDA has been reported to adduct cytosine residues, 
mediating oxidized low-density lipoprotein-induced coronary toxicity [6]. Examples showing the 
direct effect of protein or DNA adduction by RCS. 
Another pathology with increased levels of AGEs is diabetes mellitus, characterized by 
hyperglycemia. Long-term high levels of glucose increase the formation of AGEs, and many 
proteins have been reported to be modified during diabetes. For example glycation of human 
serum albumin (HSA) has been shown to play an important role during the progression of the 
disease and related pathologies, such as diabetic retinopathy [7]. Fibrinogen may also be glycated 
during diabetes, resulting in impaired fibrinolysis and vascular dysfunction [8, 9]. Collagen is 
another important protein affected by the high sugar levels, once glycated reports have shown 
that it may contribute to skeletal fragility and development of atherosclerotic plaques and fibrosis 
[10-12]. 
Adduction of RCS to proteins can also lead to circulating AGEs/ALEs, which do not show a direct 
effect on the protein, yet are potential modulators of numerous biological functions and have been 
shown to contribute in the pathogenesis of several diseases. Numerous pathologies have been 
shown to have an increased level of protein adducts with HNE, such as in Alzheimer’s disease, 
systemic lupus erythematosus, diabetes and chronic pancreatitis [13-16]. 
Some biological functions are receptor-mediated, as in the case of galectin-3, a glycan binding 
protein suggested to aid in the removal of circulating AGEs and ALEs [17]. Receptors from the 
macrophage scavenger receptor family, like CD36 and LOX-1, have also been reported to bind 
AGEs. These receptors are mainly located on endothelial cells and immune cells, and their main 
function is the uptake and degradation of AGEs [18]. AGEs also bind the Receptor for advanced 
glycation end products (RAGE), activating different signalling pathways further explained in 
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 paragraph 1.6. Whereas AGEs have been shown to have a wide variety of receptors, a specific 
receptor for ALEs has not been elucidated yet, despite sharing the same chemical characteristics. 
1.5 Identification and characterization 
AGEs/ALEs are a heterogeneous group of biomolecules, meaning, many different proteins can 
be adducted by a wide variety of small molecules arising from different oxidative pathways, thus 
many different modifications can be induced on different amino acids [3]. These AGEs/ALEs, and 
their involvement in many different pathologies, can be considered as biomarkers, to predict 
disease outcome. Likewise, diseases can be prevented if AGEs/ALEs are considered as drug 
targets.  
However, the analysis of this group of biomolecules has proven to be quite challenging due to 
several reasons. As previously mentioned, it is a heterogeneous group of biomolecules, and above 
all, modified proteins are contained in very low amount (nanomolar range) in complex matrices 
compared to native proteins, implicating the need for an enrichment strategy. Several enrichment 
strategies are described in chapter 4, as well as the currently available analytical techniques for 
identification, characterization and quantification of AGEs and ALEs. 
1.6 Receptor for advanced glycation end products (RAGE) 
A functional-based strategy for selectively isolating pro-inflammatory modified proteins is an 
emerging approach, and recently a VC1 interaction assay was designed to achieve this goal [19]. 
The idea behind this enrichment procedure is to employ the binder of AGEs, the receptor RAGE, 
as a stationary phase, explained in more detail in our previous paper [19]. Whereas AGEs are 
known binders of RAGE, ALEs have been partially explored as ligands of the receptor. 
RAGE is a type I cell surface receptor that is expressed in several cells, such as endothelial cells, 
smooth muscle cells, but also dendritic cells and T-lymphocytes and is predominantly located in 
the lungs [18]. The full-length isoform of the receptor consists of three extracellular domains, V C1 
and C2, a transmembrane and a intracellular domain. RAGE has been involved in many different 
pathologies with a marked oxidative base, such as diabetes, atherosclerosis, neurodegenerative 
diseases and many different ligands of RAGE have been identified, such as amyloid β peptide, 
S100/calgranulin protein, HMGB1 [20]. Two different pathways can be activated upon binding to 
the receptor; 1) the activation of the NADPH oxidase, resulting in the production of reactive oxygen 
species (ROS), aiding in the formation of AGEs/ALEs and 2) the activation of the NF-κB pathway 
leading to a sustained pro-inflammatory and pro-fibrotic response. One of the genes activated 
upon NF-κB activation is the advanced glycation end products specific receptor (AGER), whose 
expression is therefore supported by a positive feedback loop. 
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 RAGE has multiple isoforms having different ligands and different biological responses, such as 
soluble RAGE (sRAGE) and two truncated isoforms, without the intracellular domain and RAGE 
without the V domain. sRAGE can be produced in two different manners, pre-mRNA alternative 
splicing and cleaved on the membrane surface by metalloproteinases. It has sequestering activity, 
since it can bind the same ligands but it does not induce a biological response and has been 
proven to be useful as a decoy in different pathologies [21-23]. 
1.7 NF-κB pathway 
One of the pathways activated upon RAGE binding is the NF-κB pathway. This is a signaling 
pathway that can be activated upon external stimuli like antigens, cytokines, reactive oxygen 
species etc. NF-κB is a transcription factor regulating expression of cytokines, chemokines, growth 
factors, apoptosis inhibitors and many more involved in cell proliferation and survival, inflammation 
and immune regulation. Firstly, receptors are bound by ligands able to induce the downstream 
pathway. Many different downstream pathways are described already, but they all have in 
common the release of a NF-κB subunit after the phosphorylation and degradation of the family 
of I-kappa-B inhibitors. After the NF-κB subunit is released, it will translocate to the nucleus where 
it will bind response elements (RE), unique for the protein that will be expressed subsequently. 
The NF-κB pathway is therefore the ideal signaling pathway to investigate the pro- or anti-
inflammatory activity induced via RAGE.  
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 Chapter II: Aim of the project 
The identification and characterization of AGEs/ALEs has proven to be crucial in the onset and 
development of many pathologies. Therefore, good analytical strategies need to be 
developed/optimized for better understanding of the exact nature of modification, to understand 
the role they play in disease progression. Identified AGEs/ALEs can serve as biomarker, as well 
as drug targets. The VC1 technique was proven to be a promising technique to accommodate the 
need for enrichment of AGEs for better characterization. The first aim of the project was therefore 
to investigate whether also ALEs are binder of RAGE, since they share the same structural 
properties than AGEs, and also have been shown to activate the NF-κB pathway, implicating a 
role for receptors, like RAGE. Furthermore, the exact molecular mechanism of protein-protein 
engagement with the receptor are not well understood. Using molecular modeling studies, we 
attempted to gain a deeper insight into the binding of ALEs with RAGE. 
Since a successful enrichment strategy was developed, the second aim of this project was focused 
on identifying AGEs/ALEs in biological samples. The first part was focused on oxidizing healthy 
human plasma in-vitro, to elucidate which proteins are prone to undergo oxidative modification 
and to characterize the chemical moiety provoked by oxidative stress. AAPH was used as a radical 
initiator to induce oxidative conditions in plasma as well as the incubation of plasma directly with 
RCS, anticipating the production of AGEs/ALEs. The VC1 pull-down assay was then used to 
identify binders of RAGE, and to enrich AGEs/ALEs for characterization. Simultaneously, other 
variables during sample preparation and analysis were optimized. As explained before, 
AGEs/ALEs are present in very low concentrations in biological samples, hence the need for very 
sensitive methods and instrumentation allowing identification. Since human serum albumin (HSA) 
is the main protein present in plasma, around 50-60%, and has multiple nucleophilic targets, it 
represents the best model for characterizing AGEs/ALEs. For this reason, the focus was on 
extracting HSA from plasma, using the newest generation of tribrid MS for the analysis of 
AGEs/ALEs in plasma samples. Accordingly, plasma from heart failure patients was used as a 
model, since this pathology is correlated with the increase of circulating AGEs/ALEs. In addition, 
AGEs/ALEs could be characterized specifically increased during the disease progression. 
AGEs are ligands for RAGE, meaning, they can bind and activate the receptor, inducing a 
signaling pathway and pro-inflammatory response. ALEs have also been shown to induce a pro-
inflammatory response; however, no specific receptor has been linked to this cellular event. 
Therefore, we have set-up a cellular model to investigate potential RAGE ligands using a cell line 
with and without RAGE with a NF-kB gene reporter. Employing this cellular model, we hoped to 
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 discriminate between RAGE binders and RAGE ligands for determining AGEs/ALEs able to induce 
a pro-inflammatory activity through RAGE. 
Lastly, anti-inflammatory properties of natural compounds were evaluated using the cell line with 
NF-kB gene reporter described previously. This cell line, allowed us to perform a high-throughput 
screening of pure compounds or crude extracts obtained from different natural compounds, 
including apple and bergamot. Besides the anti-inflammatory effect, another assay was utilized 
that could correlate to the activation of the nrf2 pathway, activated under oxidative stress. 
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Abstract 
It has been clearly demonstrated that non-enzymatic protein post-translational modifications 
(nePTMs) induced by chemically reactive compounds occur progressively and are amplified in 
various oxidative-based diseases, making nePTM-derived products not also as interesting 
biomarkers but also as drug target when involved in pathogenetic mechanisms. The analytical 
aspects of nePTMs (identification, characterization and quantification) represents a scientific 
challenge due to the fact that are heterogeneous, contained in a negligible amount in respect to 
native proteins and quite chemically and metabolically unstable.  Several analytical techniques 
have so far been reported to fully profile nePTMs and to this regards, mass spectrometry is one 
of the most promising techniques since it offers many analytical alternatives for the development 
of accurate assays for the detection of the modification itself, for the mapping of the modification 
sites and for the precise quantification of the modified peptide in different biological conditions. 
This chapter is focused on taking an inventory of the most updated analytical methods available 
for the measurement of nePTM – derived products in biological fluids, focusing on colorimetric 
assays, fluorescence measurements, immunological, chromatographic and mass spectrometry 
methods. In the last section a comprehensive description of the quantification using mass 
spectrometry is described. 
Key Words 
Non-Enzymatic Post-Translational Modifications; nePTMs; analytical methods; mass 
spectrometry; MS; Top-down MS Approach; Bottom-Up MS Approach; Quantitative MS;  
4.1 Introduction 
In biological systems proteins undergo a wide array of modifications (post-translational 
modifications – PTMs) that alter their function and their structure. Many post-translational 
modifications (PTMs) of proteins have already been described, and have been found to determine 
protein activity, stability, specificity, transportability and lifespan [1].  
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 It is possible to distinguish two types of protein modification, one initiated / catalyzed in the 
presence of specific enzymes (enzymatic modifications) and the other which occurs in the 
presence of chemically reactive compounds (e.g. reactive oxygen- and nitrogen-species); the 
latter type of modification is known as non-enzymatic (nePTM) and usually occurs stochastically 
[2]. While such modifications are essential for the protein functionality, depending on the ternary 
structure they can be physiologically damaging. Such nePTMs which alter the structural and 
biological properties of proteins in living organisms include oxidation, racemization, isomerization, 
deamidation, nitration, carbonylation, carbamylation and glycation (or glycoxidation) [2, 3].  
These cumulative modifications, which affect all proteins over their lifespan, are generally 
characterized by the binding of small metabolites to free reactive groups of proteins, followed by 
subsequent molecular rearrangements. Diverse reactive species are responsible for the formation 
of a range of oxidative products, while different amino-acid side chains can undergo modification 
contributing to an additional variety of final derivatives. Some of these end-products are unstable, 
present in very low quantities and decompose quickly, in which case the physiological response 
of an organism to nePTM proteins can be to repair and/or to degrade [3]. Other modified proteins 
acquire stability by further structural adjustments, which may end with misfolding, with, for 
instance, an increased chance of self-aggregation into insoluble fibrillar structures, which 
accumulate in cells and tissues [3]. One of the most prevalent covalent modifications is protein 
glycation, usually followed by a sequence of further reactions and rearrangements producing the 
so-called advanced glycosylation end products (AGEs). Glycated proteins are more prone to form 
cross-links with other proteins, leading to structural and functional alterations [3].  
By virtue of scientific progress, it has been more clearly demonstrated in recent years, that non-
enzymatic post-translational modifications (nePTMs) occur progressively and are amplified in 
various diseases such as diabetes mellitus, chronic renal failure or atherosclerosis (Table 1.) [4]. 
Accordingly, nePTM –derived products are considered promising and useful biomarkers for these 
diseases. 
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 Table 1. Involvement of nePTMs of proteins in aging and disease [1]. 
Another important aspect requires an understanding of the biochemistry and metabolism of 
modified proteins. The nature, site and extent of nePTM give rise to a population of that specific 
protein with alterations in structure and function ranging from being fully active to totally inactive 
molecules. Since there is an extremely low probability that any two molecules will be 
modified/damaged in exactly the same way and to the same extent, an increase in molecular 
heterogeneity is inevitable [5]. Therefore, accurate identification, detection and quantification of 
nePTM has gained increased attention in the last two decades since they are essential for 
establishing connection between specific protein structure and specific biological role [3].  
Analysis of nePTM covers two distinct features: (i) determination of the modification itself (i.e. 
chemical group or small entity), such as the number of carbonyl groups, disulfide bonds, etc. and 
their specific location in the protein sequence and (ii) determination of the quantity of the 
specifically-modified protein, such as AGE-albumin or hemoglobin, in relation to the non-modified 
form and/or between two distinct conditions, e.g. healthy and diseased [3].  
Disease Reaction Involved 
Aging Oxidation  
Glycation / Glycoxidation 
Carbonylation 
Amino Acid Modifications 
Atherosclerosis Glycation / Glycoxidation 
Carbonylation 
Carbamylation 
Oxidation / Nitration 
Chronic renal failure Carbamylation 
Glycation / Glycoxidation 
Carbonylation 
Oxidation  
Diabetes Mellitus Glycation / Glycoxidation 
Carbonylation 
Neurodegenerative Diseases  Glycation / Glycoxidation 
Carbonylation 
Oxidation / Nitration 
Osteoporosis Glycation / Glycoxidation 
Retinopathy Glycation / Glycoxidation 
Carbonylation 
Carbamylation 
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 However, the complexity of proteins makes analysis, detection and quantification of non-
enzymatic post-translational modification a very difficult challenge.  
This chapter is focused on taking an inventory of the analytical methods available for the 
measurement of nePTM – derived products. 
4.2 Analytical methods for qualitative identification of nePTMs  
The connection of the molecular aging of protein with the development of long term complication 
of several diseases has been well established, making nePTM-derived products interesting 
biomarkers. Unfortunately, thus far they are not currently used in routine clinical laboratory 
practice, except for glycated hemoglobin.   
In this context three major problems have been encountered: 
- The huge variability of the structure of these compounds: from a chemical point of view 
nePTM–derived products are quite heterogeneous and some of them are probably still 
unknown; 
- The chemical and metabolic instability of nePTM–derived products:  
- The lack of specific and highly sensitive methods suited to the low basal rate of most of 
the nePTMs involved in the molecular damaging of proteins [4]. nePTM–derived products 
are usually contained in a negligible amount (nanomolar range concentration, or less) in 
respect to the native protein. 
The methods used for the detection of nePTMs should be characterized by high specificity and 
sensitivity, but also robustness and reproducibility [4]. In fact the methods used range from simple 
techniques such as the colorimetric or immunoassay methods, easily implementable in every 
research or clinical laboratory but which are generally poorly specific, to more specific methods, 
such as mass spectrometry, which however requires specific sophisticated instrumentations and 
specific skills [4].  
The recent implementation in clinical chemistry laboratories of mass spectrometry–based 
methods that provide higher specificity and sensitivity has facilitated the measurement of nePTM 
–derived products [4]. Mass spectrometry (MS) is certainly one of the most promising techniques 
since it offers many advantages and analytical alternatives for the development of fast and 
accurate assays to study modified proteins [6]. 
In detail, mass spectrometry can identify and separately quantitate multiple analytes (including 
macromolecules – i.e. proteins) in one single scan. Identification is performed by the analyzer, 
which allows the determination of the molecular weight through the measurement of the mass to 
charge ratio of a molecule’s gas phase ions. The ions are then separately counted by the detector, 
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 which produces a signal that is proportional to their concentration therefore allowing quantitation 
[6].  
The evolution of instrument technology has led to the development of commercial analyzers able 
to detect analytes at trace levels (sensitivity), reducing, therefore, the sample amount required for 
the analysis [6]. Instrument selectivity (the ability to distinguish molecules with similar molecular 
weight) has also been improved over the years. In this field one of the most important discoveries 
has been the so-called high-resolution mass analyzers (HR-MS), which are capable of separating 
molecules with very similar molecular weight but different elemental composition. This innovation 
is accompanied by a continuous updating of the analyzers capable of multistage mass 
spectrometry experiments (i.e. tandem mass spectrometry). This technology is still the basis for 
the development of many MS-based methods since it enables the collection of tandem mass 
spectra, which can be considered as molecule fingerprints usually allowing their unambiguous 
identification [6].  
Importantly, MS does not require the analytes to be labelled before detection, although there is a 
panel of labelling procedures uniquely designed for mass spectrometry with the scope of 
expanding the use of this technique. 
Thus, MS appears to be the ultimate tool that should be used for the detection and the accurate 
mapping of modification sites in the primary structure of a protein. It can also be used to quantify 
the abundance of the peptide carrying the modified residue compared to that of the unmodified 
peptide or such abundance in different biological conditions [3]. 
The unique feature of MS is that it can be used to analyze any protein modification without a priori 
assumptions about the type of modification (untargeted approach). nePTM can be analyzed by 
MS in “top-down” experiments that analyze intact proteins, or in “bottom up” experiments that 
rely on sample proteolysis prior to mass spectrometric detection. The top down experiments 
provide more information about individual proteins, including full characterization of each present 
protein form and its modifications (Figure 1). 
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Figure 1. Schematic of bottom-up vs. top-down approaches in proteomics. 
Using the mass difference between the genome deduced protein sequence and peptide masses 
observed experimentally it is possible to identify any protein modification [7]. For example, 
oxidation of a Met residue (131 Da) increases its mass to 147 Da by the addition of a single oxygen 
atom (16 Da). Through observation of the discrete mass difference of the intact protein (top-down 
approach) it is possible to assign the respective modification. However, top-down proteomics is a 
relatively immature field compared to bottom-up proteomics, and still suffers from serious 
limitations [3]. Mass spectrometry based sequencing allows for site-specific assignment of 
modifications at the resolution of individual amino-acids (bottom-up approach) [3, 7]. 
4.2.1 MS top down  
Given the importance of PTMs in the regulation of intracellular signalling and the link between the 
aberrant or altered PTM of a number of proteins and certain human diseases, the top-down MS 
approach holds significant promise for the elucidation of nePTM-associated disease mechanisms 
by providing a powerful method for the identification, characterization, and quantification of 
nePTM, which can subsequently be correlated with disease etiology [8]. This top-down technology 
is beginning to capture the interest of biologists and mass spectrometrists, whose main goal is the 
elucidation of the interaction networks operative in cellular pathways [9].  
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 Top-down mass spectrometry is a technology which strives to preserve the post-translationally 
modified forms of proteins present in vivo by measuring them intact, rather than measuring 
peptides produced from them by proteolysis. Intact protein analysis results in reduced sample 
complexity (in terms of the number of individual species present in the sample) in comparison to 
the protein digests analyzed using the bottom-up approach [8]. 
Intact protein ions are introduced into the gas phase by ESI and all intact protein forms in a sample 
are analysed by MS. In this way a specific protein form of interest can be directly isolated and, 
subsequently, fragmented in the mass spectrometer by MS/MS strategies to map both amino acid 
variations (arising from alternative splicing events and poly-morphisms/mutations) and PTMs. If a 
sufficient number of informative fragment ions are observed, this analysis can provide a complete 
description of the primary sequence of the protein and reveal all of its modifications, as well as 
any correlations that exist between these modifications. Although the molecular masses of intact 
proteins have been successfully measured by MALDI– and ESI–mass spectrometry for some time 
[10], it has proved difficult to produce extensive gas-phase fragmentation of intact protein ions, 
especially from large proteins. 
The establishment of electron-based MS/MS techniques, namely, electron capture dissociation 
(ECD) and electron transfer dissociation (ETD), represents a significant advance for top-down MS 
by providing reliable methods for the localization and characterization of labile PTMs, such as 
phosphorylation and glycosylation [8]. Top-down MS with ECD/ETD has unique advantages for 
the dissection of molecular complexity via the quantification of protein forms, unambiguous 
localization of PTMs and polymorphisms/mutations, discovery of unexpected PTMs and sequence 
variations, identification and quantification of positional isomers, and the interrogation of PTM 
interdependence [8]. Recently, a number of top-down proteomics studies have linked protein form 
alterations to disease phenotypes, highlighting the potential for top-down proteomics in the 
elucidation of nePTM-associated disease mechanisms [8]. However, the top-down approach is 
still facing challenges associated with protein solubility, separation, and the detection of large 
intact proteins, as well as the complexity of the human proteome. Due to the high dynamic range 
of protein expression and extreme complexity of the proteome, its fractionation/separation is a 
critical step prior to MS analysis. While bottom-up proteomics boasts mature and reliable 
separation methods, which include gel- and LC-based separation methodologies, effective 
separation strategies that are high-throughput, rapid, and compatible with top-down MS analysis 
are still scarce [8]. Moreover, top-down analysis of proteins larger than approximately 70 kDa 
remains challenging due to the difficulty associated with detecting and fragmenting these 
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 molecular behemoths. Thus, new technological developments are urgently needed to advance 
the field of top-down proteomics [8]. 
4.2.2 MS Bottom UP 
In contrast to the top-down approach, the bottom-up approach is significantly more sensitive and, 
in fact, has been successful in identifying proteins and determining details of their sequence and 
PTMs [11].  
The bottom-up approach involves proteolysis of proteins into short peptides (8–30 amino acids) 
prior to LC-MS/MS analysis. Protein digestion into short peptides facilitates both LC separation 
and high-resolution MS detection. Different proteolytic enzymes can be used, but trypsin is the 
protease of choice for its efficiency and specificity of cleavage. The resulting “tryptic peptides” are 
then analyzed by electrospray ionization (ESI) or matrix-assisted laser desorption/ionization 
(MALDI). These mass spectrometry techniques allow peptide and protein molecular ions to be put 
into the gas phase without fragmentation [10]. The ESI– or MALDI–mass spectrometry analyses 
take place in two stages. First, the masses of the intact tryptic peptides are determined; these 
peptide ions are then fragmented in the gas phase to reveal their sequence and modifications. 
The bottom-up approach is especially useful in protein identification, since tryptic peptides are 
readily solubilized and separated, tasks that are considerably more difficult for the parent proteins. 
In addition, many tryptic peptides can be readily analyzed by mass spectrometry analysis, 
providing useful fragmentation ladders [10] that often yield sufficient information to identify the 
parent protein. Due to the availability of human and other species genomic databases, irrespective 
of the MS platform used, raw MS data can be compared to protein databases using searching 
tools such as MASCOT and SEQUEST [12]. 
Unfortunately, only a small amount of the tryptic peptides are normally detected, and only a 
fraction of these yield useful fragmentation ladders. It is similar to a jigsaw puzzle, where many of 
the pieces are missing. But even if we had all the pieces, the picture would still be incomplete, 
because to produce a sufficient number of tryptic peptide ions to allow for their detection by mass 
spectrometry it is currently necessary to examine the pieces of a billion or more copies of the 
protein of interest. So really we have a billion puzzles, some of which are the same, but many of 
which are slightly different, because they correspond to copies of the protein containing different 
modifications. Additionally, mass spectrometry relies on ionization of the peptides that are 
measured. In positive-ion operating mode, ionization of peptides largely depends on the presence 
of basic sites like N-terminal amine and the side groups of Lys, Arg and His residues. Generation 
of some modifications, e.g. carbonyl products of Arg and Lys (to give glutamic and 2-amino-adipic 
semialdehydes) is associated with the loss of the guanidine and ammonia groups, typically 
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 carrying a positive charge. This leads to decreased ionization efficiency and reduces the chance 
of detecting those peptides using positive-ion mode MS, making analysis of oxidized proteins 
exceptionally challenging [3].  
The complexity of investigating PTMs within protein proteolytic peptides is due to: (i) the frequent 
existence of isobaric peptides, (ii) the uncertain positioning of PTMs on neighbouring modifiable 
residues and (iii) the difficulty of distinguishing between several isobaric PTM combinations [13]. 
Finally, the above aspects not only complicate identification of the correct sequence and of the 
PTM sites, they also make it very difficult to quantify the relative abundance of positional isomers 
that often co-elute, at least partially. 
Comprehensive interpretation of MS data obtained from nePTM focused experiments is an 
additional analytical challenge. The complexity of the data and the limitations of the existing tools 
for bioinformatics very often lead to misinterpretation of the results. For example, modification of 
Lys and Arg residues frequently makes them inaccessible for trypsin proteolysis leading to a large 
number of missed cleavages. The resulting peptides require large numbers of missed cleavages 
to be included in data analysis algorithms increasing the chance of false positive identifications. 
Another difficulty stems from the many different modifications that need to be included. Searching 
algorithms (e.g. MASCOT, SEQUEST) often cannot search with an unlimited number of 
modifications, necessitating several searches of the same data. This increases data processing 
time and the risk of false positive identifications. New types of modification can only be found if 
manual data analysis is carried out, but this approach is labour intensive, time consuming and 
cannot be used effectively with complex protein mixtures. Identification of oxidized peptides with 
a search algorithm poses several other technical problems [3]. In spite of the difficulties in 
identifying nePTM sites, the combination of labelling and enrichment methods could lead to the 
identification of several hundred modification sites in specific proteins [3]. 
4.2.3 Chemical derivatization and enrichment methods  
Although modern mass spectrometry instruments are characterized by an exceptional sensitivity 
that permits the detection of peptides at sub-femtomole levels, the investigation of protein nePTM 
is still an analytical challenge [14]. This is mainly because, as stated above, modified proteins 
occur in negligible amounts with respect to the native protein. Therefore, modification of a given 
site is often present in only a small fraction of the protein molecules of a given type [3].  
The technical challenges related to the identification of nePTM proteins led scientists to develop 
specific strategies that allow the analysis to be focused on a particular type of protein modification. 
In particular, due to their low abundance, modified proteins need to be selectively isolated from 
native proteins; a possible strategy to reverse this dynamic range in favour of the protein adducts 
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 is the specific enrichment and/or chemical derivatization methods that target a certain class of 
modifications (Figure 2.). This creates a “handle” by which modified peptides/proteins can be 
pulled out from the complex mixture, which of course includes the non-modified peptides/proteins 
[3]. 
 
Figure 2. Enrichment strategy to reverse this dynamic range in favour of the protein adducts. 
Different analytical strategies have been developed for the enrichment of specific nePMTs, and 
they can be grouped into two major approaches: gel-based and non-gel-based methods. In the 
gel-based methods, modified proteins extracted from biological tissues are separated using 
one/two-dimensional gel electrophoresis separation, whereby proteins migrate into a 
polyacrylamide gel according to their relative mobilities. Separated proteins can be transferred 
onto a Western blot membrane and specific antibodies used to visualize target spots. Antibodies 
are selected based on the type of the modification (nePTM) to be studied (e.g., protein carbonyls, 
4-HNE, 3-NT, and glutathionylation). 
Spots of interest are excised from the gel and modified proteins identified using a bottom-up MS 
approach [15-18]. Gel-based methods are advantageous because they target a specific subset of 
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 the proteome and numerous gels can be run and aligned, using sophisticated software tools. 
Alternative approaches, which do not involve gels but rather liquid chromatography separations, 
and MS and tandem MS (MS/MS), have also been applied in this context. Non-gel proteomic 
methods include derivatization and/or enrichment procedures of modified proteins, in-solution 
proteolytic digestion, followed by the nanoflow LC separation of peptides and automated MS and 
MS/MS data acquisition [19]. 
4.3 Overview of the analytical methods for the measurements of specific nePTM 
In the following section we report an overview of the analytical methods for the measurements of 
specific nePTM in biological fluids, focusing in particular on colorimetric assays, fluorescence 
measurements, immunological, chromatographic and mass spectrometry methods. In the last  
section a comprehensive description of the quantification using mass spectrometry will be 
described. 
4.3.1 Carbonylation 
Carbonylation is one of the most commonly occurring oxidative nePTMs and its measurement is 
considered a good indicator of the extent of oxidative damage of proteins associated with various 
conditions of oxidative stress, aging, and physiological disorders [20]. Thus, the number of 
carbonyl groups observed within a protein usually correlates with protein damage caused by 
oxidative stress.  
Protein carbonyl groups are generated by direct oxidation of several amino acid side chains (i.e., 
Lys, Arg, Pro, Thr, His, and others), backbone fragmentation, hydrogen atom abstraction from 
alpha carbons and Michael addition reactions of His, Lys, and Cys residues with products of lipid 
peroxidation causing inactivation, crosslinking, or breakdown of proteins. The most abundant 
carbonyls in aged cells are 2-amino-adipic semialdehyde (AAS) and gamma-glutamyl 
semialdehyde (GGS). Protein carbonyls are also produced by glycation/ glycoxidation of Lys 
amino groups, forming AGEs [20, 21], and Michael adducts of a,b-unsaturated aldehydes 
produced by lipid peroxidation (Figure 3.) [22]. 
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Figure 3. Primary and secondary protein carbonyls generated by direct oxidation of amino acid side 
chains (i.e., Lys, Arg, Pro, Thr, His, and others) – Panel A; hydrogen atom abstraction from alpha 
carbons causing crosslinking or breakdown of proteins – Panel B; and Michael addition reactions 
of His, Lys, and Cys residues with products of lipid peroxidation – Panel C. 
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 For the derivatization of carbonyls the Oxyblot gel-based technique was developed. In this 
procedure, carbonyls react with 2,4-dinitrophenylhydrazine (DNPH) to form 2,4-
dinitrophenylhydrazone (DNP-hydrazone) characterized by an absorbance at 370 nm (Figure 4. – 
panel A). After treatment, protein samples can be resolved by gel electrophoresis (mono- or two-
dimensional), transferred onto a nitrocellulose or PVDF membrane (Western Blot) (Figure 4. – 
panel A), and recognized by specific antibodies against DNP [2]. As stated above, spots of interest 
are excised from the gel and modified proteins identified using a bottom-up approach. This 
strategy permits the detection of protein carbolnyls (PCO) on low abundant proteins. Despite the 
extensive usage of DNPH for derivatizing PCO it should be noted that DNPH is not exclusive to 
carbonyl groups, since it could also react with sulfenic acids—oxidized thiol groups—under acidic 
catalysis conditions [23]. Biotin-hydrazide may be used to selectively label carbonyl groups with 
fluorescein or peroxidase linked avidin [24, 25]. 
 
Figure 4. Summary of the selected protein-carbonylation detection methods. Depending on the 
sample type, experimental aims and instrumentation available analysis of protein-carbonylation 
may be carried out via DNPH labelling (Spectrophotometric, ELISA, Western blot, APCI-MS) – Panel 
A; or by using Affinity chromatography to enrich the protein-carbonyl adducts, subsequently 
analyzed by MS – Panel B. Depending on the depth of the analysis, the techniques might be used 
individually or in combination. 
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 With the DNPH derivatization of PCO groups, the number of modification sites identified is limited 
when using ESI-MS. This could be attributed to the low ESI efficiency of DNPH-derivatized peptide 
ionization in positive mode. The two nitro groups present on the benzene ring of DNPH have a 
strong electron withdrawing effect which may diminish the stability of the protonated peptide. 
Detection of the nanomolar range of aldehyde-DNPH derivatives can be achieved in negative 
mode by using the atmospheric pressure chemical ionization source (APCI) (Figure 4. – panel A) 
[26]. More favourable ionization behaviours of DNPH-labelled carbonylated peptides arise in 
negative ion mode ESI which has the advantage that the DNPH moiety is useful for the easy 
identification of the PCO site [27]. 
Non-gel proteomics approaches have been widely applied in the study of protein carbonylation; a 
key step in these approaches is the incorporation of enrichment procedures for PCO which is 
necessary since the average abundance of carbonylated proteins has been reported as ~0.2% in 
human plasma. Through the elimination of the majority of unmodified proteins the chemical 
interference in the LC and MS dimensions can be minimized increasing the identification of PCO 
modified proteins. One of the most common methods uses avidin-affinity chromatography to 
enrich biotin-hydrazide derivatized carbonylated peptides and proteins (Figure 4. – panel B). 
Derivatization with biotin hydrazide also results in the formation of a Schiff base which can be 
reduced to a more stable C-N bond. Mirzaei and co-workers have successfully applied 
biotin/avidin affinity chromatography proteomics to study PCOs in in vitro metal-catalyzed 
oxidation models: yeast, rat and human plasma tissues, and diabetic rats [28-30]. A similar tag 
uses a biotin-based hydrazide instead of DNPH, the N-(Aminooxyacetyl)-N'-biotinylhydrazine, 
also called Aldehyde reactive probe (ARP) [31-33]. The biotin-derivatized protein can be 
visualized by standard detection methods such as Western blot using horseradish peroxidase-
conjugated streptavidin (HRP-streptavidin) or enriched using streptavidin or avidin-affinity 
chromatography. This ARP however undergoes substantial fragmentation in MS/MS experiments, 
decreasing peptide confidence after database searching due to the complexity of the spectra. The 
development of an algorithm which incorporates ARP fragment ions and neutral loss into the 
database searching has enhanced PCO identification with ARPs. 
In addition to biotin/avidin-based approaches, other enrichment reagents such as Girard’s P and 
Oxidation-specific Element-Coded Affinity Tags for PCO have been reported in literature [30]. 
Some reagents are able to directly increase the ionization efficiency of PCO prior to MS analysis. 
An example is the dansylhydrazide which enhances efficiency of ionization due to its secondary 
nitrogens. Dansylhydrazide generates reproducible fragmentation patterns which allow MS3 scans 
to be employed for localization of PCO sites in proteins [34]. 
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 4.3.2 Glycation (Early and Advanced Glycation end Products) 
Glycation is a spontaneous nePTM of proteins that involves the non-enzymatic covalent 
attachment of a reducing sugar or sugar derivative to a protein. Glycation adducts are classified 
into two groups: early-stage glycation adducts and advanced glycation end products (AGEs) [35]. 
Carbonyl groups of sugars react with the free amino groups of amino acids (mostly occuring at 
lysine residue side chains) to form a Schiff base that rapidly undergoes molecular rearrangement 
to form a stable ketoamine called an Amadori product (Figure 5.). The Amadori products, like 
fructosamines, are typical early-stage glycation adducts [4, 35]. 
 
Figure 5. Early-stage glycation adducts and advanced glycation end products (AGEs) mainly derived 
from the glycation pathway. Carbonyl groups of sugars react with the free amino groups of amino 
acids (mostly occuring at lysine residue side chains) to form a Schiff base that rapidly undergoes 
molecular rearrangement to form a stable ketoamine called an Amadori product. 
For the measurement of fructosamines in serum samples, a colorimetric technique has been 
reported. It exploits the ability of ketoamines, such as fructosamines, to reduce, under alkaline 
conditions, the nitro-blue tetrazolium chloride (NBT) salt. The colour developed is assayed at 
absorbance of 520 nm and is directly proportional to the serum fructosamine concentration [36, 
37]. Another technique consisting of the HPLC measurement of furosine, which results from the 
degradation of fructosamines during the acid hydrolysis of proteins, can also provide valuable 
information [2, 4]. 
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 The identification of the first glycated form of Hemoglobin (Hb) dates to the late 1950s and to this 
day glycated hemoglobin evaluation is used in routine practice in monitoring diabetic patients and 
provides a retrospective indication of the quality of glycemic level [4, 35, 38, 39]. Hb A1c is the 
most abundant glycated species of hemoglobin in human blood and corresponds to the binding of 
glucose on the N-terminal valine residue of the hemoglobin β chain. Hb A1c may be specifically 
evaluated by ion exchange chromatography (minicolumns, low-pressure liquid chromatography, 
HPLC) or by immunological assays [4, 39]. Electrophoretic and isoelectrofocusing methods have 
been described, but have not provided enough sensitivity or resolution for clinical purposes [40]. 
Other methods have been proposed to evaluate total glycated hemoglobin, by affinity-based 
chromatography on boronic acid, using minicolumns or HPLC [41]. In the absence of any 
internationally agreed reference method for the quantification of glucose adducts on hemoglobin 
chains, in 2002 the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) 
Working Group reported a reference method for Hb A1c measurement [42]. Using this method, 
Hb is cleaved into peptides by enzymatic digestion with endoproteinase Glu-C. Then the obtained 
glycated and non-glycated N-terminal hexapeptides of the β chain are separated and quantified 
by HPLC coupled to ESI mass spectrometry. Alternatively a two-dimensional approach consisting 
of HPLC and capillary electrophoresis with UV-detection could be used. Hb A1c is measured as 
the ratio between the glycated and non-glycated hexapeptides [4, 42].  
In later stage reactions of glycation, Schiff base and fructosamine adducts are further processed 
by an irreversible set of reactions including dehydratation, cyclization, fragmentation and oxidation 
to generate many stable end-stage adducts named AGEs [4, 35, 36]. The terminology used to 
classify end products is sometimes unsuitable, since the reactions that involve glycation, oxidation 
and carbonylation are often intertwined [4]. 
It is known that some AGEs are fluorescent compounds, therefore total AGEs can be determined 
measuring AGE-fluorescence. Three different ranges of AGE-fluorescence were established 
(excitation/emission: 330/395, 365/440, 485/530 nm) [37, 43]. However, not all AGEs are 
fluorescent molecules, for example carboxy-methyl lysine (CML), a member of the group, does 
not fluoresce [43]. Moreover the sensitivity is low and it is not possible to detect specific 
modifications. Nevertheless, a device called AGE Reader was recently developed by DiagnOptics 
B.V. (Groningen, The Netherlands). The AGE Reader uses ultra-violet light to excite auto 
fluorescence of AGEs in human skin tissue. This method for the quantitation of AGEs actually 
finds an increasing propagation in the diagnosis and assessment of complications in diseases 
since it is fast and non-invasive [43].  
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 Common analytical methods for the quantitative determination of AGEs are based on ELISA or 
Western blot, however the existence of commercially available antibodies is limited for example 
to total AGEs or to specific adducts such as CML or carboxy ethyl lysine (CEL) [36, 43]. Detected 
protein adducts using the canonical immuno-techniques could be easily identified by the above 
described MS protein sequencing (bottom-up) approach. Proteomics studies provide a powerful 
approach to the identification of proteins susceptible to glycation in complex protein mixtures and 
also the identification of the lysine and arginine residues within proteins particularly susceptible to 
glycation.  
With a view to the enrichment of AGEs, all the hitherto mentioned techniques have some 
limitations. In fact, even though the keto/aldehydic groups are characteristic of some AGEs, not 
all AGEs contain free carbonyl groups. Thus, the derivatization/enrichment strategy allows the 
identification of only a small fraction of AGEs. Moreover carbonyl groups are characterized by 
instability since they could readily undergo Schiff base formation with proximate lysine residues, 
even when stored at -80°C [18]. 
Based on such premises, recently a novel function based enrichment strategy that enables the 
capture of the modified proteins on the basis of their biological interactions rather than their 
structure has been developed. For the development of this strategy use has been made of the 
interaction of AGEs with the receptor for advanced glycation end products (RAGE). In addition to 
the damaging effects that AGEs induce, they also activate RAGE resulting in the induction of pro-
inflammatory and pro-fibrotic responses. RAGE is a transmembrane glycoprotein and its 
extracellular portion contains one V-type (V) and two consecutive C-type Ig-like domains (C1-C2). 
The V and C1 domains are involved in ligand binding and form a single integrated unit connected 
to the C2 domain through a flexible linker. RAGE has a short cytoplasmic tail that is devoid of any 
enzymatic activity but is essential for the intracellular signal transduction activated by the binding 
with the ligands. The enrichment strategy we set up is based on RAGE affinity chromatography. 
A recombinant form of the RAGE domain involved in ligand binding (VC1) was expressed and 
purified from the yeast Pichia pastoris, a suitable host for the production of soluble and stable 
forms of human RAGE (Figure 6. – panel A) [59]. The recombinant protein was designed with a 
C-terminal tandem tag: one tag to facilitate the purification procedure, the other for the 
immobilization of the recombinant protein on an insoluble matrix. The method (pull-down) 
consisted of (i) attaching the VC1 domain to magnetic beads exploiting the C-terminal tag (Figure 
6. – panel B), (ii) isolating proteins that are retained by their specific binding to VC1 (Figure 6. – 
panel C), (iii) protease digestion of the retained polypeptides, (iv) analysis by LC-MS/MS in order 
to identify the protein and the type and site of AGEs modification (Figure 6. – panel D). The method 
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 was firstly validated by using RCS modified human serum albumin (HSA). The adducts isolated 
by pull-down experiments were fully elucidated by LC-ESI-MS. Selectivity was tested by spiking 
AGEs-HSA in sera. Moreover, this method also led to the isolation of Advanced Lipoxidation end 
Products (ALEs) [60]. 
 
Figure 6. Schematic representation of the pull-down assay strategy. 
4.3.3 Deamidation, isomerization or racemization  
Proteins and peptides are susceptible, both in vivo and in vitro (e.g. during storage of proteins), to 
a variety of chemical modifications that can affect their structure and biological functions, and one 
of the most frequent modifications is the deamidation of asparagine residues , a spontaneous non-
enzymatic reaction [44]. Usually this reaction is associated with protein degradation [45-48], but 
recently deamidation has been linked to triggering apoptosis in cancer cells [49-51] as well as 
other regulatory functions [52-55]. 
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 The rates of deamidation depend on pH, temperature and protein structure. Therefore, it is difficult 
to distinguish natural protein deamidation from artefactual deamidation occurring during sample 
preparation [4, 56, 57]. Under physiological conditions, deamidation proceeds through formation 
of a five-membered succinimide ring intermediate by the condensation of the side-chain amide 
group of asparagine with the carbonyl group of the following amino acid. A similar nucleophilic 
attack on the Asp side chain leads to the dehydration of the aspartic acid (Figure 7.). 
 
Figure 7. Deamidation proceeds through the formation of a five-membered succinimide ring 
intermediate by the condensation of the side-chain amide group of asparagine with the carbonyl 
group of the following amino acid. The L-succinimidyl intermediate then undergoes a relatively rapid 
hydrolysis at either the α- or β-carbonyl group to generate L-isoaspartate (L-iso-Asp) and normal L-
aspartate (L-Asp). The free α-carbonyl group of L-iso-Asp can be methylated by the enzyme L-
isoaspartyl O-methyltransferase (PIMT) with S-adenosylmethionine (SAM) as the methyl donor 
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 which is transformed to S-adenosylhomocysteine (SAH). Enzymatic methylation is usually followed 
by spontaneous ester hydrolysis leads to reformation of the L-succinimide intermediate. The 
formation of L-succinimide can also be accompanied by enhanced racemization at the α-carbon to 
generate a mixture of D-succinimidyl, D-aspartyl, and D-isoaspartyl compounds. 
The L-succinimidyl intermediate then undergoes a relatively rapid hydrolysis at either the α- or β-
carbonyl group to generate L-isoaspartate (L-iso-Asp) and normal L-aspartate (L-Asp) in a ratio of 
approximately 3 : 1 [44, 58]. The formation of L-succinimide can also be accompanied by 
enhanced racemization at the α-carbon to generate a mixture of D-succinimidyl, D-aspartyl, and 
D-isoaspartyl compounds (Figure 7.). The final products of asparagine deamidation are a mixture 
of these acidic isomers of aspartic acid and isoaspartic acid, with the same mass shift. 
Among the products of non-enzymatic reaction, L-iso-Asp is typically the predominant form, and 
leads to a significant change in the backbone structure of the protein, which is often accompanied 
by a loss of biological activity [59].  
The free α-carbonyl group of L-iso-Asp can be methylated by the enzyme L-isoaspartyl O-
methyltransferase (PIMT) with S-adenosylmethionine (SAM) as the methyl donor which is 
transformed to S-adenosylhomocysteine (SAH). Enzymatic methylation followed by spontaneous 
ester hydrolysis leads to reformation of the L-succinimide intermediate, which is again hydrolyzed 
to a mixture of L-Asp and L-iso-Asp. The overall result of this “repair” process is that a certain 
percentage (15%–25%) of the original L-iso-Asp population is converted back to L-Asp. D-Asp 
residues undergo similar enzymatic repair. 
Just as asparagine deamidates under acidic conditions so too does glutamine, proceeding via a 
glutarimide intermediate at neutral or alkaline conditions. The deamidation rate of glutamine is 
slower in comparison with asparagine. The final products of glutamine deamidation are α- and γ-
glutamic acid.  
In general, deamidation introduces an additional negative charge to the protein and can be 
detected by charge-sensitive separation methods such as isoelettrofocusing, 2D electrophoresis 
or ion-exchange chromatography, possibly in combination with mass spectrometry [59-61].  
The use of specific antibodies against iso-Asp and D-Asp have only recently been reported [62-
65] and have not as yet been commercialized. Global analysis of iso-Asp residue content in the 
protein sample is usually performed by the ISOQUANT detection kit (Promega, Madison, WI) as 
follows. The enzyme Protein Isoaspartyl Methyltransferase (PIMT) is used to specifically detect 
the presence of isoaspartic acid residues in a target protein. PIMT catalyzes the transfer of a 
methyl group from S-adenosyl-L-methionine (SAM) to isoaspartic acid at the a-carboxyl position, 
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 generating S-adenosyl homocysteine (SAH) which can be detected by reversed phase HPLC and 
its quantity estimated by comparing the chromatographic peak area with a standard curve [66-68]. 
ISOQUANT and similar global approaches require at least picomolar quantities of the target, 
cannot identify proteins where this process occurs and do not reveal the protein site of the 
deamidation/isomerization. Therefore, there is a growing interest in the use of mass 
spectrometry, which is a much more sensitive technique (femtomoles to attomoles) that produces 
site- and molecule-specific information. 
The general procedure starts from the separation on a SDS-PAGE or 2D gel of the crude protein; 
the band or spot density in the stained gel serves as a semi-quantitative measure of the relative 
abundances of different isoforms. Electrophoresis-separated isoforms are then subjected to 
enzymatic digestion, typically with trypsin. The tryptic mixture is either directly analyzed with 
MALDI TOF mass spectrometry, or additionally separated by reverse-phase HPLC and ionized by 
on-line electrospray ionization (ESI).  
Mass spectrometric identification of deamidated peptides is relatively straightforward, as 
deamidation adds to the mass of intact molecule +0.984 Da (the mass difference between –OH 
and –NH2 groups).  
Deamidation at the identified sites was found to be slow for the intact, folded protein, and 
accelerated for partially unfolded molecules at degradation conditions. Deamidation was also 
enhanced after reduction, alkylation, and tryptic digestion, i.e. the typical sample preparation 
procedures used in proteomics, which raises the risk of overestimating the quantification of  
deamidation at proteome level. Recently the use of a short, modified digestion protocol that does 
not induce measureable deamidation in vivo has been suggested [69]. Alternatively, in vitro and 
in vivo occurring deamidation processes can be distinguished by using H218O instead of ordinary 
water for protein digestion and sample storage [70]. Deamidation that occurs during protein 
digestion and storage will then give peptides 2Da heavier than those undergoing in vivo 
deamidation. 
Protein digestion and associated in vitro deamidation can be avoided altogether if the top-down 
approach is applied, involving tandem mass spectrometry of individual protein molecules having 
the same or similar mass. Because of technical and other limitations, the top-down approach 
works best for molecules below 20–25 kDa, and thus, remains relatively low-throughput and is 
limited in terms of protein molecular mass and sample amount. 
Unlike Asn deamidation, Asp isomerization analysis presents a significant challenge for mass 
spectrometry, as isomerization by definition does not change the elemental composition and thus 
is “silent” in the mass spectrometric sense. Fortunately, structural changes induced by 
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 isomerization usually change the retention time of the peptide in reversed-phase liquid 
chromatography, which thus permits isomer separation; the Asp isoforms were assigned based 
on the known order of peptide elution at given HPLC conditions (iso-Asp, L-Asp, D-Asp and 
succinimide). 
However, in high-throughput proteomics experiments the presence of a peak at a certain mass is 
not specific enough for reliable iso-Asp identification because of the noise present in MS/MS 
spectra as well as the probability of accidental match with unrelated ionic species. Identification of 
the iso-Asp sites by mass spectrometry requires MS/MS method specific to iso-Asp. Lehmann et 
al.  [71] have noticed that replacement of L-Asp by L-iso-Asp resulted in shifts in the b/y intensity 
ratio of complementary b and y ions generated by cleavages N- and C-terminal to the iso-Asp, 
with the Asp immonium ion abundance at m/z 88 also decreased. However, these authors 
conceded that the b/y ion intensity ratio and the immonium ion intensity vary considerably 
depending on the peptide sequence and instrumental settings. Thus the abundance changes are 
difficult to use in practice for detection of iso-Asp. 
A set of iso-Asp specific fragments in electron capture dissociation (ECD) of synthetic peptides 
were found to be a more reliable criterion [72]. Besides the conventional N-Cα̳ bond cleavage in 
ECD that leads to complementary c and z fragments, a research group detected a diagnostic 
cleavage giving cn• + 58.0054 (C2H2O2) and zl–n − 56.9976 (C2HO2), where n is the position of the 
isoaspartyl residue and l is the peptide length. These diagnostic fragments are usually less 
abundant than the adjacent conventional cn and zl–n species. The same fragments are observed 
with the electron transfer dissociation (ETD [73]) technique which is similar to ECD but employs 
radical anions instead of free electrons. Elsewhere, it was found that higher-energy collisional 
dissociation (HCD [74]) of both positive as well as negative ions also fails in this task. This means 
that ECD/ETD are the only MS/MS technologies applied to electrospray-produced ions that 
provide reliable diagnostic ions for iso-Asp detection. 
The above approach to iso-Asp analysis provides high throughput in respect to peptide candidate 
detection but requires time-consuming validation of the detected iso-Asp candidates. Another 
limitation of the current approach is the relatively low speed and sensitivity of ECD/ETD when 
high-resolution mass analyzers are used [75].  
4.3.4 Methionine and cysteine oxidation 
Oxidation is involved not only in the formation of AGEs, but also in protein aging where proteins 
are directly altered by reactive oxygen species (ROS). Among ROS modifications methionine and 
cysteine oxidation are the most studied.  
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 Methionine (Met) has a sulphur-containing side chain that is susceptible to oxidation; methionine 
is usually oxidized yielding to methionine sulfoxide and methionine sulfone. Under physiological 
conditions, sulfoxide formation can be enzymatically reversed by the action of specific reductases 
including methionine sulfoxide reductase (MSRA) [76]. The Met oxidation-reduction process has 
been found to play a key role in the activation-deactivation cycle of several crucial signalling 
proteins and the maintenance of homeostatic balance in physiological systems [77, 78]. Apart 
from its regulation effect, Met oxidation in proteins plays a prominent role in aging and age-related 
degenerative diseases [20, 21, 79, 80]  resulting in the loss of protein function [59, 81, 82].  
Despite its significance in cellular functions and implications for various pathological conditions, 
Met oxidation has been largely overlooked in protein structural characterization. This is partly due 
to the fact that Met oxidation can be artefactually introduced during sample preparation, 
purification and analysis [83-85], presenting another degree of complexity in characterization of 
Met oxidation in proteins. 
For the detection of methionine oxidative products, anti-methionine sulfoxide antibodies against 
an oxidized methionine-rich zein protein (MetO-DZS18) have been obtained, but their specificity 
is questionable  [86].  
Several mass spectrometry (MS)-based methods have recently been introduced to characterize 
Met(O) in proteins and peptides, overcoming the limitations of the conventional protein analysis 
methods, such as Edman degradation, gel electrophoresis and amino acid analysis, where 
methionine sulfoxide residues are reduced, and detected as methionines [87-89].  
An advanced peptide-based method to map in vivo oxidized methionines and quantify their degree 
of oxidation has been described and is based on combined fractional diagonal chromatography 
(COFRADIC). With COFRADIC it is possible to isolate a specific set of peptides by altering a 
peptide functional group or the side-chain of targeted amino acids in between consecutive and 
identical reverse phase-HPLC. According to this method it is possible to separate the methionine 
sulfoxide containing peptides taking advantage of the hydrophobic shift introduced in the peptides 
due to enzymatic reduction of methionine sulfoxides with methionine sulfoxide reductase. The 
shifted peptides are collected for further LC-MS/MS analysis [59].  
Among the MS-based techniques, tandem MS (MS/MS) [90] is particularly attractive; the peptide 
sequence and the position of Met(O) can be directly determined through the gas-phase 
fragmentation [14], usually through collision-induced dissociation (CID) (a popular technique 
currently implemented on most commercial MS/MS instruments). A distinct fragmentation pathway 
in CID of Met(O)-containing peptides is the neutral loss of 64 Da from the precursor and/or product 
ions [83, 84]. The characteristic neutral loss of 64 Da corresponds to the ejection of 
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 methanesulfenic acid (CH3SOH, 64 Da) from the side chain of Met(O). The loss of 64 Da is unique, 
in proteins and peptides, to Met(O), and is particularly useful to differentiate between Met(O) and 
phenylalanine (both residues have the same nominal mass of 147 Da) in MS/MS peptide 
sequencing (Figure 8.). However, this low-energy pathway can further inhibit the backbone 
sequence fragmentation by CID, especially for larger polypeptides. In fact, the complete MS/MS 
characterization of Met(O) using CID has so far been limited to small peptides, such as those from 
enzymatic digestion [83, 84]. 
 
Figure 8. The neutral loss of 64 Da, due to the ejection of methanesulfenic acid (CH3SOH, 64 Da) 
from the side chain of Met(O), is unique and particularly useful to differentiate between Met(O) and 
phenylalanine (same nominal mass of 147 Da) in peptide mass fingerprint analysis. 
Electron capture dissociation (ECD) [91-93] has recently emerged as a powerful alternative in 
MS/MS of multiply charged proteins and peptides generated by electrospray ionization (ESI) [94] 
using Fourier transform ion cyclotron resonance (FTICR) mass spectrometry. ECD, a technique 
based on partial neutralization of multiply-protonated ions with electrons, typically renders 
extensive inter-residue backbone cleavage to yield c and z fragment ions, in contrast to the b and 
y fragment ions produced from the amide bond cleavage by conventional energetic fragmentation 
methods, including CID. Furthermore, ECD is a nonergodic fragmentation technique, i.e., a feature 
exemplified by the ability of ECD to preserve the labile side chain modification groups on the 
peptide backbone fragments [95-98], in contrast to CID and other conventional fragmentation 
techniques which typically eject the labile modifications first, resulting in the case of Met(O) in the 
loss of CH3SOH. 
ECD and CAD are complementary fragmentation techniques that provide “easy-to-interpret” 
spectra for rapid identification and localization of the Met(O) residues in peptides. The 
characteristic elimination of CH3SOH (64 Da) in CID serves as a signature tag for the presence of 
Met(O) in peptides. ECD then offers extensive backbone fragmentation without detaching the 
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 labile side chain, to allow for the direct localization of the Met(O) residues. The accurate mass 
measurement of FTICR/MS can also assist in the unequivocal determination of Phe and Met(O), 
as these two residues share the same nominal mass (147 Da) but differ in exact mass by 0.033 
Da (Phe, 147.0684; Met(O), 147.0354).  
Cysteine residues have become the subject of intensifying research interest in redox-proteomics 
because of their redox-reactive thiol side chain. Certain reactive cysteine residues can function as 
redox-switches, which sense changes in the local redox-environment by flipping between the 
reduced and oxidized states, in response to fluctuations in the various ROS. Protein cysteine 
residues exist not only as free thiols or disulfides, that help maintain the 3D structure of proteins, 
but depending on their local concentration, Cys can react with ROS to form one of several 
reversible (S-glutathionylation, sulfenic acid, inter- and intramolecular disulfide bonds and S-
sulfhydration) or irreversible (sulfininc or sulfonic acid) modifications (Figure 9.) [99, 100]. Due to 
the variety, and in some cases, unstable nature of the different Cys modifications, several 
techniques have been developed for their investigation. 
 
Figure 9. Common oxidative cysteine modifications: physiologically reversible and irreversible 
oxidative post-translational modifications that can occur to the thiol side chain of a Cys. 
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 The formation of sulphenic acid may be reversed, for example by glutathione (GSH), while the 
formation of the sulphinic or sulphonic acids is usually irreversible [59]. The easiest method 
available for the detection of disulfide bonds is electrophoretic separation under first non-reducing 
and then reducing conditions. Some cysteine modifications can also be detected using specific 
antibodies against S-glutathionylated proteins, sulfenic or sulfonic acid modifications. However, 
their use has been limited to targeting and assaying the modification status of single proteins [59]. 
Another approach for the detection of oxidized cysteine residues takes advantage of the fact that 
the reversibly oxidized thiols can be labelled. First the unmodified cysteine residues are blocked 
using thiol-specific reagents such as maleimides, iodoacetic acid or iodoacetamide, then oxidized 
thiols are reduced using specific agents for the modification of interest. The newly exposed thiols 
are labelled with fluorescent dyes such as Cy3 and Cy5, which have a maleimide group that forms 
a thioether bond with the free thiols of cysteines. Comparison of gels stained with these dyes and 
a total protein staining (for example by using Sypro Ruby) provides information about cysteine 
modifications [101]. Alternatively, reduced cysteine residues can be labelled with a thiol-reactive 
biotin. This method could be used for both detection and/or enrichment using anti-biotin 
immunoblotting and/or streptavidin affinity chromatography.  
The identification of individual modified Cys residues and of the specific redox-modification have 
been achieved using proteomics techniques, often by coupling enrichment strategies (biotin-
streptavidin enrichment-based methods) with high throughput mass spectrometry (MS) analysis 
[102].  
S-Sulfenylation - Sulfenylation, also known as sulfenic acid modifications, are reversible, labile 
moieties that have been challenging to study with traditional techniques. Sulfenic acid is the first 
oxidative form generated by hydrogen peroxide oxidation of a thiolate forming an R-SOH group 
[103]. Proteomics analysis of sulfenyl has been performed using a few different methodologies. 
A biotin switch style assay which used m-arsenite in place of ascorbate in order to specifically 
reduce sulfenic acids has been developed [104]. The method validation demonstrated the 
progressive loss of sulfenated signal with increased peroxide treatment, indicating that m-arsenite 
is specific to sulfenic acid and not the further oxidative forms [105].  
More commonly, sulfenic acid modifications have been targeted using dimedone chemistry. 
Dimedone-based probes, conjugated with biotin or azide, have been reported to stably and 
specifically label sulfenylated thiols [106, 107]. This reaction has been shown to directly target 
SOH groups and does not require the blocking step or specific reducing agent necessary for biotin 
switch style approaches. Once labelled, the biotin group or, in the case of azide conjugated 
probes, a ‘click’ chemistry addition of a biotin moiety, can be used for enrichment and detection.  
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 Recently, the sulfenic acid ligation reaction using aryl-nitroso compounds has been reported; the 
approach reacts rapidly in aqueous conditions and is highly selective for sulfenic acid 
modifications, including being orthogonal to free cysteine-thiols. The 2-nitrosobenzoic ester 
derivative they examined is more stable and specific at neutral pH than the aryl diazonium salts 
[108]. With further development, this chemistry has great promise for the detection of sulfenic acid 
modifications in complex biological systems. 
Disulfide bonds - Cys can also be modified through reaction with another available Cys forming 
a protein disulfide bond. The introduction of new disulfide interactions has the potential to 
significantly alter protein conformation or association, affecting function. Analysis of these 
modifications presents a particular problem: the relatively large number of static disulfides can 
make isolation/detection of the smaller pool of dynamic bonds difficult. Several strategies have 
been utilized to detect and identify regulatory disulfides. 
One of the longest standing and most successful techniques for examining intermolecular disulfide 
bonds is the direct identification of disulfide bonded peptides by MS. This is challenging but it 
offers the most conclusive evidence of a disulfide interaction. In the majority of MS studies, Cys 
are reduced and alkylated prior to analysis removing any possibility of disulfide observation. 
Disulfide linked or looped peptides can be difficult to ionize and have been found to be more 
resistant to fragmentation in collision induced dissociation (CID) [109, 110]. Recently, two 
approaches have been presented which attempt to improve this situation. Electrospray ionization 
(ESI) coupled with CID can produce an asymmetric cleavage of the disulfide bond resulting in Cys 
with a disulfohydral and dehydroalanine residue across the cleavage site; representing signature 
masses which can be used for unambiguous identification of the residues involved [111]. In an 
alternative approach, disulfide bonds are cleaved electrolytically immediately prior to analysis 
[112]. The disulfide bonded peptides can be recognized by the loss of ionization energy when 
compared to a control sample. Unfortunately, neither of these approaches is currently suitable for 
complex samples or high throughput analysis; however, software is being developed that will aid 
in this endeavour [112].  
It is important to note that in dealing with disulfide bonds or other thiol-modifications, many MS 
protocols perform trypsin digestion in ammonium bicarbonate at pH 8.5. This may be above the 
pKa of many Cys causing their conversion to more reactive thiolates which can lead to disulfide 
rearrangement during sample processing. When dealing with cysteine sensitive samples the use 
of a lower pH buffer, such as ammonium acetate (pH 6.5), is recommend to achieve better disulfide 
bond fidelity [113]. 
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 Sulfinic and Sulfonic Acid - Unlike the previously discussed thiol-modifications, those involving 
sulfinic and sulfonic acids are biologically irreversible and have generally been regarded as 
oxidative damage rather than signalling modifications [114]. These modifications arise from the 
additional oxidation of a sulfenic (RS-OH) to form a sulfinic (RS-O2H) and subsequently a sulfonic 
group (RS-O3H) [115]. Due to their relative stability compared to the reversible thiol modifications 
they do not require a replacement strategy and can be detected directly by mass spectrometry; 
however, this presents its own complications. 
Sulfonic acid modified residues can be captured using a polyarginine resin. This technique is 
based on the coordination between the positive amine groups of the arginine and negatively 
charged sulfo-groups resulting in a sensitive and specific capture of sulfonated peptides.  
Unfortunately, there is currently no specific enrichment chemistry for sulfinic acid modified thiols. 
In some cases antibodies have been raised against the specific sulfinic and sulfonic acid modified 
forms of individual proteins such as GAPDH, DJ-1 and Prx [116].  
Once these irreversible modifications have been enriched, detecting them by either MALDI or ESI 
MS can be difficult. The high negative charge associated with the sulfo-group can inhibit ionization 
by MALDI. To improve detection, groups have included diammonium hydrogencitrate in the matrix 
which have been found to improve ionization [117]. Additionally, sulfinic and sulfonic acid 
fragmentation can be difficult to distinguish from the fragmentation patterns of other post-
translational modifications necessitating high resolution MS instruments to differentiate them. Both 
sulfinic acid and hydropersulfide modifications result in a 32 Da mass shift while sulfonic acid and 
phophorylation can experience an 80 Da neutral loss by CID [118]. The loss of the sulfo-group 
can make determination of the specific Cys difficult. Electron transfer dissociation (ETD) is 
preferable to electron capture dissociation (ECD) for sulfonic acid-containing peptide 
fragmentation since it prevents the neutral loss of the moiety. Also, it has been reported that 
sodium adducts can stabilize the SO3 groups, further helping to prevent loss and improving site 
assignment [119]. 
S-Glutathionylation - In addition to the reactive oxygen species, there are other potential thiol-
reactive agents such as glutathione (GSH) which can result in oxidative post-translational 
modifications. GSH is a cysteine-containing tripeptide (glutamate-cysteine-glycine) which can be 
an electron donor for oxidative species and form stable but reversible mixed disulfide bonds with 
available Cys [120]. The selective addition of a glutathione group to a protein has been found to 
regulate protein function. Cellular levels of S-glutathionylation increase during oxidative stress and 
it has been proposed that S-glutathionylation functions as a temporary thiol ‘cap’, protecting critical 
Cys from potentially damaging irreversible oxidative modifications [121]. 
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 S-glutathionlyation modifications have been enriched and identified using a protocol similar to the 
biotin switch assay previously outlined. For this application, glutaredoxin (Grx), which specifically 
targets GSH modifications, is used as the specific reducing agent [122-124]. After reduction, newly 
exposed thiols can be labelled and detected using any of the various thiol-reactive tags discussed 
above for MS analysis. Compared with other oxidative PTMs, S-glutathionlyation is a relatively 
stable modification with a unique mass and therefore direct analysis is also possible. S-
glutathionylation can be specifically targeted through the use of a biotin-labelled glutathione ester 
[125-127]. This cell permeable reagent can be loaded into cells and when harvested the proteins 
and individual Cys that received the biotinylated glutathione can be easily captured with avidin 
and identified by MS. Another potential option is the use of antibodies to detect and enrich S-
glutathionylated proteins. As mentioned above, this modification is sufficiently stable and 
antibodies raised against a GSH epitope can be used for detection in immuno-based assays (e.g. 
ELISA, immunohistochemistry, Western blots). 
4.3.5 Protein nitration 
Reactive nitrogen species (RNS), together with ROS, could act to damage proteins, causing 
cellular stress [4]. Among RNS-induced modifications, tyrosine and tryptophan nitration and 
cysteine nitrosylation are the most studied (Figure 10). 
Reactive nitrogen species are generated in vivo during an inflammatory reaction. As other nePTM-
derived products, nitration products could be considered general biomarkers of disease 
progression. 
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Figure 10. The most studied RNS-induced modifications: tyrosine and tryptophan nitration, and 
cysteine S-nitrosylation (also known as S-nitrosation). 
Tyrosine and Tryptophan nitration - The most common products resulting from protein nitration 
are nitrotyrosine and nitrotryptophan. Nitrotyrosine is derived from the reaction between tyrosine 
and peroxynitrite, a strong nitrating agent [59, 60]. Nitrotyrosine has an absorption peak at 280 
nm as does tyrosine, but nitrotyrosine in acidic solutions presents an additional peak at 357 nm 
and in basic solutions at 430 nm. Thus, nitrotyrosine can be traced by UV–Vis photometry, but 
only in samples characterized by low complexity [128]. Regarding nitrotryptophan, since 
tryptophan exhibits the strongest fluorescence with an excitation maximum at 280 nm and an 
emission maximum between 305 nm and 355 nm, nitrotryptophan formation can be detected by 
fluorescence quenching. Both nitrotyrosine and nitrotryptophan are relatively stable modifications, 
thus they can be suitably analyzed by immunochemical detection with specific antibodies [34], 
followed by a peptide mass fingerprinting (PMF) MS analysis [129]. Moreover, exploiting the fact 
that nitration changes the chemical properties of tyrosine, it is possible to selectively 
derivatize/enrich the modified proteins. The Biotin/avidin-based method is widely used to enrich 
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 nitrotyrosine (3-NT) – modified proteins or peptides [130]. To label with biotin tags, primary amino 
groups of nitrated peptides have to be blocked, prior to 3-NT reduction to 3-aminotyrosine. Amine-
reactive biotin tags are then incubated with 3-NT reduced peptides and enriched through avidin 
chromatography. This general strategy can employ different blocking reagents and biotin-based 
tags, making it a flexible method of protein nitration identification [130].  
S-Nitrosylation – S-nitrosylation (SNO), also known as S-nitrosation, results from the covalent 
addition of a nitrosonium ion (NO+) equivalent to a Cys-thiol. Since SNO-modifications are very 
labile, they are challenging to study using traditional biochemical techniques.  
Typically, two steps are needed to analyze the thiol proteome (S-nitrosylated proteins - PSNO), 
avoiding the gel-separation step: blocking free thiols and reducing reversibly oxidized thiols [131]. 
For instance, free thiol groups (SH) can be blocked with a reagent that does not react with 
nitrosothiols, which are then reduced to thiols with ascorbate and the SH goups thus produced 
are derivatized with a biotinylated thiol reagent so that derivatized proteins can then be identified 
by immunoblotting and/or immunoaffinity. Anti-SNO antibodies have recently been developed and 
can be used in proteomics approaches. On the other hand, once the modified sites are labelled 
with the stable biotin group, they can be easily detected or enriched by streptavidin affinity 
chromatography. 
Another derivatization method aimed at purifying reversibly oxidized proteins (PROP) uses N-
ethylmaleimide (NEM) to block unmodified thiol groups and reduce oxidized thiols to generate new 
free thiols. Commercially available thiol reactive beads which contain a 2- pyridyl disulfide group 
can be used to react with newly formed thiols and isolate oxidized proteins. After isolation, the 
bead-SS- protein disulfide bond can be reduced by dithiothreitol which can be labelled with 
iodoacetamide. Different blocking reagents can be differentiated by MS, so unmodified and 
oxidized cysteines can be identified simultaneously. Selecting the best label for an experiment 
depends on two factors: (i) the need for a permanent mass tag in the MS analysis and (ii) the 
amenability to relative quantification. 
4.4 MS Quantification  
Modern protein mass spectrometry techniques are used both to detect nePTMs and to quantify 
their amounts. This can be done either as a relative measurement defining the difference between 
two conditions, e.g. diseased versus control sample or as an absolute measurement. Combined 
measurements of modified and unmodified forms of a particular peptide allow the percentage site 
occupancy to be defined, i.e. the number of modified molecules in relation to the number of 
unmodified molecules [3].  
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 In fact, relative quantitation is the most commonly used quantitative strategy in proteomics. This 
can be achieved using several different techniques, for example the stable isotope labelling by 
amino acids in cell culture (SILAC) approach [136, 137], various chemical labelling procedures, 
e.g. trypsin-catalyzed 18O labelling [138], dimethyl labelling [139, 140] or by isobaric labelling, i.e. 
Isobaric tag for relative and absolute quantitation (iTRAQ) and Tandem mass tag (TMT) (Figure 
11. – panel A). 
 
Figure 11. Summary of the main quantitative MS methods. Panel-A. Stable isotope labelling by amino 
acids in cell culture (SILAC) approach (Panel-A1) or chemical (isotopic or isobaric) labelling 
procedures, e.g. trypsin-catalyzed 18O labelling, iTRAQ, TMT (Panel-A2); Panel-B. Absolute 
quantitation of peptides and proteins by B1. Multiple reactions monitoring (MRM) or Single / selected 
reaction monitoring (SRM) (Panel-B1), or by spiking known amounts of heavy-labelled standards 
into the sample prior to LC–MS/MS analysis and subsequently comparing the intensities of such 
standards with the analyte (Panel-B2). 
Absolute quantitation of peptides and proteins is used to determine exact amounts of the analyzed 
samples [3]. Multiple reactions monitoring (MRM) or single or selected reaction monitoring (SRM) 
is a targeted MS based quantitative approach (Figure 11. – panel B). This technique allows 
measurement of the quantity of specific peptides of interest, selected according to their m/z and 
fragment ions generated upon MS–MS fragmentation. The resulting fragment ions confirm the 
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 identity of the precursor and their intensity is proportional to its abundance. This technique is often 
described as large scale quantitative analysis since it allows for simultaneous quantification of up 
to 100 proteins in one LC MS-SRM experiment [3].  
Alternatively, the absolute quantitation of peptides and proteins is achieved by spiking known 
amounts of heavy-labelled standards into the sample prior to LC–MS/MS analysis and 
subsequently comparing the intensities of such standards with the analyte (Figure 11. – panel B) 
[3]. Unfortunately, most oxidative modifications are not available through commercial sources of 
synthetic peptides. Nevertheless, SRM using heavy-labelled internal standards has the potential 
to be a powerful technique for monitoring oxidative modifications [141].  
Methods for quantification of simple and small analytes are relatively easily and reliably 
standardized; it is a much harder task to standardize methods for quantification of complex and 
large analytes, such as proteins, in physiological fluids or cell/tissue samples. There are many 
requirements for the standardization of a quantitative method and its quality control, some specific 
ones for PTMs are listed below: 
• Reliable identification of nePTM which are directly correlated to the specific modifying 
reaction or reactive species which causes it. 
• High specificity of intra-molecular nePTM recognition (as little as possible cross-
recognition with similar nePTM within the same protein). 
• High specificity of inter-molecular nePTM recognition (as little as possible cross-
recognition of the same nePTM in different proteins). 
• High sensitivity of nePTM recognition (detection of minor modification). 
• “Acceptable justification” concerning determination of specific nePTM in relation to the 
specific (patho)physiological disturbance. 
• “High-throughput” method and the equipment to support it. 
The implementation of new technologies based on proteomics (mass spectrometry) in clinical 
laboratories constitutes a decisive step in the development of their use, even though 
methodological problems, such as the lack of standardization, have to be resolved [4].  
Since there are two aspects of PTM protein quantification, each standardization needs to be 
handled separately. If the idea is to quantify certain PTMs which may be present on many proteins, 
a common standard possessing the particular PTM may be used. If the idea is to quantify a certain 
PTM on a specific protein, the standard can be that same protein modified to express that 
particular PTM. Alternatively, for the second purpose, the specific protein may be isolated and 
then measured against a common protein standard which has the appropriate PTM. In both cases, 
the first step is to define suitable standard(s) [3]. 
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 It is reasonable to choose a standard from among already existing commercial products rather 
than of creating new one(s), as manufacturers have probably already solved practical problems 
concerning continuous production of PTM proteins, their stabilization and storage. Several 
producers of PTM proteins and also a number of products have been found there way onto the 
market [3]. Nowadays it is also possible to synthesize peptides with specific PTM commercially. 
This approach is widely used in the field of phosphoproteomics, but other modifications can also 
be synthesized. Unfortunately, this does not work very well with protein oxidation for many 
reasons, e.g. stability and cross reactivity of the products. In the case of carbonyls some pseudo-
aldehydes can be used.  
Obviously, there is a need for reliable standards, produced and tested under strict conditions and 
precisely characterized in respect to the type of PTM, the quantity and, if possible, the position 
within the relevant protein molecule.  
The most difficult analytical task dependent on the quality of standardization is detection and 
accurate quantification of minor proteins in complex (physiological) specimens. Since one specific 
nePTM protein is most often a minor fraction of the entire population of that protein, the detection 
range of the nePTM molecule is several fold lower than for the entire protein. As no official 
standardization in the field of PTM proteins exists except for HbA1c, it is reasonable to start with 
standardization and quality control in the quantification of specific nePTMs present on all (or many) 
proteins in a chosen sample, as this is an easier task [3].  
Since no method is perfect and no standard will suit all methods equally, some consensus 
decisions have to be made. The most important concern the assessment of the inaccuracy and 
uncertainty measurement. If the test is standardized to have very high sensitivity, it may record 
false negative results. If the test is standardized to have relatively low specificity, it may give false 
positive results. 
Standardization and quality control are instruments to achieve comparability of nePTM protein 
quantification results over time and space, enabling definition of decision-making criteria that can 
be used in the assessment of health in relation to ageing and diseases [3].  
It is very difficult to obtain inter-laboratory standardization in the analysis of modified proteins. This 
is due to the existence of a wide variety of instrumental and experimental setups. Over recent 
years scientists have become aware of this drawback and now acknowledge the necessity of 
standardization and unification. International initiatives have been undertaken during the last few 
years. The most prominent is The Human Proteome Organization (HUPO) Proteomics Standard 
Initiative (PSI). Its major focus is standardization of large scale proteomics experiments to facilitate 
data validation, accessibility and experimental transparency [142]. As an example of such work it 
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 has become a quality standard to use phosphoRS or similar algorithms to evaluate the 
probabilities associated with the precise localization of phosphorylation sites in peptide sequences 
[143]. 
In summary, the range of mass spectrometry based tools for characterization of protein 
nePTMs is broad. All of these tools have strong points and limitations. To take full 
advantage of MS technology experimental aims and all instrumentation at hand should be 
carefully considered. 
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A B S T R A C T
Advanced Lipoxidation End-products (ALEs) are modiﬁed proteins that can act as pathogenic factors in several
chronic diseases. Several molecular mechanisms have so far been considered to explain the damaging action of
ALEs and among these a pathway involving the receptor for advanced glycation end products (RAGE) should be
considered. The aim of the present work is to understand if ALEs formed from lipid peroxidation derived reactive
carbonyl species (RCS) are able to act as RAGE binders and also to gain a deeper insight into the molecular
mechanisms involved in the protein-protein engagement. ALEs were produced in vitro, by incubating human
serum albumin (HSA) with 4-hydroxy-trans− 2-nonenal (HNE), acrolein (ACR) and malondialdehyde (MDA).
The identiﬁcation of ALEs was performed by MS. ALEs were then subjected to the VC1 Pull-Down assay (VC1 is
the ligand binding domain of RAGE) and the enrichment factor (the diﬀerence between the relative abundance
in the enriched sample minus the amount in the untreated one) as an index of aﬃnity, was determined.
Computation studies were then carried out to explain the factors governing the aﬃnity of the adducted moieties
and the site of interaction on adducted HSA for VC1-binding. The in silico analyses revealed the key role played
by those adducts which strongly reduce the basicity of the modiﬁed residues and thus occur at their neutral state
at physiological conditions (e.g. the MDA adducts, dihydropyridine-Lysine (DHPK) and N-2-pyrimidyl-ornithine
(NPO), and acrolein derivatives, N-(3-formyl-3,4-dehydro-piperidinyl) lysine, FDPK). These neutral adducts
become unable to stabilize ion-pairs with the surrounding negative residues which thus can contact the RAGE
positive residues.
In conclusion, ALEs derived from lipid peroxidation-RCS are binders of RAGE and this aﬃnity depends on the
eﬀect of the adduct moiety to reduce the basicity of the target amino acid and on the acid moieties surrounding
the aminoacidic target.
1. Introduction
The oxidative degradation of lipids (lipid peroxidation) results in
the formation of a wide variety of break-down products including small
molecules containing a carbonyl moiety and characterized by chemical
reactivity and for this reason called reactive carbonyl species (RCS) [1].
Lipid-derived reactive carbonyl species (RCS) are quite heterogeneous,
belonging to diﬀerent chemical classes including α,β-unsaturated al-
dehydes [4-hydroxynonenal (HNE), acrolein (ACR)], keto-aldehydes
[methylglyoxal (MGO), 4-oxo-nonenal (ONE)] and di-aldehydes [mal-
ondialdehyde (MDA) and glyoxal (GO)] [2]. RCS react with diﬀerent
nucleophilic substrates and in particular with the nucleophilic amino
acids of protein (arginine, lysine, cysteine and histidine) through a re-
action called protein lipoxidation and involving the carbonyl moiety
and the electrophilic center (e.g. the C3 of an α,β-unsaturated moiety).
The reaction products between proteins and RCS, advanced lipoxida-
tion products (ALEs), are now recognized not only as biomarker of RCS
formation but also as bioactive/damaging biomolecules [3,4]. More-
over, RCS are currently recognized as being involved in the onset and
progression of several diseases including diabetic retinopathy [5],
atherosclerosis [6], renal disease [7] and metabolic disorders [8]. Based
on their pathogenetic role, ALEs are now considered as promising drug
target and molecules eﬀective in preventing ALE formation have been
reported to have beneﬁcial eﬀects in some animal models [9,10].
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However, it should be considered that the eﬀect of protein lipoxidation
and of RCS can be double-sided, because besides a damaging me-
chanism as above mentioned, in some conditions and depending on
their levels, they can exert protective eﬀects associated with the in-
duction of antioxidant defense mechanisms [11].
Several molecular mechanisms have so far been considered to ex-
plain the damaging action of ALEs, which can include one of the fol-
lowing mechanisms, depending on the damaging process and the target
protein itself: protein dysfunction, protein oligomerization, signal
transduction and immune response [3,6]. Moreover, adduction of RCS
to proteins can also lead to the formation of ALEs acting as binders and
activators of some receptors as in the case of galectin-3, a glycan
binding protein which has been suggested to aid in the removal of
circulating AGEs and ALEs [12].
ALEs which are formed from RCS deriving either from lipid and
reducing sugar oxidation, such as glyoxal and methylglyoxal, (in this
paper called AGEs/ALEs) are known to act as binders and activators of
the receptor RAGE [13,14]. RAGE is a type I cell surface receptor that is
expressed in several cells, such as endothelial cells, smooth muscle cells,
but also dendritic cells and T-lymphocytes and is predominantly located
in the lungs [15]. RAGE has been involved in many diﬀerent patholo-
gies with a marked oxidative base, such as diabetes, atherosclerosis,
neurodegenerative diseases and many diﬀerent ligands of RAGE have
been identiﬁed, such as amyloid β peptide, S100/calgranulin protein,
HMGB1 [16]. Two diﬀerent pathways can be activated upon binding to
the receptor: 1) the activation of the NADPH oxidase, resulting in the
production of reactive oxygen species (ROS), which are detrimental to
the cells and 2) the activation of the NF-κB pathway leading to a sus-
tained pro-inﬂammatory and pro-ﬁbrotic response [17].
However, there are some ALEs (in this paper called as ALEs-lipox),
widely detected in several oxidative based and inﬂammatory diseases
[6,18], which are formed by RCS only deriving from a lipid peroxida-
tion process, such as MDA, HNE and ACR. For these ALEs-lipox very few
data are available on their RAGE interaction. Shanmugam et al. [19]
reported that synthetic ALE (malondialdehyde-lysine [MDA-Lys]) in-
duces oxidative stress and also activates the transcriptional factor nu-
clear factor-kB (NF-kB) in THP-1 monocytes partly via the receptor for
AGEs (RAGE).
The aim of the present paper is to understand whether ALEs-lipox
are able to act as RAGE binders as do AGEs and AGEs/ALEs and also to
gain a deeper insight into the molecular mechanisms involved in the
protein-protein engagement. Our starting hypothesis, the involvement
of ALEs-lipox in RAGE activation, is supported by several facts such as
that ALEs/AGEs and ALEs-lipox share some structural properties such
as the covalent modiﬁcations by aldehydes of nucleophilic residues and
that ALEs-lipox are pro-inﬂammatory and pro-ﬁbrotic compounds ac-
tivating the NF-kB pathway, a mechanism which could be addressed to
a RAGE activation pathway. Fig. 1 shows the work ﬂow of the study.
To test this hypothesis, a set of ALEs was ﬁrstly prepared and fully
characterized by MS. ALEs were formed using the well-known lipid
peroxidation derived RCS and in particular HNE, ACR and MDA. Since
ALEs are quite heterogeneous also when formed by a single attacking
RCS, for each tested RCS the diﬀerent ALEs were fully identiﬁed by a
bottom-up MS approach in terms of adducted moiety and modiﬁcation
site. The RAGE binding ability of each identiﬁed ALE was then de-
termined using the VC1 assay as previously reported [20]. For each
identiﬁed ALE the VC1 binding ability was then related to the variation
in the ionization state of the adducted residues as well as to the
abundance of surrounding negative residues that, after the ALE gen-
eration, become available for RAGE binding. Computation studies were
then carried out to explain the factors governing the aﬃnity of the
adducted moieties and the site of interaction on adducted HSA for VC1-
binding.
The overall data permit the elucidation of the structural require-
ments for ALEs to become RAGE binders together with the molecular
mechanisms involved in the protein-protein engagement.
2. Materials and methods
2.1. Reagents
Formic acid (FA), triﬂuoroacetic acid (TFA) and acetonitrile (ACN)
were LC-MS grade; sodium dodecyl sulfate (SDS), ammonium bi-
carbonate, malondialdehyde tetrabutylammonium salt (MDA-TS), ac-
rolein (ACR), HEPES, NaCl, sodium dihydrophosphate, disodium
phosphate and all other chemicals were analytical grade and purchased
from Sigma-Aldrich (Milan, Italy). 4-Hydroxy-2-trans-nonenal di-
methylacetal (HNE-DMA, catalog Number H9538) was purchased from
Sigma-Aldrich (Milan, Italy) and recombinant HSA expressed in P.
pastoris were purchased from Sigma Aldrich (Milan, Italy). Streptavidin-
coated magnetic beads (Streptavidin Mag Sepharose™) were purchased
from GE Healthcare (Milan, Italy)
Ultrapure water was prepared by a Milli-Q puriﬁcation system
(Millipore, Bedford, MA, USA).
Any KD ™ Mini Protean® TGX ™ precast gel, Standard Precision Plus
prestained protein standards, Laemmli sample buﬀer (2×/ 4×),
Running buﬀer and Bio-Safe Coomassie, together with the threo-1,4-
Dimercapto-2,3-butanediol (DTT) and iodoacetamide (IAA) were sup-
plied by Bio-Rad Laboratories, Inc. Trypsin and Chymotrypsin sequen-
cing grade were purchased from Roche Diagnostics SpA (Monza, Italy).
Digestion buﬀer was 50mM ammonium bicarbonate; destaining
solution was prepared mixing acetonitrile with digestion buﬀer (1:1 v/
v); reducing solution was 10mM DTT in digestion buﬀer; alkylating
solution was 55mM iodoacetamide in digestion buﬀer; extraction so-
lution was prepared as follows: 3% TFA/30% ACN in H2O MilliQ.
2.2. In vitro generation of ALEs-HSA
4-hydroxy-trans− 2-nonenal (HNE) was prepared as previously de-
scribed [21]. HSA modiﬁed with MDA was prepared dissolving HSA in
10mM phosphate buﬀer pH 7.4 at a concentration equal to 100 μM
(6.7mgml−1). HSA was incubated, as previously described [20] in the
dark at 37 °C and 400 rpm and using the following molar ratios between
protein and MDA: 1:6.3, 1:63, 1:630, 1:6300, 1: 12600. HSA modiﬁed
with ACR or HNE was prepared dissolving HSA in 10mM phosphate
buﬀer pH 7.4 at a concentration equal to 75 μM (5mgml−1). HSA was
incubated in the dark at 37 °C and at 400 rpm in molar ratios protein:
ACR equal to 1:10, 1:100, 1:1000, 1:2500 and 1:5000 and in molar
ration protein: HNE equal to 1:10, 1:100, 1:200, 1:1000 and 1:2000.
HSA incubated without RCS was used as a control untreated sample.
The reactions were stopped after 24, 48 or 72 h removing the excess of
RCS by ultraﬁltration using Amicon Ultra ﬁlter units 0.5 ml, cut-oﬀ
10 kDa (Millipore).
2.3. Intact protein analysis by MS
ALEs obtained by incubating HSA with RCSs were analyzed by di-
rect infusion on a triple-quadrupole (TQ) mass spectrometer (Finnigan
TSQ Quantum Ultra, ThermoQuest, Milan, Italy) equipped with an
Electrospray Finnigan Ion Max source. For MS analyses, samples were
desalted by using Amicon Ultra ﬁlter units 0.5ml, cut-oﬀ 10 kDa
(Millipore) and washed three times with water. Samples were then
diluted to 1 mgml−1 with a ﬁnal composition of CH3CN–H2O–HCOOH
(30:70:0.1, v/v/v). Aliquots of 50 μl were injected into the mass spec-
trometer at a ﬂow rate of 25 μl min−1 by using a ThermoQuest auto-
sampler. Each sample was analyzed for 5min under the following in-
strumental conditions: positive-ion mode; ESI voltage 3.5 kV, capillary
temperature 350 °C, Q3 scan range 1200–1500m/z, Q3 power 0.4 amu,
scan time 1 s, Q2 gas pressure 1.5 Torr, skimmer oﬀset 10 V, microscan
set to 3. Full instrument control and ESI mass spectra acquisitions were
carried out by Xcalibur software (version 2.0.7, Thermo Fisher
Scientiﬁc, Rodano, MI, Italy). Mass spectra deconvolution was per-
formed using MagTran software (version 1.02) [22].
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2.4. VC1 pull-down assay
VC1-His-Strep was expressed and puriﬁed from Pichia pastoris cul-
ture supernatant as previously described [23]. The recombinant protein
was immobilized on streptavidin-coated magnetic beads by exploiting
the aﬃnity of the Strep tag towards streptavidin. In order to obtain the
VC1-resin, 50 μg of puriﬁed VC1-His-Strep in 170 μl of 20mM HEPES
pH 7.1, 100mM NaCl were added to 5 μl of packed streptavidin coated-
beads, previously equilibrated with the same buﬀer. A volume of 170 μl
of 20mM HEPES pH 7.1, 100mM NaCl were added to the same amount
of beads in a diﬀerent tube in order to obtained the Control-resin. After
1 h of incubation at 4 °C on a rotary mixer, the unbound material was
carefully removed and the magnetic beads were washed with 500 μl of
buﬀer (20mM HEPES pH 7.1, 100mM NaCl). The VC1- and Control-
resin were incubated for 1 h at 4 °C with 160 μl of ALE-HSA or untreated
HSA at the concentration of 125 μgml−1 in 20mM HEPES pH 7.1,
100mM NaCl. The unbound material was carefully removed and the
beads were washed twice with 500 μl of Buﬀer (20mM HEPES pH 7.1,
100mM NaCl). The elution was performed by boiling the beads for
5min in 15 μl of Laemmli Sample Buﬀer 4x mixed with 400mM DTT,
then with other 15 μl of buﬀer (20mM HEPES pH 7.1, 100mM NaCl).
The two eluates were pooled.
2.5. Electrophoretic procedures
The fractions obtained from pull-down experiments were analyzed
by SDS PAGE. To 20 μl of input and unbound fractions, 7 μl of Laemmli
Sample Buﬀer 4x mixed with 400mM DTT were added. The samples
were denatured incubating for 5min at 95 °C. Input, unbound and
elution samples were separated by SDS-PAGE on Any KD ™ Mini
Protean® TGX ™ precast gels and stained with Bio-Safe Coomassie blue
(Bio-Rad). Images were acquired using the calibrated densitometer GS-
800 and analyzed by the software Quantity one (Bio-Rad).
2.6. ALE-HSA in-gel digestion
Proteins bands corresponding to ALEs-HSA and obtained by in-
cubating HSA with HNE, ACR and MDA (input), and those cut from the
fraction retained by VC1, were excised from gels using a scalpel, ﬁnely
chopped, transferred to a new eppendorf and washed with 200 μl of
digestion buﬀer. An aliquot of 200 μl of destaining solution was added
to each gel portion and heated at 37 °C for 10min in the thermomixer
(1400 rpm); the destaining solution was then discarded and this step
was repeated until destaining was completed. Afterwards, gel pieces
were incubated with 150 μl of reducing solution at 56 °C for 1 h and
then with 150 μl of alkylating solution at room temperature for 45min
in the dark. In-gel digestion of ALE-HSA adducts was performed by
overnight-incubation at 37 °C with 1 µg of sequencing-grade trypsin
(Roche) dissolved in digestion buﬀer. ALE-HSA samples were also
subjected to a second digestion by a sequencing-grade chymotrypsin
(1 µg) for 7 h at 25 °C in the presence of calcium chloride (10mM). The
peptide mixtures were acidiﬁed with formic acid up to a ﬁnal con-
centration of 1%.
To guarantee better protein detection, peptide mixtures were
Fig. 1. Work ﬂow of the study. ALEs-lipox were ﬁrstly prepared by incubating HSA with lipid peroxidation derived RCS (HNE, ACR and MDA) and then fully
characterized by MS. The RAGE binding ability of each identiﬁed ALE was then determined by using the VC1 assay as previously reported [20]. Computation studies
were then carried out to explain the factors governing the aﬃnity of the adducted moieties and the site of interaction on adducted HSA for VC1-binding.
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extracted by a 10min-incubation with extraction solution and by an
additional 10 min-incubation with pure acetonitrile. The two extracts
were combined and dried in a vacuum concentrator (Martin Christ.).
Digested peptide mixtures were then dissolved in an appropriate vo-
lume (20 μl) of 0.1% formic acid for mass spectrometry (MS) analysis.
2.7. Mass spectrometry analyses
Peptides from the in-gel digestion were separated by reversed-phase
(RP) nanoscale capillary liquid chromatography (nanoLC) and analyzed
by electrospray tandem mass spectrometry (ESI-MS/MS). For each
analysis 5 μl of solubilized peptides were injected onto a C18HALO
PicoFrit column (75mM x 10 cm, 2.7mM particles, pores 100 Å, New
Objective, USA) by means of an autosampler. Samples were loaded onto
the fused silica column at 400 nl/min of mobile phase consisting of 99%
of phase A and 1% of phase B (0.1% HCOOH in CH3CN) for 15min.
Peptide separation was performed with a 55min linear gradient of
phase B (1–35%). The separative gradient was followed by 5min at
80% of phase B to rinse the column, and 15min of 99% of phase A and
1% of phase B served to re-equilibrate the column to the initial con-
ditions. The nano-chromatographic system, an UltiMate 3000
RSLCnano System (Dionex), was connected to an LTQ-Orbitrap XL mass
spectrometer (Thermo Scientiﬁc Inc., Milan, Italy) equipped with a
nanospray ion source (dynamic nanospray probe, Thermo Scientiﬁc
Inc., Milan, Italy) set as follows: positive ion mode, spray voltage 1.8
Kv; capillary temperature 220 °C, capillary voltage 35 V; tube lens oﬀset
120 V. The LTQ-Orbitrap XL mass spectrometer was operated in data-
dependent acquisition mode (DDA) to acquire both the full MS spectra
and the MS/MS spectra. Full MS spectra were acquired in "proﬁle"
mode, by the Orbitrap (FT) analyzer, in a scanning range between 300
and 1500m/z, using a capillary temperature of 220 °C, AGC target
= 5×105 and resolving power 60,000 (FWHM at 400m/z). Tandem
mass spectra MS/MS were acquired by the Linear Ion Trap (LTQ) in CID
mode, automatically set to fragment the nine most intense ions in each
full MS spectrum (exceeding 1×104 counts) under the following con-
ditions: centroid mode, isolation width of the precursor ion of 2.5m/z,
AGC target 1×104 and normalized collision energy of 35 eV. Dynamic
exclusion was enabled (exclusion dynamics for 45 s for those ions ob-
served 3 times in 30 s). Charge state screening and monoisotopic pre-
cursor selection were enabled, singly and unassigned charged ions were
not fragmented. Xcalibur software (version 2.0.7, Thermo Scientiﬁc
Inc., Milan, Italy) was used to control the mass spectrometer.
2.8. Identiﬁcation and localization of protein adducts
The software Proteome Discoverer (version 1.3.0.339, Thermo
Scientiﬁc, USA), implemented with the algorithm SEQUEST, was used
to compare the experimental full and tandem mass spectra with the
theoretical ones obtained by the in silico digestion of the HSA sequence
(Uniprot P02768). Trypsin and chymotrypsin were selected as the
cleaving proteases, allowing a maximum of 2 missed cleavages. Peptide
and fragment ion tolerances were set to 5 ppm and 10 mmu, respec-
tively. Cysteine carbamidomethylation was set as ﬁx modiﬁcation
(+57.02147); methionine oxidation was allowed as a variable mod-
iﬁcation in addition to the known HNE-, ACR- or MDA-derived mod-
iﬁcations as listed in Table S1.
As a quality ﬁlter, only peptide with an Xcore value grater then 2.2
for doubly-charged peptides, 2.5 for triply-charged, 2.75 for quadruply-
charged peptide ions, and 3 for charge states quintuple or higher were
considered as genuine peptide identiﬁcations. To ensure the lowest
number of false positives, the mass values experimentally recorded
were further processed through a combined search with the Database
Decoy, where the protein sequences are inverted and randomized. This
operation allows the calculation of the false discovery rate (FDR) for
each match, so that all the proteins out of range of FDR between to 0.01
(strict) and 0.05 (relaxed) were rejected.
For the localization of ALE-deriving modiﬁcations, the MS/MS
spectra of modiﬁed peptides were manually inspected; for the conﬁdent
mapping of the modiﬁcation sites, spectra were requested to match the
expected ions (b and/or y) neighboring the modiﬁed amino acid residue
both at the N- and C-termini.
2.9. Semi-quantitative analysis of ALE-HSA adducts
The relative extent of each protein modiﬁcation has been calculated
by determining the amount of the modiﬁed peptide in respect to the
native one, by assuming that the ionization eﬃciency of the native and
the modiﬁed peptides are equal. In particular, the single ion traces (SIC)
of the native and modiﬁed peptides were ﬁrstly reconstituted by setting
as ﬁlter ion the m/z values of the corresponding precursor protonated
peptides. The peak areas were then automatically calculated by the
Qual Browser tool of the Xcalibur data system (version 2.0.7, Thermo
Scientiﬁc Inc., Milan, Italy) and then the relative abundance calculated
by using the Eq. (1).
=
+
Relative Abundance%
Modified Peptide Peak Area
(Modified Peptide Peak Area Native Peptide Peak Area)
*100
(1)
The relative abundance of each modiﬁed peptide was determined in
both the input and enriched samples. The retention eﬃciency of each
identiﬁed ALEs towards VC1 was then determined by the Enrichment
Factor value, calculated as the diﬀerences between the relative abun-
dance in the enriched sample minus the amount in the untreated one
(Enrichment factor= %VC1-%NoVC1).
2.10. Computational studies
The prediction of the pK values of the simulated adducts was per-
formed by PM7-based semi-empirical calculations using MOPAC [24].
The simulations involved simpliﬁed model compounds by focusing on
the adducted side chains and neglecting the backbone atoms. Speciﬁ-
cally, the predictions involved the FDPK, mono and double N-propenal
MA adducts of lysine. Indeed and as experimentally known, 2-amino
pyrimidine and dihydropyridine (i.e., NPO and DHPK adducts) are
neutral at physiological pH, while cyclic guanidines (see HTP0) retain
the strong basicity of the guanidine group. With regard to HSA protein,
the retrieved resolved structure (PDB Id 1A06) was used, after a pre-
liminary optimization, to calculate the negative residues within a 5 Å
radius sphere around each adducted residues and to generate the cor-
responding adducts as induced by MDA e ACR. As discussed in the
Results section, two adducted HSA structures were manually generated
using the VEGA suite of program [25]: the ﬁrst carrying all the ACR-
based adducts and the second structure with all the MDA-based ad-
ducts. The analysis was focused on Arg and Lys adducts only because
they are numerous enough to derive a sort of structure-aﬃnity re-
lationships (SAR). Similarly, these analyses do not consider the HNE-
induced modiﬁcations because they are too limited to develop clear
relationships. In order to allow a suitable reorganization of the en-
vironments around all inserted adducts, the minimized adducted HSA
structures underwent 1 ns of MD simulations by Namd [26] keeping the
backbone atoms constrained to avoid excessive distortions of the re-
solved folding. With regard to RAGE structure, the NMR-derived V
structure (PDB Id: 2mov) was prepared and utilized as done in previous
studies. Protein-protein docking was performed using GRAMM [27]
with the default parameters and generating 1000 complexes for each
adducted HSA structure.
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3. Results
3.1. Intact protein analysis of HSA and ALEs-HSA by MS
In order to investigate the interaction between RAGE and ALEs-
lipox, diﬀerent ALEs-lipox were produced in-vitro by incubating HSA
with diﬀerent concentrations of the well-known lipid derived RCS and
in particular: acrolein (ACR), malondialdehyde (MDA) and 4-hydroxy-
trans− 2-nonenal (HNE). After 24, 48 and 72 h, aliquots of the in-
cubation mixtures were withdrawn, and the reaction was stopped by
removing the excess of RCS by ultraﬁltration. Intact protein analysis by
direct infusion MS was used to evaluate the extent of HSA modiﬁca-
tions. Fig. 2 shows the spectra of native HSA (panel A) and HSA in-
cubated with increasing molar ratios of HNE [1:1 (B), 1:5 (C), 1:10 (D),
1:100 (E), 1:200 (F) and 1:1000 (G)]. Panel A) shows the MS-spectrum
(mass range between m/z 1400 and 1500) of native and non-modiﬁed
HSA, characterized by three sharp multicharged ions at m/z 1414.99,
1445.71 and 1477.87 relative to the three multicharged ions at 47+ ,
46+ and 45+ . When HSA was incubated with HNE in a 1:1M ratio,
besides the three peaks relative to native HSA, a new set of peaks at m/z
1418.43, 1449.15, and 1481.40 is detectable and relative to the HNE
Michael adduct of native HSA (MW shifted by 156 Da), as conﬁrmed in
Fig. 2. Direct infusion ESI-MS analysis of native and HNE-modiﬁed HSA. Mass spectra of HSA recorded in a mass range between m/z 1400 and 1500. A) Native
HSA shows sharp intense peaks referred to the charge ions 47+ , 46+ and 45+ ; the deconvoluted spectrum reports a MW 66,455 Da (H). When HSA is reacted with
HNE at increasing molar ratios 1:1 (B), 1:5 (C), 1:10 (D), additional peaks relative to HNE adducts appear. At higher molar ratios 1:100 (E), 1:200 (F) and 1:1000 (G)
the MS spectra lose resolution and become ﬂat due to the presence of multiple adducts. H) Deconvoluted spectra showing the MS of HSA and protein adducts. MS
spectra relative to HSA incubated with HNE at 1:100M ratio and higher cannot be deconvoluted due to the extent of modiﬁcation.
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the deconvoluted spectrum (panel H). The number of adducted HNE
moieties per molecule of HSA increases proportionally with the increase
of molar ratios reaching 3 and 5 HNE moles per mole of HSA at 1:5 and
1:10 HSA: HNE molar ratios, as also conﬁrmed by the deconvoluted
spectra (panel H shows the deconvoluted spectra HSA incubated in the
presence of HNE at a 1:5 M ratio). At higher HNE molar ratios (1:100,
1:200 and 1:1000, panels E, F and G, respectively) the MS spectra do
not show any detectable peaks due the formation of such a large
number of adducts and consequently of so many ions which cover the
m/z scan range thus eliminating the detection of sharp ions.
Intact protein analysis was also performed on ALEs-lipox formed by
incubating HSA with ACR and MDA, showing the same stepwise in-
crease of modiﬁcations with the higher amount of RCS incubated with
HSA (Supplementary Figs. 1 and 2).
Intact protein analysis well indicates that by using a wide range of
molar ratios and diﬀerent time-points a quite wide array of ALEs for
each tested RCS was generated.
3.2. Pull-down assay with modiﬁed albumins
In order to characterize ALE-lipox modiﬁcations selectively en-
riched by RAGE, we performed a VC1 pull-down assay as previously
described [20]. HSA and HSA treated with MDA, ACR or HNE were
assayed for binding to VC1-resins and to control resin. As expected,
unmodiﬁed HSA was not retained by the VC1-resin (Fig. 3, panel A).
HSA modiﬁed by MDA and ACR are characterized by a diﬀerent mi-
gration pattern on a SDS-PAGE analysis, with the appearance of oli-
gomeric bands proportional to the increase of the HSA-RCS molar ratio
(Fig. 3, panel B: HSA-MDA at 72 h, panel D: HSA-ACR 72 h, panel F:
HSA-HNE 72 h). At increasing molar ratios and incubation time, higher
amounts of albumin modiﬁed with MDA or ACR were eluted from the
VC1 resin, with a predominance of the high molecular weight (HMW)
species. The modiﬁed albumins were retained by the VC1-resin, but not
by the control resin, as shown in Fig. 3 (panel C: HSA-MDA molar ratio
1:12,600, 72 h; panel: E HSA-ACR molar ratio 1:5000, 72 h, panel: G
HSA-HNE molar ratio 1:2000, 72 h). The time course analysis and the
pull-down experiments with HSA-MDA have previously been published
[20]. The time course analysis and the pull-down experiments with
HSA-ACR and HSA-HNE are reported in Supplementary Fig. 3 and
Supplementary Fig. 4 respectively.
3.3. Identiﬁcation and localization of protein adducts by mass spectrometry
ALEs-lipox in the reaction mixtures and those enriched by VC1 were
analyzed by bottom-up MS in order to identify the PTMs and to localize
the amino acid residues involved in the protein adduct formation.
Tables 1 and 2 summarize the identiﬁed ALEs before and after VC1
enrichment, respectively. It should be noted that the tables summarize
the overall PTMs identiﬁed at diﬀerent molar ratios and incubation
times. The ALEs not retained (identiﬁed only in the input samples),
retained (identiﬁed after VC1 enrichment) and present in both input
and elution samples are reported in the Venn diagrams of Fig. 4.
With regard to MDA (Table 2), only di-hydropyridine adducts on
lysines (DHPK), and N-2-pyrimidyl-ornithine adducts on arginines
(NPO) were retained by VC1-domain. The n-propenal modiﬁcations of
lysine (NPK), largely identiﬁed before enrichment, were not identiﬁed
after the enrichment.
ACR induced a set of modiﬁcations which were identiﬁed only after
VC1 enrichment and in particular the N-(3-formyl-3,4-dehydro-piper-
idinyl) lysine (FDPK) modiﬁcations, the Michael adduct on cysteines,
the double Michael adduct of lysines, the Michael adduct of histidine,
the N-2-(4 hydroxy-tetrahydro-pyrimidyl) ornitine (propane-arginine,
HTPO) and the Nε-(3-methylpyridinium)-lysine (MP-lysine) (Table 2).
Most of the ALEs generated by HNE were found both before or after
enrichment, with the exception of few Michael adducts which were
selectively retained by VC1 (not detected before enrichment) (Table 2).
Interestingly, a novel + 138 Da adduct was detected on Arg209 and
Arg485 with HNE (novel cyclic aduct, HNE-CY, Table 2). In agreement
with the adducts which arginine yields with other RCS (as seen for ACR
and MDA) and by considering the well-known reactivity of the guani-
dine function [see for example [28]) this adduct can be supposed to
include a 2-amino pyrimidine scaﬀold even though its precise structural
characterization would require additional studies.
3.4. Semi-quantitative analysis of ALE-HSA adducts
A semiquantitative analysis reporting the relative abundance of
each modiﬁed peptide in respect of the native peptide was then carried
out for each identiﬁed modiﬁcation in both the input (% No VC1) and
enriched samples (%VC1). The values were then used to calculate the
enrichment factor (EF) calculated as reported in the method section.
The values of the EF range between − 100 and +100, where − 100
means that the modiﬁcation has not been retained at all by the VC1
domain (it is only present in the input but not in the enriched sample),
+ 100 means that the modiﬁcation has been identiﬁed because it is
enriched by the VC1 (the modiﬁcation is not detected in the input due
to low abundance) and 0 means that they are equally distributed.
Values between 0 and + 100 indicate that the modiﬁcation is retained
by VC1 and that the retention eﬃciency increases as the value increases
above 0.
In Fig. 5, panels A, B and C show the EF for ALEs-lipox obtained by
using MDA, ACR and HNE, respectively. Regarding MDA, an overview
analysis indicates that most of the N-Propenal-Lys and NPO adducts are
not retained, with a few exception, while DHPK modiﬁcations sig-
niﬁcantly increase the aﬃnity of ALEs. As better described in the
computational analysis paragraph the data indicate that for MDA, VC1
aﬃnity is determined by the nature of the adduct.
In the case of ACR, with some exceptions explained in the following
paragraph, the FDPK adduct is more eﬀective in respect to the mono
and bis Michael adducts in increasing the binding towards VC1. In the
case of HNE, most of the identiﬁed adducts were not found to be ef-
fective in increasing the retention aﬃnity with the exception of few
residues.
3.5. Computational results
With a view to rationalizing the key factors inﬂuencing the RAGE
binding of the monitored adducts, in silico studies were performed. They
were focused on the adducts on arginine and lysine residues as formed
by ACR and MDA since they are numerous, with a very broad range of
aﬃnity, thus allowing the development of clear structure-aﬃnity re-
lationships.
As a preamble it should be remembered that the RAGE-ligand in-
teracting regions (i.e. the VC1 domain) are characterized by a rich set of
positively charged residues especially in the V portion: the resulting
positive RAGE surface shows an understandable non-speciﬁc aﬃnity for
acidic proteins which can bind RAGE by stabilizing extended sets of salt
bridges. On these grounds, one may ﬁgure out that a given covalent
adduct can induce RAGE binding via two major mechanisms: it can
introduce acid moieties which directly contact the RAGE residues (as
seen for example with CML and CEL adducts) or it can reduce the ba-
sicity of the adducted residues. In this second indirect mechanism, the
adducts can elicit RAGE binding mostly because they are able to de-
stabilize ionic clusters on the protein surface and to liberate negatively
charged residues which enhance their accessibility and they become
available to stabilize ion-pairs with the positive RAGE residues.
The here monitored covalent adducts do not introduce negative
functions and thus they should induce RAGE binding by the second
indirect mechanism. Such a hypothesis implies that the monitored
RAGE binding might be explained by considering two major factors: the
basicity of the formed adducts and the number of the surrounding ne-
gatively charged residues. Indeed, when the generated adduct retains a
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marked basicity which renders the protonated form still predominant at
physiological pH, the surrounding negative residues would remain
shielded around it and unavailable to contact the RAGE residues. On
the other hand, an adduct devoid of surrounding negative residues
would be unable to induce strong ionic contacts with RAGE regardless
of its basicity. On these grounds the here reported in silico analyses can
be subdivided into three steps: in the ﬁrst, the basicity of the considered
adducts was predicted by semi-empirical calculations; in the second,
Fig. 3. Modiﬁed albumin obtained by incubation of re-
combinant HSA in the presence of diﬀerent molar ratio of
RCS and VC1 pull-down assay. A) VC1 pull-down assay with
untreated HSA. SDS PAGE analysis followed by Coomassie
staining of the modiﬁed HSA obtained by 72 h incubation with
the indicated molar ratio of RCS (panel B: MDA; panel D: ACR;
panel F: HNE). The highest molar ratio of HSA-MDA
(1:12,600), HSA-ACR (1:5000) or HSA-HNE (1:2000) were
used as input (IN) in the pull-down assays with the VC1 and
control (CTRL)-resins. The IN fractions, the unbound fractions
(UNB) and eluates (E) were analyzed by SDS-PAGE followed
by Coomassie staining. The gels show that untreated HSA does
not bind VC1 (panel A), whereas high MW species of HSA-
MDA (panel C), HSA-ACR (panel E) and HSA-HNE (panel G)
are retained by the VC1-resin, but not by the CTRL-resin. Since
the elution is performed in denaturing conditions, this step
removes any associated molecule from the resin, including the
two VC1 glycovariants (34 and 36 kDa) and streptavidin (Stv,
14 kDa), indicated by arrows.
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the number of surrounding negative residues was calculated by using
the reﬁned HSA structure and by considering the number of aspartates
and glutamates in a 5 Å radius sphere around each adducted residue.
Finally, protein-protein docking simulations were performed by con-
sidering the V-domain of RAGE and the adducted HSA structures. For
simplicity, the docking simulations involved the HSA structure in-
cluding simultaneously all found adducts. Such a strategy clearly re-
duces the computational time and allows synergistic eﬀects between
adjacent adducts to be revealed.
Fig. 6 shows the ALEs structures and for some of them reports the
predicted basicity for the considered adducts and reveals that they can
be subdivided into two main groups depending on whether they retain
part of the basicity of the unmodiﬁed residues or become non-ionizable
derivatives at physiological conditions. When focusing attention on
arginine adducts, N-2-pyrimidyl-ornithine (NPO, from MDA) is com-
pletely neutral at physiological pH, while HTPO retains a large part of
the arginines strong basicity. Similarly, and with regard to lysine ad-
ducts, the DHPK adduct (from MDA) is a neutral adduct, the single
Michael adduct (N-Propenal lysine, from MDA) is slightly less basic
than lysine (Δ=−0.6), while the double Michael adduct and the FDPK
derivative (from ACR) show a similarly reduced basicity (Δ=−2.0)
compared to the unmodiﬁed residue. In other words, and at physiolo-
gical conditions, one may assume that (a) RP and DHPK adducts are
always neutral, (b) HTPR and NP-lysine are still protonated, (c) double
MA and FDPK are in equilibrium between the two forms and the neutral
state can play a signiﬁcant role.
This simple observation can explain: (a) why NPO is the only argi-
nine adduct (considering both MDA and ACR) which shows some aﬃ-
nitive residues; (b) why the DHPK adducts show a retention eﬃciency
markedly higher than N-propenal-lysines (among the MDA-induced
lysine adducts) and (c) why double MA and FDPK show a comparable
retention eﬃciency (among the ACR-induced lysine adducts). In gen-
eral, one may conclude that the ionization properties of the monitored
adducts play a pivotal role in determining their overall aﬃnity towards
RAGE, while the binding of each single adduct might be rationalized by
considering its speciﬁc environment as discussed below.
Table S2 (supplementary material) compiles the number of negative
residues included within a 5 Å radius sphere around each adducted
residue and allows for some insightful considerations. With regard to
neutral arginine adducts (NPO), Table S2 (supplementary materials)
clearly evidences that the two highly aﬃnitive adducts are surrounded
by a markedly higher number of negative residues (5 for Arg10 and 4
for Arg472). Interestingly the other three NPO adducts showing a po-
sitive EF value (Arg117, Arg337 and Arg428) show 2 surrounding ne-
gative residues while all adducts with negative EF value show at most 1
residue.
The compiled results for lysine adducts appear to be less clear even
though one may observe that almost all aﬃnitive adducts possess more
than 2 surrounding residues. The more diﬃcult interpretability of the
data concerning the lysine adducts can be explained by considering that
(a) they include diﬀerent adducts with diﬀerent ionization properties
and (b) some adducts (e.g. DHPK) can be directly involved in RAGE
binding, thus requiring less surrounding negative residues. Moreover
and due to the very high number of adducted lysines one may ﬁgure out
synergistic eﬀects between adjacent lysine adducts which may generate
very extended ionic networks not conveniently described by con-
sidering 5 Å radius spheres.
Taken together, the obtained results seem to conﬁrm that the MDA
Table 1
List of the PTMs identiﬁed on the indicated Amino acid residues in the ALEs samples obtained by in vitro incubation of HSA with RCS.
PTMs Amino Acid residue
MDA N-propenal-Lysine (NPK) Lys12, Lys20, Lys41, Lys162, Lys174, Lys212, Lys225, Lys233, Lys140, Lys262, Lys274, Lys281, Lys323, Lys359, Lys351,
Lys372, Lys378, Lys389, Lys402, Lys414, Lys466, Lys475, Lys500, Lys525, Lys545, Lys564, Lys573, Lys574
dihydropyridine-lysine (DHPK) Lys41, Lys174, Lys225, Lys233, Lys274, Lys276, Lys313, Lys323, Lys359, Lys378, Lys389, Lys402, Lys466, Lys500,
Lys519, Lys545, Lys573
N-2-pyrimidyl-ornithine (NPO) Arg209, Arg218, Arg144, Arg145, Arg257, Arg337, Arg484
ACR Michael Adduct (N-propanal derivative) (ACR-
MA)
His39, Cys75, His128, Cys169, His338, Cys392, His510
N-2-(4 hydroxy-tetrahydro-pyrimidyl) ornitine
(propane-arginine, HTPO) Arg209, Arg257, Arg337
N,N-bispropenal-Lysine (2ACR-K-MA) Lys41, Lys73, Lys174
N-(3-formyl-3,4-dehydro-piperidinyl) lysine
(FDPK)
Lys174, Lys225, Lys233, Lys274, Lys323, Lys372, Lys378, Lys389, Lys500
HNE Michael adduct (HNE-MA) His105, Lys106, His242, His288, His338, Arg428
Schiﬀ Base (HNE-SB) Lys106
Novel cyclic adduct (HNE-CY) Arg209
2-pentyl-pyrrole (PP) Lys106
2,3 dihydro-pentyl-furan (DHPF) Cys53, His105, Cys448, Cys487
Table 2
List of the PTMs identiﬁed on the indicated Amino acid residues in the ALEs-HSA samples retained by VC1.
PTMs Amino Acid residue
MDA dihydropyridine-lysine (DHPK) Lys41, Lys51, Lys195, Lys205, Lys233, Lys274, Lys276, Lys313, Lys359, Lys378, Lys389,
Lys414, Lys432, Lys436, Lys466, Lys500, Lys541, Lys545, Lys560, Lys564, Lys574
N− 2-pyrimidyl-ornithine (NPO) Arg10, Arg117, Arg144, Arg257, Arg337, Arg428, Arg472
ACR Michael Adduct (N-propanal derivative) (ACR-MA) Cys200, His338, His510
N− 2-(4 hydroxy-tetrahydro-pyrimidyl) ornitine (propano-arginine,
HTPO)
Arg337
N,N-bispropenal-Lysine (2ACR-K-MA) Lys41
N-(3-formyl−3,4-dehydro-piperidinyl) lysine (FDPK) Lys225, Lys233, Lys262, Lys274, Lys323, Lys372, Lys378, Lys389, Lys500, Lys545
N-(3-Methylpyridinium)-lysine (MPK) Lys 233
HNE Michael adduct (HNE-MA) His105, Lys106, His242, Cys289, His288, His338, Arg428
Schiﬀ Base (HNE-SB) Lys106
Novel cyclic adduct (HNE-CY) Arg485
2-pentyl-pyrrole (PP) Lys106
2,3 dihydro-pentyl-furan (DHPF) His105, Cys476, Cys477, Cys487
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and ACR-induced adducts act as RAGE binders mostly when they occur
in their neutral state at physiological pH and thus they are able to de-
stabilize ionic clusters on protein surface and to liberate negatively
charged residues which are no longer shielded and expose their car-
boxylate groups with a sort of “ﬂowering eﬀect” which promotes ion-
pairing between adducted HSA and RAGE. With a view to conﬁrming
the supposed binding mechanism, the last part of these in silico studies
involved protein-protein docking simulations which were performed to
generate the corresponding RAGE-adducted HSA complexes. While
avoiding a systematic analysis of all simulated HSA adducts, some re-
presentative putative complexes will be presented in order to further
corroborate the proposed mechanism and to gain deeper insights on the
involved interactions.
Fig. 7 (panel A) shows the putative complex as computed for the
most aﬃnitive NPO adduct (Arg472, from MDA) and reveals that the
several negative residues surrounding the adduct are involved in an
extended network of ion-pairs with the RAGE residues. In detail,
Asp494 and Glu495 approach Arg70 of RAGE while Glu492 contacts
RAGE-Lys90. Interestingly and although the RAGE surface is rich in
positive residues, the complex also shows a salt bridge in which the
positive residue comes from the HSA surface as seen in the salt bridge
between RAGE-Glu88 and Arg410. It should be noted that also the si-
mulated NPO adduct is found to elicit a charge transfer interaction with
Fig. 4. Venn diagrams of the identiﬁed ALEs as reported in Table 1 and 2.
ALEs are reported as the modiﬁed amino acid residues. The upper diagram
refers to ALEs obtained by treating HSA with MDA, the middle with ACR and
the lower with HNE. The input reports ALEs not retained by VC1 and present
only in the input samples; VC1 are the ALEs identiﬁed only after VC1-enrich-
ment; the intersections report the ALEs found both in the input and VC1-en-
riched samples.
Fig. 5. Enrichment Factor (EF) graphical distribution. Enrichment Factor
(EF) graphical distribution by means of vertical scatter plot overviewing the
aﬃnity of each identiﬁed ALEs towards VC1; all EF values spotted have been
calculated as the diﬀerences between the relative abundance in the enriched
sample minus the amount in the untreated one (Enrichment factor= %VC1-%
NoVC1), and graphically grouped as: MDA-adducts (panel A), ACR-adducts
(panel B) and HNE-adducts (panel C).
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RAGE-Arg78. In this way, the interaction surface between HSA and
RAGE is stabilized by a rich set of ionic interactions which are clearly
promoted by the neutralization of Arg472 and which can explain the
observed RAGE binding.
Fig. 7 (panel B) shows the computed complex for a very aﬃnitive
DHPK adduct (Lys436, from MDA) and highlights the potential sy-
nergistic role between adjacent adducts as supposed above. Indeed, the
complex reveals that Lys433 is closely surrounded by several other
MDA-based adducts (i.e., DHPK432 and DHPK519 plus NPO-Arg117
and NPO-Arg428) which contribute to the overall binding by directly
interacting with the RAGE residues (see for example the reinforced H-
bonds that DHPK436 elicits with Arg78 and Arg94), and through the
surrounding negative residues (not reported in Fig. 7 for clarity). The
found ion-pairs include Arg78-Glu400, Arg94-Asp183, Lys80-Glu188
and Lys32-Glu396. Notably, all the reported adducts show a positive EF
value apart from DHPK519, whose poor results can be ascribed to the
shielding eﬀect played by the close Arg186 residue and which further
conﬁrms the key role of the ionizable surrounding residues.
Finally, Fig. 7 panel C reports the putative complex for a highly
aﬃnitive FPDK adduct (on Lys262, from ACR) and emphasizes the key
role played by the three negative residues surrounding it and which are
involved in clear ionic interactions with the positive RAGE residues.
Interestingly and despite such a favorable environment Lys262 does not
give aﬃnitive adducts with MDA. This ﬁnding can be explained by
considering that Lys262 generates only the ionized N-propenal adduct
with MDA. Such a result suggests that the ionization properties play a
largely dominant role which cannot be counteracted by the surrounding
negative residues. Remarkably, the ﬁgure describing the entire RAGE-
HSA complex shows that the ionic contacts are not limited to the region
surrounding the FPD adduct but additional salt bridges are present in
the entire contact surface. This suggests that the RAGE-HSA binding is
initially promoted by the focused set of ionic contacts which can be
stabilized around the adduct and then is reinforced by a more extended
set of additional ion-pairs which characterize the entire contact surface.
Notably, these additional contacts which do not involve adducted re-
sidues are per se unable to promote the RAGE-HSA binding but they
play a clearly beneﬁcial role in that the initial binding is triggered by
the contacts stabilized by the residues surrounding the adduct with a
sort of hierarchical mechanism which brings to mind that described for
protein folding.
Although the aﬃnity of the HNE-based adducts was not analyzed in
silico, the observed EF values of the peptides including Lys106 are in
clear agreement with the basicity of the detected adducts. Indeed, the
retention eﬃciency is found to be quite high for those adducts which
abrogate the lysine basicity (i.e. Schiﬀ base and 2-pentylpyrrole) to
markedly decrease when the adduct only slightly reduces the basicity as
in the Michael adduct.
Even though HSA is not the ideal protein target to study in-depth
the RAGE binding on cysteines since most HSA cysteines are involved in
disulﬁde bridges, the general incapacity of the cysteine adducts to bind
RAGE can be clearly rationalized in terms of the proposed ﬂowering
eﬀect. Carbonylation of cysteines does not result in neutralization of
Fig. 6. Chemical structures of ALEs-lipox formed by incubating HSA with MDA, ACR and HNE and identiﬁed by MS. For some ALEs the pK values are reported in
brackets.
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positively charged residues but conversely it can neutralize particularly
acid cysteines with an opposite and unfavorable electron-deﬁcient ef-
fect on the protein surface
4. Discussion
Much evidence indicates that the pro-inﬂammatory and pro-ﬁbrotic
eﬀects of AGEs and AGEs/ALEs are due, among other mechanisms, to
RAGE binding and activation [18,29–31]. The engagement mechanisms
between AGEs and RAGE are still not fully elucidated and great scien-
tiﬁc interest is now focused on understanding which are the structural
moieties of AGEs that turn a protein to a RAGE binder and hence to a
pro-inﬂammatory mediator. The study is further complicated by the
fact that AGEs and AGEs/ALEs are characterized by a wide
heterogeneity not only due to the variability of the adducted moieties
which diﬀer on the basis of the attacking RCS but also due to the
variable target protein and sites of modiﬁcation.
A rich set of positively charged residues represents a structural
feature of RAGE which could explain its binding properties with ligands
[32]. In particular such positive charges result in a positive RAGE
surface, which drives the engagement with ligands characterized by
acidic or in general negatively charge residues, able to stabilize the
protein-protein interaction by an extended set of salt bridges [33].
While considering that the RAGE binding is clearly promoted by those
AGEs/ALEs, which are characterized by the presence of carboxylic
moieties such as CML and CEL [13], the mechanisms, by which a local
and structurally limited modiﬁcation, such as that induced by a AGE/
ALE adduct, can trigger the RAGE aﬃnity in large biomacromolecules,
Fig. 7. Putative RAGE-HSA complex as computed by protein-protein docking and induced by RP-Arg472 (6 A), DHPK-Lys436 (6B) and FDP-Lys262 (6 C). For each
simulated adduct, the right panel shows the entire RAGE-HSA complex while the left panel focuses on key interactions stabilized by the adduct and its surrounding
residues.
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are still not precisely understood. This lack of understanding is even
more pronounced when considering that many AGEs and almost all
ALEs (see below) do not introduce acid functions but at most they
modulate the basicity of the adducted residues.
While on one hand several studies have reported on the engagement
between AGEs and AGEs/ALEs on VC1 and RAGE, on the other, little is
known about the eﬀect of ALEs from RCS formed only by lipid perox-
idation such as HNE, MDA and ACR. These ALEs, here called ALEs-
lipox, are formed abundantly in several oxidative based conditions and
their damaging property has been widely reported. Several molecular
mechanisms have been suggested to explain the ALEs-lipox damaging
eﬀect and among these are protein dysfunction, protein oligomeriza-
tion, signal transduction and immune response [19]. Moreover, by
considering a pro-inﬂammatory and pro-ﬁbrotic response induced by
ALEs-lipox, a RAGE dependent mechanism could also be considered.
In the present report we have evaluated the binding property of a
wide set of ALEs-lipox formed by incubating HSA with the three most
abundant lipid peroxidation RCS, namely HNE, ACR and MDA. The
wide set of modiﬁcations were achieved by incubating the target pro-
tein with RCS at diﬀerent molar ratios and time points as conﬁrmed by
MS intact protein analysis.
The high concentrations of the aldehydes and in particular their
content in high molar excess in respect to the substrate, very far from
biological conditions, were used in order to obtain the maximum
number of adducts which can be generated from the reaction of RCS
with the protein substrate. Although the resulting ALEs are not char-
acterized by acid moieties, as reported in the literature and here con-
ﬁrmed by bottom-up analyses, we found using a VC1 pull-down assay
that some of the generated ALEs bind to the VC1. This is a quite novel
ﬁnding since to our knowledge no study has so far reported the ability
of ALEs from lipid peroxidation RCS to interact with VC1. The VC1
binding assay coupled to a high resolution MS approach has also per-
mitted the identiﬁcation of which ALEs moieties are responsible for the
VC1 binding and the sites of modiﬁcation. The wide set of data and in
particular the chemical diversity of the structures identiﬁed as binder
and non binder, have also permitted a SAR study leading to the mole-
cular explanation of why only some ALEs bind to VC1. As shown in
Fig. 8, besides the well known VC1 engagement based on the acid re-
sidues of the protein ligand, we here found another potential me-
chanism which may involve adducts that do not introduce acid groups
but only reduce the basicity of the modiﬁed residues. The mechanism,
called the ﬂowering eﬀect, is based on a two-step process and involves
exposed basic residues (mainly Lys and Arg) which in the non-adducted
protein form a set of ionic bridges with the carboxylic groups of sur-
rounding aspartate and glutamate residues. In the ﬁrst step, the RCS
form a covalent adduct with the positively charged residues, abolishing
or greatly reducing their basicity. Consequently, the adducted residues
are present in their neutral form at physiological conditions and such a
change in their ionization state destabilizes the ionic bridges and ren-
ders the surrounding anionic residues more accessible and available to
stabilize ion-pairs with the positive RAGE residues. Such a mechanism
explains why only one set of the identiﬁed ALEs acts as RAGE binder. In
other words we found the basic features that make an ALE a RAGE
binder and which strictly depend on the type of the adduct and on the
site of modiﬁcation. In particular we found that only some of the sev-
eral adducts formed by lipid peroxidation RCS abolish or greatly reduce
the basicity of the target amino acids and among these RP (from MDA)
and DHPK adducts are always neutral while HTPR, MA-Arg and NP-
lysine do not aﬀect the basic character. The second requirement is the
presence of a cluster of negative side chains surrounding the target
residue, which then becomes available to RAGE positive charges once
the amino acid is modiﬁed, thus stabilizing the protein-protein com-
plex.
We currently do not know whether ALEs-VC1 binding elicits RAGE
activation and hence if they lead a RAGE-dependent biological re-
sponse. Some studies such as that by Shanmugam et al. [34] reporting
that ALEs from MDA can induce a RAGE dependent biological response,
would suggest this. We are now working on this aspect by using cell
models and ALEs enriched by the VC1 assay as potential RAGE acti-
vators.
5. Conclusions
In summary by using an integrated MS (intact protein and bottom-
up approach) and computational approach we have found that some
ALEs generated from lipid peroxidation RCS are RAGE binders. We
have also found the basic features that ALEs from HNE, MDA and ACR
must have to be a RAGE binder: 1) the covalent adducts should greatly
reduce or abolish the basicity of the target amino acid, 2) the basic
amino acid should be at the center of a set of carboxylic acids which,
once the residue is modiﬁed, become available to freely contact the
RAGE positive residues. Interestingly, the here proposed ﬂowering eﬀect
can also be involved in the RAGE binding of the adducts which insert an
acid function. Indeed and besides the direct contacts stabilized by the
adduct, one may suppose that introduced anionic function exerts a si-
milar eﬀect on the surrounding negative residues thus promoting their
ionic interactions with the positive residues on RAGE surface. Stated
diﬀerently, the ﬂowering eﬀect might be a common mechanism trig-
gering the aﬃnity of adducted proteins towards RAGE even though it
signiﬁcantly increases its relevance for the adducts that do not add
Fig. 8. Mechanism explaining AGEs/ALEs
and ALEs-lipox binding to VC1. A) VC1 en-
gagement based on the acid residues of the
protein ligand. Such a mechanism occurs when
RCS, such as GO and MGO react with the basic
residue forming a carboxylated adduct (CML
and CEL) which directly contacts the RAGE
residues. B) Panel B summarizes the me-
chanism described in the present paper for
explaining the binding of ALEs-lipox to VC1
and called the “ﬂowering eﬀect”. It is based on a
two-step process and involves exposed basic
residues (mainly Lys and Arg) which in the
non-adducted protein form a set of ionic
bridges with the carboxylic groups of sur-
rounding aspartate and glutamate residues.
Lipid peroxidation derived RCS react with the
basic residue and abolish or greatly reduce
their basicity. Consequently, the adducted re-
sidues shift in a neutral form and such a change in the ionization state destabilizes the ionic bridges and renders the surrounding anionic residues more accessible and
available to stabilize ion-pairs with the positive RAGE residues.
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carboxylic functions such as those as seen here.
Moreover, one may expect that such a mechanism can modulate the
aﬃnity of carbonylated proteins towards a variety of target proteins not
necessarily limited to RAGE. More generally and since a similar me-
chanism was proposed to explain the protein-protein interactions trig-
gered by the acetylation of lysines, one may hypothesize that the ionic
perturbation of the protein surface, that shifts from a polyzwitterionic
situation to a polyanionic or polycationic condition, can be a general
mechanism, by which post translational modiﬁcations involving ioniz-
able side chains modulate the interacting capacity of the modiﬁed
proteins.
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 Appendix A 
 
 
Supplementary Figure 1. Direct infusion ESI-MS analysis of native and ACR-modified HSA. Spectra 
of HSA with charge 47 + , 46 + and 45 + are shown. A) Native HSA shows a sharp intense peak with 
multiple low abundant peaks. When HSA is reacted with increasing concentrations of ACR, 1: 10 
(B), 1: 100 (C), 1: 1000 (D), 1: 2500 (E) and 1: 5000 (F), the sharp peak diminishes and new peaks 
appear, confirming that HSA has been modified with different adducts of ACR. 
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Supplementary Figure 2. Direct infusion ESI-MS analysis of native and MDA-modified HSA. Spectra 
of HSA with charge 47 + , 46 + and 45 + are shown. A) Native HSA shows a sharp intense peak with 
multiple low abundant peaks. When HSA is reacted with increasing concentrations of MDA, 1: 6.3 
(B), 1: 63 (C), 1: 630 (D), 1: 6.300 (E) and 1: 12.600 (F), the sharp peak diminishes and new peaks 
appear, confirming that HSA has been modified with different adducts of MDA. 
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Supplementary Figure 3: Time course analysis of the dose-dependent modification of HSA by ACR. 
Recombinant HSA was incubated with increasing concentrations of ACR (molar ration HSA-ACR 
from 1:10–1:5000) as reported in Materials and methods. At 24, 48 and 72 h of incubation, aliquots 
were withdrawn and after removal of free acrolein, pull-down assays with the VC1-resin or control 
(CTRL)-resin were performed. A specific binding of both the monomer of modified HSA and of the 
HMW-species to the VC1-resin was detected at increasing concentrations, starting from the molar 
ratio 1:1000. 
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Supplementary Figure 4: Analysis of the dose-dependent modification of HSA by HNE. Recombinant 
HSA was incubated with increasing concentrations of HNE (molar ration HSA-HNE from 1:10–
1:2000) as reported in Materials and methods. At 24, 48 and 72 h of incubation, aliquots were 
withdrawn and after removal of free HNE, pull-down assays with the VC1-resin or control (CTRL)-
resin were performed. A specific binding of modified HSA to the VC1-resin was detected at 
increasing concentrations, starting from the molar ratio 1:200. At 1:1000 is evident the interaction 
with VC1 of both the monomer of modified HSA and the HMW-species. 
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 Table S1. Known (literature based) covalent adducts induced by HNE, MDA and ACR and set as 
variable modifications within the PD parameters for the identification and localization of ALE-
deriving adducts. 
HNE 
PTM AA Res. Involved ΔM 
Michael adduct (HNE-MA) 
Cys 
His 
Lys 
Arg 
+ 156.110502 Da 
Schiff Base (HNE-SB) Lys Arg + 138.01446 Da 
2-pentilpyrrole (PP) Lys Arg + 120.0939 Da 
Dehydropentylfuran (DHPF) 
Cys 
His 
Lys 
Arg 
+ 138.10446 Da 
MDA 
PTM AA Res. Involved ΔM 
N-propenal-Lysine (NPK) Lys  + 54.01056 Da 
Di-dihydropyridine-lysine (DHPK) Lys + 134.03678 Da 
Malondialdehyde argpyrimidine(MDA-RP) Arg + 36.0000 Da 
ACR 
PTM AA Res. Involved ΔM 
Michael Adduct (propanal derivative) (ACR-
MA) 
Cys 
+ 56.02621 Da Lys 
His 
Hydroxy-tetra-hydropyrimidine (Propane-
arginine) (HTPR) (HTPR) Arg + 56.02621 Da 
Double Michael Adduct (2ACR-KMA) Lys + 112.05243 Da 
Schiff Base (ACR-SB) Lys + 38.01565 Da 
Formyl-dehydro-piperidyl-lysine (FDPK) Lys + 94.04186 Da 
Methylpyridine-lysine (MPK) Lys + 77.03912 Da 
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 Table S2 - Number of negatively charged residues found within a 5Å radius sphere around the 
adducted residues 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Adducted 
residue 
n. of negative 
residues 
Adducted 
residue 
n. of negative 
residues 
Arg 10 5 Lys 276 2 
Arg 117 2 Lys 281 2 
Arg 144 1 Lys 313 2 
Arg 145 1 Lys 323 2 
Arg 209 1 Lys 351 2 
Arg 218 1 Lys 359 2 
Arg 257 1 Lys 372 3 
Arg 337 2 Lys 378 4 
Arg 428 2 Lys 389 2 
Arg 472 4 Lys 402 1 
Arg 484 0 Lys 414 2 
Lys 12 2 Lys 432 2 
Lys 20 5 Lys 436 2 
Lys 41 3 Lys 466 1 
Lys 51 2 Lys 475 1 
Lys 106 2 Lys 500 2 
Lys 162 2 Lys 519 2 
Lys 174 1 Lys 525 3 
Lys 195 1 Lys 541 2 
Lys 205 1 Lys 545 3 
Lys 212 1 Lys 560 3 
Lys 225 2 Lys 564 3 
Lys 233 1 Lys 573 2 
Lys 240 3 Lys 574 2 
Lys 262 3   
Lys 274 3   
115
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter VI: Analysis of AGEs/ALEs in 
plasma samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This Chapter will be submitted to Free Radical Research entitled: “Identification of low-
abundant AGEs/ALEs in plasma of heart-failure patients using Orbitrap Fusion.”.  
Publication expected: December 2019.  
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 Chapter VI – Analysis of AGEs/ALEs in plasma samples 
Abstract 
Advanced Glycation/Lipoxidation End Products (AGEs/ALEs) are protein adducts arising from 
oxidative degradation pathways and have been described in the onset/progress of many 
pathologies, including diabetes and cardiovascular diseases. Many techniques have been set up 
already in order to identify and characterize AGEs/ALEs, nonetheless it remains very challenging 
since they are contained in very low amounts in plasma samples. Previously, we set up the VC1 
pull-down, based on the Receptor for Advanced Glycation End Products (RAGE), to enrich 
AGEs/ALEs in-vitro. This project focused on validating the use of this technique for ex-vivo 
samples, such as healthy human plasma oxidized by the radical initiator AAPH, or incubated with 
RCS directly to produce AGEs/ALEs. Unfortunately, the VC1 pull-down with the current methods 
was not sufficient for identifying AGEs/ALEs. Therefore, other parameters were optimized 
throughout the sample preparation and analysis, including the use of the newest generation MS 
and solely focusing on HSA. For this purpose, plasma of heart failure patients was used, 
characterized by an increase of circulating AGEs/ALEs, and we determined 21 unique AGEs/ALEs 
in heart failure patients compared to control subjects. In conclusion, this project describes for the 
first time a large number of identified protein adducts in plasma samples. 
6.1. Introduction 
The identification and characterization of Post-Translational modifications (PTMs) has become 
more important over the last decades due to increasing exogenous influences, including exposure 
to UV light, tobacco smoke, exhaust fumes and ingestion of processed foods. Exposure to UV 
light causes direct oxidation, whereas tobacco smoke, exhaust fumes and processed foods 
contain many reactive carbonyl species (RCS) and/or reducing sugars. These compounds can 
adduct for example proteins, forming the so-called Advanced Glycation/Lipoxidation End Products 
(AGEs/ALEs). AGEs/ALEs can lead to detrimental effects as described already in many 
pathologies, such as diabetes, cardiovascular and neurodegenerative diseases. Therefore, much 
research is focused on optimizing methods for easier detection of AGEs/ALEs, since they are 
present in very low amounts, yet can contribute to disease onset and/or progression. Due to the 
low presence, various enrichment techniques have been described to aid the identification, like 
the aldehyde reactive probe (ARP) which have been shown to be successful in enriching 
carbonylated proteins/peptides from samples [1]. However, AGEs/ALEs also contain chemical 
moieties without a carbonyl and therefore will be missed by this enrichment. Previously, we have 
set-up a functional enrichment procedure, based on an affinity chromatography technique using 
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 the Receptor for Advanced Glycation End Products (RAGE) [2]. This enrichment technique, the 
VC1 pull-down assay, has shown positive results for enriching well-known in-vitro produced 
AGEs/ALEs [3]. Nevertheless, it is still unclear whether circulating AGEs/ALEs in plasma can be 
enriched using this technique. Furthermore, it remains to be elucidated which proteins turning into 
AGEs/ALEs become a binder for RAGE and most likely contribute to the particular pathology. 
Besides enrichment strategies, very sensitive mass spectrometers are vital in order to obtain a 
comprehensive characterization of AGEs/ALEs. Much progress has been made since the 
introduction of the most sensitive mass analyzer available, the orbitrap, yet another improvement 
has increased the sensitivity of identifying peptides with the introduction of the newest generation 
of tribrid mass spectrometers [4]. The Orbitrap Fusion provides besides the increased resolution, 
also faster MS detectors, parallel scanning and detection mechanisms and multiple fragmentation 
technique, which can aid the identification of PTMs. This combination makes the Orbitrap tribid 
MS by far the best instrument for identifying and characterizing AGEs/ALEs. 
Good models are essential for validating the use of new enrichment techniques or instruments. 
Such as inducing the production of AGEs/ALEs in healthy human plasma in-vitro. 2,2'-Azobis(2-
amidinopropane) dihydrochloride (AAPH) is a radical initiator and could potentially lead to the 
production of RCS in plasma and the subsequent adduction to proteins forming AGEs/ALEs. 
Likewise, plasma could be directly incubated with the most abundant RCS known, such as 4-
hydroxy-2-nonenal (HNE), malondialdehyde (MDA) and acrolein (ACR). Preferably, plasma 
samples from different pathologies would be the best model, known to have an increase in 
AGEs/ALEs, since forcing oxidation in-vitro could lead to an excess of AGEs/ALEs, and/or non-
physiological AGEs/ALEs. For this purpose, plasma samples from heart-failure (HF) patients 
would be more accurate to use for better validation of the methods, due to the physiological 
increase of AGEs/ALEs in these patients [5]. HF is characterized by the decrease in blood flow 
due to degeneration of the heart muscle that can be caused by various reasons, including 
myocardial infarction, coronary artery disease, high blood pressure and more. AGEs can 
contribute to the disease either via cross-links of extracellular matrix proteins or by interacting with 
AGE-receptors. 
This study aimed to validate the enrichment technique, VC1 Pull-Down, and to identify novel 
AGEs/ALEs as RAGE binders. Furthermore, the Orbitrap Fusion was used for extensive mapping 
of AGEs/ALEs due to the better performance of the instrument. 
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 6.2. Materials and methods 
6.2.1. Reagents 
Formic acid (FA), trifluoroacetic acid (TFA) and acetonitrile (ACN) were LC-MS grade; sodium 
dodecyl sulfate (SDS), ammonium bicarbonate, malondialdehyde tetrabutylammonium salt 
(MDA), acrolein (ACR), glyoxal (GO), methylglyoxal (MG), HEPES, NaCl, sodium 
dihydrophosphate, disodium phosphate, 2′,7′-Dichlorofluorescin diacetate (DCFH-DA), 2,2'-
Azobis(2-amidinopropane) dihydrochloride (AAPH) and all other chemicals were analytical grade 
and purchased from Sigma-Aldrich (Milan, Italy). 4-Hydroxy-2-trans-nonenal dimethylacetal (HNE-
DMA, catalog Number H9538) and recombinant HSA expressed in P. pastoris were purchased 
from Sigma Aldrich (Milan, Italy). Streptavidin- coated magnetic beads (Streptavidin Mag 
SepharoseTM) were purchased from GE Healthcare (Milan, Italy). Protein carbonyl fluorometric 
assay kit and protein carbonyl immunoblot kit were purchased from Cell Biolabs-OxiSelectTM (San 
Diego, USA). Ultrapure water was prepared by a Milli-Q purification system (Millipore, Bedford, 
MA, USA). Any KD TM Mini Protean® TGX TM precast gel, Standard Precision Plus prestained 
protein standards, Laemmli sample buffer (2 ×/ 4 ×), Running buffer and Bio-Safe Coomassie, 
together with the threo-1,4- Dimercapto-2,3-butanediol (DTT) and iodoacetamide (IAA) were sup- 
plied by Bio-Rad Laboratories, Inc. PierceTM Albumin Depletion Kit was purchased from Thermo 
Fisher Scientific (Milam, Italy). Trypsin and chymotrypsin sequencing grade was purchased from 
Roche Diagnostics SpA (Monza, Italy). Digestion buffer was 50mM ammonium bicarbonate; 
destaining solution was prepared mixing acetonitrile with digestion buffer (1:1 v/ v); reducing 
solution was 10 mM DTT in digestion buffer; alkylating solution was 55 mM iodoacetamide in 
digestion buffer; extraction solution was prepared as follows: 3% TFA/30% ACN in H2O MilliQ. 
6.2.3 Blood collection 
Blood was collected from a subset of healthy subjects (8) and HF stage III patients (9) matched 
according to their age, sex, and clinical characteristics. Blood was collected into pre-cooled 
sample tubes containing EDTA and immediately spun down for 10 minutes, 2000 × g, at 4 °C to 
obtain plasma as supernatant. Plasma of healthy individuals was pooled and marked as control. 
Also plasma of HF patients was pooled and marked as HF. 
6.2.4 In-vitro oxidation of plasma 
Blood was collected from two healthy individuals into pre-cooled sample tubes containing EDTA 
and immediately spun down for 10 minutes, 2000 × g, at 4 °C to obtain plasma as supernatant. 
Plasma samples were pooled and diluted in PBS containing different concentrations of AAPH and 
incubated in the dark at 37°C while shaking at 450 rpm. At different timepoints, the reactions were 
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 stopped by removing excess of AAPH by ultrafiltration using Amicon Ultra filter units 0.5 ml, cut-
off 3 kDa (Millipore). Bradford assay was used to determine protein concentration, and samples 
were used immediately or stored at -80°C. 
6.2.5 Plasma incubation with RCS 
Different concentrations of HNE, ACR, GO, MG and MDA were added to plasma samples 
separately and incubated in the dark at 37°C while shaking at 450 rpm. After 6 hours, the reactions 
were stopped by removing excess of each RCS by ultrafiltration using Amicon Ultra filter units 0.5 
ml, cut-off 3 kDa (Millipore). Differently treated plasma samples were pooled together and Bradford 
assay was used to determine protein concentration. Samples were used immediately or stored at 
-80°C. 
6.2.6 Measurement of plasma oxidation 
Plasma oxidation was measured fluorometrically using DCFH [6]. DCFH was prepared from 
DCFH-DA by basic hydrolysis. Briefly 500 µl of DCFH-DA stock solution (1 mM) was mixed with 
2 ml of NaOH (0.01 N at 4°C) for 20 min. while protected from the light. The mixture was then 
neutralized with 2 ml of HCl (0.01 N), diluted with PBS to a final concentration of 10 µM and stored 
in ice for no longer than 8 h (working solution); an aliquot of 20 µl was added to 40 µl of plasma 
and then diluted to a final volume of 200 µl PBS containing different concentrations of AAPH in 
triplicate in a 96-well plate. Plasma oxidation was measured monitoring the 2-electron oxidation 
of DCFH to the highly fluorescent compound 2’,7’-dichlorofluorescein (DCF). Fluorescence was 
measured at different timepoints using a multilabel, multitask plate reader (Victor-1420 Multilabel 
Counter; Wallac, Turku, Finland) and excitation wavelength (λex) was set at 485 nm and emission 
(λem) at 535 nm.  
6.2.7 Protein carbonyl measurement 
Oxidized plasma samples were analyzed for protein carbonyl content using two different 
commercial assays, protein carbonyl fluorometric assay kit and protein carbonyl immunoblot kit 
from Cell Biolabs-OxiSelectTM (San Diego, USA). Protein carbonyls were determined 
fluorometrically (485 nm excitation/535 nm emission) following manufacturer’s instructions. 
Protein carbonyls were also determined by immunoblotting according to the manufacturer’s 
protocol. 
6.2.8 VC1 pull-down assay 
VC1-His-Strep was expressed and purified from Pichia pastoris culture supernatant as previously 
described [7]. The recombinant protein was immobilized on streptavidin-coated magnetic beads 
120
 by exploiting the affinity of the Strep tag towards streptavidin. In order to obtain the VC1-resin, 100 
μg of purified VC1-His-Strep in 340 μl of 20 mM HEPES pH 7.1, 100 mM NaCl were added to 10 
μl of packed streptavidin coated-beads, previously equilibrated with the same buffer. A volume of 
340 μl of 20 mM HEPES pH 7.1, 100 mM NaCl were added to the same amount of beads in a 
different tube in order to obtain the Control-resin. After 1 h of incubation at 4 °C on a rotary mixer, 
the unbound material was carefully removed and the magnetic beads were washed twice with 500 
μl of buffer (20 mM HEPES pH 7.1, 100 mM NaCl). The VC1- and Control- resin were incubated 
for 1 h at 4 °C with 320 μl of plasma or plasma treated with RCS at the concentration of 5 mg ml−1 
in 20 mM HEPES pH 7.1, 100 mM NaCl. The unbound material was carefully removed and the 
beads were washed three times with 500 μl of Buffer (20 mM HEPES pH 7.1, 100 mM NaCl). The 
elution was performed by boiling the beads for 5 min in 15 μl of Laemmli Sample Buffer 4x mixed 
with 400 mM DTT, then with other 15 μl of buffer (20 mM HEPES pH 7.1, 100 mM NaCl). The two 
eluates were pooled. 
6.2.9 HSA extraction 
HSA extraction was performed using the PierceTM Albumin Depletion Kit according to the 
manufacturer's recommendations. Briefly, 50μL of plasma was applied to equilibrated resin 
(25mM Tris-HCl, 75mM NaCl, pH 7.5 (equilibration/ washing buffer)) supplied in the kit and 
incubated for 2 min. at RT. Flow through was collected by centrifugation at 12,000 x g for 1 min. 
and reapplied to the column. Column was washed with 50 μL of buffer for 5 times. To elute bound 
albumin, resin was washed with 200μL of 20mM sodium phosphate, 250mM sodium thiocyanate, 
pH 7.2. Beads were spun at 12,000 x g for 1 min. and F-T was collected. This was repeated 4 
additional times. All fractions were collected and analyzed by SDS-PAGE. 
6.2.10 Reduction with sodium borohydride 
Extracted HSA was diluted to 20 µM with PBS and incubated with sodium borohydride at a final 
concentration of 5 mM. The reaction was then incubated at room temperature for 60 min. The 
reaction was stopped by removing excess of sodium borohydride by ultrafiltration using Amicon 
Ultra filter units 0.5 ml, cut-off 3 kDa (Millipore), followed by in-solution digestion. 
6.2.11 Intact protein analysis by MS 
Plasma was analyzed by direct infusion on a triple-quadrupole (TQ) mass spectrometer (Finnigan 
TSQ Quantum Ultra, ThermoQuest, Milan, Italy) equipped with an Electrospray Finnigan Ion Max 
source. For MS analyses, samples were desalted by using Amicon Ultra filter units 0.5 ml, cut-off 
10 kDa (Millipore) and washed three times with water. Samples were then diluted to 1 mg/ml with 
a final composition of CH3CN–H2O–HCOOH (30 : 70 : 0.1, v/v/v). Aliquots of 50 µl were injected 
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 into the mass spectrometer at a flow rate of 25 μl min-1 by using a ThermoQuest autosampler. 
Each sample was analyzed for 5 minutes under the following instrumental conditions: positive-ion 
mode; ESI voltage 3.5 kV, capillary temperature 350 °C, Q3 scan range 1200–1500 m/z, Q3 power 
0.4 amu, scan time 1 s, Q2 gas pressure 1.5 Torr, skimmer offset 10 V, microscan set to 3. Full 
instrument control and ESI mass spectra acquisitions were carried out by Xcalibur software 
(version 2.0.7, Thermo Fisher Scientific, Rodano, MI, Italy). Mass spectra deconvolution was 
performed using MagTran software (version 1.02) [8]. 
6.2.12 In-gel and in-solution digestion 
In-gel digestion; protein bands were excised from gels using a scalpel, finely chopped, transferred 
to a new eppendorf and washed with 200 μl of digestion buffer. An aliquot of 200 μl of destaining 
solution was added to each gel portion and heated at 37 °C for 10 min in the thermomixer (1400 
rpm); the destaining solution was then discarded and this step was repeated until destaining was 
completed. In-solution digestion; extracted HSA was diluted to 1 µg/µl with ammonium bicarbonate 
buffer. Afterwards, gel pieces or extracted HSA were incubated with 10 mM DTT at 56 °C for 1 h 
and then with 55 mM iodocetamide at room temperature for 45 min in the dark. Digestion was 
performed by overnight-incubation at 37°C with sequencing-grade trypsin (Roche) dissolved in 
digestion buffer. Samples could also be subjected to a second digestion by a sequencing-grade 
chymotrypsin for 4 h at 25 °C in the presence of calcium chloride (10 mM). In-solution digestion 
was stopped by adding 1% formic acid and desalted using µ-C18 ZipTip. In-gel digestion was 
proceeded with peptide extraction by a 10 min-incubation with extraction solution and by an 
additional 10 min-incubation with pure acetonitrile. The two in-gel digested extracts were 
combined and dried in a vacuum concentrator (Martin Christ.). Digested peptide mixtures were 
then dissolved in an appropriate volume (10 μl) of 0.1% formic acid for sample cleaning with µ-
C18 ZipTip. 
6.2.13 Mass spectrometry analyses 
Peptides were analyzed using a Dionex Ultimate 3000 nano-LC system (Sunnyvale CA, USA) 
connected to an Orbitrap FusionTM TribridTM Mass Spectrometer (Thermo Scientific, Bremen, 
Germany) equipped with a nano-electrospray ion source. Peptide mixtures were pre-concentrated 
onto an Acclaim PepMap 100 – 100 μm x 2 cm C18 and separated on EASY-Spray column, 15 
cm x 75 μm ID packed with Thermo Scientific Acclaim PepMap RSLC C18, 3 μm, 100 Å. The 
temperature was set to 35 °C and the flow rate was 300 nL min−1. Mobile phases were the 
following: 0.1% Formic acid (FA) in water (solvent A); 0.1% FA in water/acetonitrile (solvent B) 
with 2/8 ratio. Peptides were eluted from the column with the following gradient: 4% to 28% of B 
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 for 90 min and then 28% to 40% of B in 10 min, and to 95% within the following 6 min to rinse the 
column. Column was re-equilibrated for 20 min. Total run time was 130 min. One blank was run 
between duplicates to prevent sample carryover. MS spectra were collected over an m/z range of 
375-1500 Da at 120,000 resolutions, operating in the data dependent mode, cycle time 3 sec 
between master scans. Higher-energy collisional dissociation (HCD) was performed with collision 
energy set at 35 eV. 
6.2.14 Identification and localization of protein adducts 
The software Proteome Discoverer (version 2.2.0.388, Thermo Scientific, USA), implemented with 
the algorithms SEQUEST, was used to compare the experimental full and tandem mass spectra 
with the theoretical ones obtained by the in-silico digestion of the human database from human 
canonical UniProtKB/Swiss-Prot database (released in 2017-07). Trypsin was selected as the 
cleaving protease, allowing a maximum of 2 missed cleavages. Peptide and fragment ion 
tolerances were set to 10 ppm and 0.6 Da, respectively. Cysteine carbamidomethylation was set 
as fixed modification while methionine oxidation as dynamic modification in combination with a list 
of dynamic modifications as listed in Table S1. 
As a quality filter, only peptides with an Xcore value grater then 2.2 were considered as genuine 
peptide identifications. To ensure the lowest number of false positives, the mass values 
experimentally recorded were further processed through a combined search with the Database 
Decoy, where the protein sequences are inverted and randomized. This operation allows the 
calculation of the false discovery rate (FDR) for each match, so that all the proteins out of range 
of FDR between to 0.01 (strict) and 0.05 (relaxed) were rejected. 
For the localization of AGE/ALE-deriving modifications, the MS/MS spectra of modified peptides 
were manually inspected; for the confident mapping of the modification sites, spectra were 
requested to match the expected ions (b and/or y) neighboring the modified amino acid residue 
both at the N- and C-termini. 
6.2.15 pFind 
All MS/MS data were analyzed using pFind 3.1.5 in this study, in which the Open-pFind workflow 
was adopted [3]. Open-pFind consists of two search steps, one open and one restricted. First, a 
sequence tag-based strategy is used to match spectra to a much larger set of possible peptide 
sequences in the open search, and no modifications are specified initially. After this step, a 
restricted search is then performed where several key parameters, including modification types 
and protein sequence entries, are automatically set by semi-supervised machine learning based 
on the open search results. Finally, the results from both open search and restricted search are 
123
 merged together and reranked based on a new semi- supervised machine learning model similar 
to Percolator. All datasets were searched against the human database from human canonical 
UniProtKB/Swiss-Prot database (released in 2018-12) consisting of 20,408 protein sequences. 
The target-decoy approach was used to control the False Discovery Rate (FDR). Where the 
decoys were generated by reversing the target protein sequences. The Open-pFind PSM results 
were FDR controlled to be less than 1% for peptides and at the protein group level. Mass 
tolerances of precursor ions was set as ± 10 ppm and fragment ions were set as ± 20 ppm. For 
the restricted search, cysteine carbamidomethylation was set as fixed modification; methionine 
oxidation, asparagine and glutamine deamidation, and acetylation at the protein N-terminus were 
set as variable modifications.  
6.3. Results 
6.3.1 Oxidizability of healthy human plasma 
In order to identify proteins prone to be modified due to oxidative pathways, and possibly serve as 
biomarker, healthy human plasma was oxidized using the radical initiator AAPH. Plasma contains 
a huge number of antioxidants, maintaining the oxidative balance in blood. Using DCFH as a 
marker of the oxidative reaction, it could be determined at which point the anti-oxidants are 
consumed after addition of AAPH (Fig. 1A). After 80 minutes of plasma incubation with 20 mM 
AAPH, there is an increase in relative green fluorescence, corresponding to the oxidation of DCFH 
to the fluorescent compound DCF. A plateau is reached around 130 min. after addition of AAPH 
to plasma. Therefore, protein carbonyl groups, an index of protein oxidation, were measured at 
different timepoints. Plasma was incubated with 20 mM AAPH and after 0, 80, 100, 130 and 180 
min. the reaction was stopped by removing AAPH by ultrafiltration. Protein carbonyl content was 
evaluated using a protein carbonyl fluorometric assay and a protein carbonyl blot. The fluorometric 
assay shows an increase, although not correlated over time, in protein carbonyl content, the 
protein carbonyl blot shows no difference before or after oxidation (Fig. 1B and C). To determine 
the type of modification, intact protein analysis by direct infusion MS was performed to understand 
the modifications induced on HSA. Figure 1D shows the deconvoluted spectra of plasma-HSA 
incubated with AAPH for different incubation times. In non-treated plasma, t=0, the peak at 66,443 
Da corresponds to HSA, with two smaller peaks at 66,566 and 66,607 Da, approximately the mass 
shift of a cysteinylated form (+ 123, theoretical increment +119 Da) and glycated form (+ 164, 
theoretical increment + 162) respectively. When incubated with AAPH, at all timepoints, roughly 
the same peak at 66,479 Da is apparent, +36, which corresponds to the addition of 2 oxygen 
atoms (theoretical increment + 32). Since the intensity of the cysteinylated peak remain 
unchanged, it is likely that Cysteine 34, the only free cysteine in HSA, is oxidized into a sulfinic 
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 acid. These data suggest that oxidation is occurring in the plasma samples, however, there is no 
formation of AGEs/ALEs yet. 
 
Figure 1. Oxidation of plasma content using AAPH. A) Oxidation of DCFH to DCF induced by AAPH. 
The reaction mixture consisted of DCFH, the azo-compound and human plasma (1:5 with PBS). 
Samples were incubated at 37°C in the dark and at fixed times the DCF content was measured by 
fluorescence (λex 485 nm, λem 535 nm). Values are mean ± SEM. B and C) At different timepoints 
protein carbonyl content was measured using a fluorometric assay (B, values are mean ± SEM) and 
by western blot (C). D) Direct infusion ESI-MS analysis of plasma and AAPH-treated plasma. 
Deconvoluted spectrum reports a peak at 66,443 Da, corresponding to HSA. Cysteinylated (66,566 
Da) and glycated (66,607 Da) form of HSA are present in all samples. AAPH treated plasma shows 
an additional peak around 66,479 Da, suggesting the oxidation of HSA. 
6.3.2 Longer incubations with AAPH 
AAPH has proven to be successful in depleting anti-oxidants in plasma, and oxidizing plasma 
proteins, however the production of AGEs/ALEs was not observed. Therefore, an attempt was 
made at increasing the concentration of AAPH, as well as longer incubation times. Similarly, 
protein carbonyl content was evaluated using the fluorometric assay and protein carbonyl blot. As 
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 can be seen from fig. 2, protein carbonyl groups are tremendously increased in AAPH treated 
plasma. Moreover, the higher the concentration of AAPH and the longer the incubation time, the 
higher the content of protein carbonyl groups in the sample.  
 
Figure 2. Oxidation of plasma content using different concentrations AAPH and longer incubation 
times. At different concentrations AAPH and timepoints protein carbonyl content was measured 
using a fluorometric assay (A, values are mean ± SEM) and by western blot (B, C, values are mean 
± SEM).  
6.3.3 Intact protein analysis 
To link the protein carbonyl groups to the formation of AGEs/ALEs, intact protein analysis was 
performed again, focusing on HSA. Figure 3 represents the mass spectra of plasma and AAPH-
treated plasma (mass range between m/z 1400 and 1500) characterized by the three sharp 
multicharged ions at m/z 1414.83, 1445.59 and 1477.71 relative to the three multicharged ions at 
47+, 46+ and 45+ associated to HSA. When plasma was incubated with 5 mM AAPH for 24 hours, 
the main peaks have shifted and in addition, many new peaks can be detected. After 
deconvolution, the HSA peak has shifted 47 Da, which could suggest a trioxidation of the free 
cysteine group. At increasing concentrations of AAPH and prolonged incubation times, the spectra 
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 cannot be deconvoluted due to the extent of modification. Moreover, the MS spectra lose 
resolution and become flat due to the presence of multiple adducts. 
 
Figure 3. Direct infusion ESI-MS analysis of plasma and AAPH-treated plasma. Mass spectra of HSA 
recorded in a mass range between m/z 1400 and 1500. Native HSA shows sharp intense peaks 
referred to the charge ions 47+, 46+ and 45+ in untreated plasma. After incubation with increasing 
concentrations AAPH, the HSA peaks disappears due to the extent of modification. 
6.3.4 Spectral counting 
Due to the heterogeneity of the modified HSA, it could not be determined if AGEs/ALEs were 
present in the sample. Therefore, we proceeded to a bottom-up analysis to fully characterize the 
modifications present in AAPH treated plasma. Samples were run on SDS PAGE (Supplementary 
fig. 1), and in-gel digestion with trypsin and chymotrypsin was performed for digestion. Peptide 
mixtures were then analyzed using high resolution LC-MS/MS in data dependent mode. Firstly, 
data analysis was performed on Proteome Discover using a targeted method, meaning, only 
known modifications present in the database were searched for. Modifications included adducts 
by ACR, MDA, HNE, GO, MG and sugars, see full list in supplementary table 1. Surprisingly, we 
did not find an increased production of AGEs/ALEs corresponding to the increasing concentration 
of AAPH. However, data analysis demonstrated many oxidation products on amino side chains, 
such as methionine oxidation. In order to obtain a schematic overview of the induced modifications 
by AAPH, the software pFind was used. This is a search engine allowing the identification of 
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 protein modifications recorded in the database of Unimod. Unimod is a comprehensive database 
with modifications that is community supported and displays accurate mass differences related to 
the modification. Results were analyzed by spectral counting; the percentage of peptide spectra 
matches (PSMs) with the specific modification was calculated compared to the total PSMs in that 
specific sample. Figure 4 shows a few examples of different oxidative products on various amino 
acids showing the same trend, increasing percentage of identified PSMs correlating to increasing 
concentration of AAPH. Oxidation of methionine was very abundant, with 8-15% of peptides 
containing the modification. Trioxidation on cysteine was also relative abundant, with 50 mM 
AAPH being very excessive in inducing oxidation on the cysteine containing peptides. Moreover, 
the percentage of identified PSMs with carbamidomethylation on cysteine are reported to validate 
the approach, since there should not be variability between samples as it is a sample preparation 
induced modification. Indeed, the graph shows minor variation between different treated plasma 
samples. 
 
Figure 4. Spectral counting shows increased oxidation correlated over time and concentration of 
AAPH. Shown are the percentages of identified PSMs from the indicated modifications.  
6.3.5 Plasma incubation with RCS 
Using this approach, oxidizing plasma with AAPH, we did not obtain the formation of AGEs/ALEs, 
but rather amino acid side chain oxidation products. Therefore, to produce AGEs/ALEs, plasma 
was directly incubated with various concentrations of different RCS, including HNE, ACR, MDA, 
GO and MG. After 6 hours incubation, the reaction was stopped by removing RCS by ultrafiltration. 
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 To confirm adducts formation, intact protein analysis was performed to visualize HSA. Figure 5 
represents mass spectra of HSA incubated with either ACR or MDA to illustrate the formation of 
adducts. Regarding ACR, at increasing concentrations the native HSA peak almost disappears, 
confirming the formation of new species. Simultaneously a new peak appears around 66,500 Da, 
depicting the adduct of ACR with HSA. Similarly, incubation with MDA shows the formation of an 
adduct around 66,500 Da and the reduction in intensity of native HSA, though to a less extent. 
 
Figure 5. Direct infusion ESI-MS analysis of plasma and plasma incubated with ACR or MDA. Mass 
spectra of HSA recorded in a mass range between m/z 1400 and 1500. Native HSA shows sharp 
intense peaks referred to the charge ions 47+, 46+ and 45+ in untreated plasma; the deconvoluted 
spectrum reports a MW 66,449 Da. After incubation with increasing concentrations of ACR or MDA, 
spectra lose resolution due to the formation of new peaks. The HSA peak diminishes in the 
deconvoluted spectra when incubated with RCS. Shown are the cysteinylated form (a) of HSA, 
glycated form (b) and the formation of an adduct (c) with ACR or MDA. 
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 6.3.6 VC1 Pull-Down assay 
This time it was evident that AGEs/ALEs were formed by treating plasma directly with different 
RCS, due to the formation of an adduct between HSA and ACR or MDA. In order to elucidate the 
main proteins involved in AGEs/ALEs formation, and to identify AGEs/ALEs that become binder 
of RAGE, different AGEs/ALEs were pooled (plasma treated with 10 or 200 µM HNE, ACR, MDA, 
GO and MG separately) and subjected to a VC1 pull-down assay as previously described [2]. 
Figure 6 represents the three different VC1 pull-down assays performed on plasma and RCS 
treated plasma. At first sight, hardly any differences can be detected between the three different 
assays, therefore we moved forward to bottom-up MS in order to identify the AGEs/ALEs retained 
by VC1. Although in the previous chapter it was demonstrated that the VC1 pull-down assay was 
successful in retaining AGEs/ALEs when using a pure protein, HSA, in a complex mixture like 
plasma, no AGEs/ALEs were identified using MS. 
 
Figure 6. VC1 pull-down assay on plasma and plasma incubated with different ratios of RCS. The 
input fractions (IN), the unbound fractions (UNB) and eluates (E) were analyzed by SDS-PAGE 
followed by Coomassie staining. The gels show the same elution profile compared between plasma 
and plasma treated with RCS with some proteins retained by VC1 around 60 and 75 kDa, and to a 
less extent by the control resin. Since the elution is performed in denaturing conditions, this step 
removes any associated molecule from the resin, including the two VC1 glycovariants (34 and 36 
kDa) and streptavidin (14 kDa). 
6.3.7 HSA extraction 
Since the VC1 pull-down assay was not sufficient to enrich AGEs/ALEs from plasma samples, the 
experimental set-up was evaluated. Firstly, focus was shifted from identifying AGEs/ALEs from 
the whole plasma proteome to the most abundant protein present in plasma, HSA. Secondly, 
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 protein adducts can be quite unstable and can be lost during sample preparation. Therefore, 
sodium borohydride was used to reduce protein adducts in order to stabilize them for easier 
identification. Lastly, an even higher resolution mass spectrometer was used compared to the 
Orbitrap LTQ XL used until now, Fusion Tribrid. This new generation MS has faster scanning 
detectors, and allows parallel isolation and detection modes, increasing the coverage of analyzed 
peptides. 
To make the plasma sample less complex, HSA was extracted using the PierceTM Albumin 
Depletion Kit. Figure 7 shows the extraction of HSA from plasma, where the flow-through (FT) 
shows almost complete depletion of HSA from plasma, and the elution (E) indicates that HSA can 
be recovered in a less complex matrix.  
 
Figure 7. HSA extraction from plasma. The input fraction (IN), the flow-through fraction (F-T), the 
wash fraction (W) and eluate (E) were analyzed by SDS-PAGE followed by Coomassie staining. 
6.3.8 Heart failure stage III samples 
Instead of forcing AGEs/ALEs formation in-vitro, we chose to use a more physiological approach 
being plasma samples from heart failure patients. Plasma from heart failure patients is 
characterized by an increase of circulating AGEs/ALEs, making it a suitable model for the set-up 
of a sensitive method for the identification and characterization of protein adducts presumably 
involved in the onset and progression of the disease. Plasma samples were collected from healthy 
individuals and patients with heart failure stage III. These patients are characterized by marked 
limitation of physical activity and suffer fatigue, palpitation or dyspnea. A pool of healthy individuals 
(8) and heart failure patients (9) were used. HSA was extracted as described before, reduced 
using NaBH4 and digested using trypsin. Peptides were then analyzed using high resolution LC-
MS/MS on the Orbitrap Fusion and protein adducts were identified using Proteome Discoverer. 
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 This new approach permitted us to identify many AGEs/ALEs in both healthy human plasma 
samples, but also AGEs/ALEs only present in plasma of heart failure patients (Fig. 8). Glycation, 
and the break-down product glyoxal, were the main modifications identified (30 different 
modification sites), present in both healthy (3 different modification sites) and heart failure plasma 
samples (11 different modification sites). Important is the HNE Michael adduct, specifically 
identified in only heart failure samples. Moreover, the importance of stabilizing adducts is 
underlined by the fact that the acrolein adduct could only be identified after reduction with NaBH4. 
Overall, there are a substantial number of modifications present only in heart failure patients which 
could be important in understanding the progression of the disease. 
 
Figure 8. Venn diagrams of the identified AGEs/ALEs in healthy individuals and heart failure 
patients, as well as if they were identified only after reduction with NaBH4. Reported are the type of 
modification followed by the site of adduction on HSA. 
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 6.3.9 Validation of identified AGEs/ALEs 
Lastly, it should be stressed that every modification identified was confirmed by manually checking 
the MS2 spectra. Using Proteome Discoverer, a list of identified b- and y-ions is available as well 
as the instrumental MS2 spectra with the annotation of identified b- and y-ions. Thereby, allowing 
us to manually check whether the annotated ions are true positives, and showing the relative 
abundance of the ions. Figure 9 shows a good identification of a glyoxal modification on a lysine 
residue of the HSA peptide K*VPQVSTPTLVEVSR. Most of the b- and y-ions are identified and 
are the main intense peaks in the spectra. Moreover, another indication that the annotated 
modification and peptide are true is the fact that the immonium ion is present of lysine with the 
glyoxal modification, the peak at m/z 187.10744. All identified modifications were validated using 
this approach.  
 
Figure 9. MS2 spectrum with the b- and y-series of a peptide containing a glyoxal modification. 
The peak at 187.10744 represents the immonium ion of a lysine residue with a glyoxal adduct. 
6.4. Discussion 
Many pathologies have been reported to have an increase in circulating AGEs/ALEs contributing 
to disease progression, emphasizing the need for sensitive techniques to allow easier 
identification. Furthermore, full characterization is necessary for understanding the role each 
AGE/ALE play in the mechanisms leading to the onset and/or progression of the disease. Low 
abundance, heterogeneity and complex chemical structures make this a very challenging 
exercise. Therefore, many enrichment strategies have been explored, including the VC1 Pull-
Down assay described in our previous papers [2, 3]. To validate the use of this technique for 
enriching low abundant AGEs/ALEs in plasma samples, healthy human plasma was oxidized 
using AAPH to identify which proteins are prone to modification, as well as the type of modification. 
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 Since AAPH is a radical initiator, we hypothesized the attack of lipids, causing break-down 
products leading to the formation of ALEs. Unfortunately, only protein side chain oxidation 
products were identified, rendering the use of AAPH not suitable for the production of AGEs/ALEs. 
Incubating plasma directly with RCS did lead to the formation of protein adducts, however, using 
the VC1 Pull-Down assay we were not able to enrich AGEs/ALEs from plasma, indicating the need 
for more sensitive methods/equipment. 
Multiple enrichment strategies are available optimized for in-vitro use or only a certain group of 
chemical structures and ex-vivo enrichment of AGEs/ALEs remains challenging as presented in 
this section and by many other papers. Besides an enrichment step, very sensitive equipment is 
a must in order to characterize AGEs/ALEs. Therefore, sample analysis was switched from the 
Orbitrap LTQ XL to Orbitrap Fusion. Orbitrap Fusion is a third generation MS providing even higher 
resolution, faster MS detectors and parallel isolation and detection increasing protein coverage 
and chance to detect PTMs. Indeed, PTM identification have shown to be more successful using 
the Orbitrap Fusion as shown by the identification of phosphorylation sites and protein 
glycosylation [9, 10]. Furthermore, sample preparation was optimized by only focusing on HSA 
and by reducing protein adducts using sodium borohydride. Reducing protein adducts is a 
necessary step in the sample preparation, since there are a variety of adducts unstable during the 
sample preparation process and can be lost during analysis. Moreover, some adducts are 
reversible like the retro Michael adduct of acrolein. Therefore, the reducing step will not only 
stabilize the adducts during sample preparation, but also inhibit reversible adducts. On the other 
hand, we only focused on HSA, since it is the most abundant protein in plasma and the main 
nucleophilic target [11]. Moreover, HSA protein adducts have been shown to contribute to the 
progression of heart failure, such as glycated HSA [12, 13]. 
To set up the new strategy, we used plasma samples from healthy individuals and heart failure 
patients stage III, since these plasma samples are known to have an increase in AGEs/ALEs 
content, making it the perfect model to investigate whether the strategy is sensitive enough for 
mapping AGEs/ALEs. Indeed, many protein adducts were identified, especially in heart failure 
samples and mainly coming from sugar oxidation pathways, such as glycation sites and the break-
down products glyoxal and methyl glyoxal. This can be explained by the fact that many heart 
failure patients are also presented with higher sugars levels, or even diabetes complications [14]. 
Besides that, reducing protein adducts also showed an increase in identifying adducts, especially 
adducts with acrolein, that only could be identified after stabilizing the Michael adduct, indicating 
the importance of reducing adducts. The majority of acrolein adducts were identified in heart failure 
patients, implicating a possible role of this adduct in the onset or progression of the disease. 
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 Particularly, His 146, already described as one of the key targets of HSA, could be a potential 
biomarker [15]. To validate the use of biomarkers, the next step will be the set-up of a selected 
ion monitoring (SIM) approach to elucidate whether the specific modifications can be targeted in 
each individual. The precursor ion will be fixed at the m/z of the detected peptide with modification 
described before. Using this approach, a fast and reliable method can be set up for the 
identification and characterization of AGEs/ALEs in plasma samples from different pathologies.  
In conclusion, this is the first technique to our knowledge, describing the identification and 
characterization of disease specific HSA adducts by using the newest generation of orbitrap MS 
instruments in combination with focusing on HSA and reducing protein adducts. This approach 
could be used in combination with enrichment techniques, including the VC1 Pull-Down, to 
perform a plasma wide AGEs/ALEs search. 
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 Appendix 
 
 
Supplementary figure 1: Protein gel of plasma treated with different concentrations of AAPH and 
different timepoints. 
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 Table S1. Known (literature based) covalent adducts induced by HNE, MDA, ACR, MG, GO, ONE and 
sugars set as variable modifications within the PD parameters for the identification and localization 
of ALE-deriving adducts. 
HNE 
PTM AA Res. Involved ΔM 
Michael adduct 
Cys 
His 
Lys 
Arg 
+ 156.110502 Da 
Schiff Base Lys Arg + 138.01446 Da 
2-pentilpyrrole Lys Arg + 120.0939 Da 
Dehydropentylfuran 
Cys 
His 
Lys 
Arg 
+ 138.10446 Da 
MDA 
PTM AA Res. Involved ΔM 
N-propenal-Lysine Lys  + 54.01056 Da 
Di-dihydropyridine-lysine Lys + 134.03678 Da 
Malondialdehyde argpyrimidine Arg + 36.0000 Da 
ACR 
PTM AA Res. Involved ΔM 
Michael Adduct (propanal derivative) 
Cys 
+ 56.02621 Da Lys 
His 
Hydroxy-tetra-hydropyrimidine (Propane-
arginine) Arg + 56.02621 Da 
Double Michael Adduct Lys + 112.05243 Da 
Schiff Base Lys + 38.01565 Da 
Formyl-dehydro-piperidyl-lysine Lys + 94.04186 Da 
Methylpyridine-lysine Lys + 77.03912 Da 
MG 
PTM AA Res. Involved ΔM 
Carboxy-ethyl 
Cys 
+ 72.021 Da Lys 
Arg 
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 Methylimidazolone Arg + 54.011 Da 
Pyrimidine Arg + 80.026 Da 
Tetra-hydro-pyrimidine Arg + 144.042 Da 
GO 
PTM AA Res. Involved ΔM 
Carboxy-methyl 
Lys 
+ 58.005 Da Arg 
 
Imidazolone Arg + 39.995 Da 
ONE 
PTM AA Res. Involved ΔM 
Michael adduct 
Cys 
His 
Lys 
Arg 
+ 154.099 Da 
Pentylfuran 
Cys 
His 
Lys 
Arg 
+ 136.089 Da 
Sugars 
PTM AA Res. Involved ΔM 
Glycation Lys Arg + 162.053 Da 
Imidazolone Arg + 144.042 Da 
Pyraline Lys + 108.172 Da 
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 Table S2. Known (literature based) reduced covalent adducts induced by HNE, MDA, ACR, MG, GO, 
ONE and sugars set as variable modifications within the PD parameters for the identification and 
localization of ALE-deriving adducts. 
HNE 
PTM AA Res. Involved ΔM 
Michael adduct Reduced 
Cys 
His 
Lys 
Arg 
+ 158.131 Da 
Schiff Base Reduced Lys Arg + 140.120 Da 
MDA 
PTM AA Res. Involved ΔM 
N-propenal-Lysine Lys  + 56.026 Da 
Di-dihydropyridine-lysine Lys + 138.068 Da 
ACR 
PTM AA Res. Involved ΔM 
Michael Adduct (propanal derivative) 
Reduced 
Cys 
+ 58.042 Da Lys 
His 
Double Michael Adduct Reduced Lys + 116.084 Da 
Schiff Base Reduced Lys + 40.031 Da 
Formyl-dehydro-piperidyl-lysine Reduced Lys + 96.058 Da 
ONE 
PTM AA Res. Involved ΔM 
Michael adduct Reduced 
Cys 
His 
Lys 
Arg 
+ 158.131 Da 
Schiff Base Reduced 
Cys 
His 
Lys 
Arg 
+ 140.120 Da 
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Chapter VII: Effect of AGEs and ALEs on NF-kB activity 
Abstract 
Advanced Glycation/Lipoxidation End Products (AGEs/ALEs) are pathogenic factors coming from 
oxidative degradation pathways and have been described in the onset/progress of many 
pathologies, including diabetes and cardiovascular diseases. AGEs/ALEs exert their damaging 
activity through different mechanisms and one of them is to bind to the receptor for AGEs (RAGE). 
The AGE-RAGE axis has already been described extensively, however there is no evidence of 
how ALEs can induce pro-inflammatory activity. Since previously we described the mechanisms 
of ALEs as binder of RAGE, we sought to determine whether ALEs can bind and induce a pro-
inflammatory activity through RAGE. We set up a cellular model with and without the expression 
of RAGE and the presence of a NF-kB gene reporter. Due to limitations of the cellular model, a 
RAGE dependent mechanism for NF-kB activation could not be set up. However, it was evident 
that both AGEs and ALEs activated the NF-kB pathway independent of RAGE. Furthermore, ALEs 
showed an increase in reducing potential of the cells most likely related to activation of the nrf2 
pathway. Further studies are necessary to elucidate the effect of AGEs/ALEs on NF-kB activation. 
7.1. Introduction 
Advanced Glycation/Lipoxidation End Products (AGEs/ALEs) are pathogenic factors implicated in 
many different diseases, including cardiovascular diseases, chronic renal failure, diabetes and 
neurological disorders [1-4]. AGEs and ALEs are similar compounds, proteins adducted by 
oxidative degradation products, and exert damaging activity directly on the protein itself, as well 
as through signaling pathways. Regarding AGEs, the involvement of the Receptor for Advanced 
Glycation End Products (RAGE) and the signaling mechanisms are well described. In contrast, 
ALEs have also been shown to induce down-stream signaling pathways, but up to date no receptor 
has been described for this event. Naturally, RAGE could be the most prominent candidate, 
considering AGEs/ALEs share a common chemical structure. In fact, our previous paper described 
the mechanisms necessary for ALEs to become a binder of RAGE [5]. 
RAGE is a multi-ligand receptor that consist of multiple isomers, including a membrane bound 
form and a soluble form. The membrane bound receptor contains an intracellular signaling 
domain, able to activate different pathways leading to a pro- or anti-inflammatory immune 
response [6]. One of the main pathways involved is the NF-kB pathway followed by the increase 
in expression of cytokines, growth factors, as well as the upregulation of the receptor itself [7]. 
Besides AGEs, well-known ligands of the receptor are HMGB-1 and S100 proteins. In addition to 
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 AGEs/ALEs, RAGE has also been implicated in many different pathologies, like Parkinson’s 
disease, Alzheimer’s disease, pulmonary inflammatory responses and inflammatory diseases in 
general [8-11]. Combining the data of sustained inflammatory activity of AGEs/ALEs and the 
receptor, it can be assumed that the NF-kB pathway is chronically activated. However, the exact 
molecular mechanisms leading to these cellular events are still not well understood. This project 
aimed to understand whether besides AGEs, also ALEs induce downstream signalling pathways 
either through RAGE or as such by utilizing a cell line with a NF-kB gene reporter. 
7.2. Materials and Methods 
7.2.1 Chemicals and reagents 
Bradford reagent, protease inhibitors, IL-1α, HSA, bardoxolone and all other chemicals were 
purchased from Sigma-Aldrich (Milan, Italy). ONE-Glo Luciferase Assay System and RealTime-
Glo MT Cell Viability Assay were purchased from Promega (USA).  
7.2.2 Cell Culture and Lentiviral Transduction 
HEK293T and R3/1 clones were grown in Dulbecco modified Eagle medium (DMEM; Lonza, 
Verviers, Belgium) supplemented with 10% fetal bovine serum (FBS; Gibco), 1% glutamine 
(Lonza), and 1% penicillin/streptomycin (Gibco, USA). R3/1-pLXSN (hereinafter referred to as 
R3/1 Control) or R3/1-FL-RAGE (hereinafter referred to as R3/1 RAGE) cells were generated as 
described in Sessa et al. [12]. For lentivirus production, 9•106 HEK293T cells were seeded in 15 
cm plate, medium was discarded after 16 hours and substituted with Iscove's Modified Dulbecco's 
Medium (IMDM; Lonza), 10% FBS, 1% penicillin/streptomicin and 1% glutamine 100U/mL. 
Transfection was performed using calcium phosphate precipitation method using lentiviral 
package vectors (7 µg pDM2-VSVG and 28 µg pCMV-ΔR8.91) and 32 µg pGreenFire-NF-κB-Puro 
(a kind gift of Dr. Darius Widera, University of Reading, UK [13]). Medium was changes 16 hours 
later with complete IMDM and butyrate sodium (1 µg/ml; Sigma, St Louis, USA) and virus particles 
were harvested after 36 h.  Medium containing virus particles was centrifuged at 1500 rpm for 5 
minutes and filtered through 0.22 µm filter (Merck, Germany) before centrifugation at 20000 rpm 
for 2 hours at 4 °C. Supernatant was discarded and virus particles were resuspended in 40 µl of 
sterile cold PBS and left in ice with gentle agitation for 30 minutes. Aliquots were stored at -80°C.  
For lentiviral transduction, 60.000 R3/1 Control or R3/1 RAGE cells were seeded in a 12 well-plate 
and the day after medium was replaced with fresh medium containing 6 µl (MOI 10) or 12 µl (MOI 
20) of virus particles solution for 24 h. Medium was changed 24 hours later and cells were selected 
with 1 µg/ml of puromycin for 4 days.  
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 7.2.3 Western blot 
R3/1 cells were harvested in RIPA buffer in the presence of proteases inhibitors, incubated in ice 
for 30 min and centrifuged at 12.000 x g for 15 minutes at 4°C. Supernatants were collected and 
protein concentration was determined. Protein extracts were separated by SDS-PAGE and 
transferred to Amersham Hybond ECL Nitrocellulose membranes (GE Healthcare, Little Chalfont, 
United Kingdom). Membranes were incubated with a goat anti-human RAGE (1 µg/ml; cat. 
AF1145; R&D Systems Minneapolis, MN, USA) or an antibody against GAPDH (0.2 µg/mL, sc-
25778, Santa Cruz Biotechnology). Proteins were visualized by the Amersham ECL Western 
Blotting Detection Reagents (GE Healthcare). 
7.2.4 Preparation of AGE/ALE albumins and natural extracts 
Recombinant human serum albumin (HSA) expressed in P. pastoris (Cat no. A7736) was obtained 
from Sigma. To obtain AGEs, HSA was incubated with glucose for 3 months or with fructose for 4 
months. After incubation, unreacted sugar was removed by diafiltration using Amicon Ultra-0.5 ml 
(Cut off 10 K) filters. To obtain ALEs, HSA was incubated at various ratios separately with HNE, 
MDA or ACR for 24 hours. After incubation, unreacted RCS were removed by diafiltration using 
Amicon Ultra-0.5 ml (Cut off 10 K) filters and same ratios different RCS were pooled together. 
7.2.5 Stimulation of Cells 
Cells for pro-inflammatory activity were stimulated with 10 ng/ml human recombinant IL-1α 
(Sigma-Aldrich), 500 µg/ml HSA or AGEs, or 10 µg/ml HMGB-1 in serum-free medium at different 
timepoints. For proliferation assays, cells were treated with 500 µg/ml HSA, AGEs/ALEs, or 
various concentrations of ALEs for 72 hours in complete medium. To assess the anti-inflammatory 
activity, cells were pre-treated with different compounds at different concentrations for 18 hours in 
complete medium, followed by a 6-hour stimulation with 10 ng/ml IL-1α. Experiments were 
assayed by NF-κB luciferase activity, RealTime-Glo assay or an MTT assay. 
7.2.6 NF-kB luciferase activity assay 
After treatment, cells were washed twice with cold PBS followed by a freeze-thaw cycle with 
reporter lysis buffer (Promega) for complete cell lysis. Experiments in 6 wells plates; protein lysate 
was collected and spun for 10 min. at 15.000 x g to remove debris. Luciferase activity was then 
measured by adding 100 µl ONE-Glo Luciferase Assay Substrate (Promega) to 50 µl protein lysate 
in a white 96-wells plate followed by a luciferase measurement performed using a luminometer 
(WALLAC 1420, Multilabel counter, Perkin Elmer life and Analytical Sciences). Experiments in 96-
wells plates; after the freeze-thaw cycle, 100 µl ONE-Glo Luciferase Assay Substrate (Promega) 
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 was directly added to the wells, followed by a luciferase measurement performed using a 
luminometer (WALLAC 1420, Multilabel counter, Perkin Elmer life and Analytical Sciences). 
7.2.7 RealTime-Glo assay 
RealTime-Glo assay was performed following manufacturer’s instructions. In brief, for continuous 
measurement, medium containing RealTime-Glo reagents and compounds to test were added 
simultaneously to the wells containing cells. Luciferase was then measured hourly up to 72 hours. 
For end-point measurements, medium containing compounds was removed and replaced with 
medium containing RealTime-Glo reagents, incubated for 30 min., and luciferase was measured. 
7.2.8 MTT assay 
After stimulation, 10 µl 5 mg/ml MTT reagent was added for 4 hours. Afterwards, medium was 
removed, and cells were lysed and MTT was solubilized by adding 100 µl DMSO. 96-wells plate 
was shaken for 1 minute, followed by an absorbance measurement at 490 nm using a plate reader 
(BioTek's PowerWave HT, USA). Cells incubated with respective concentration of DMSO (<0.1%) 
were used as a control for 100% cell proliferation. Statistical analysis was performed in the 
GraphPad software. Experiments were performed with biological and technical replicates. 
7.3. Results 
7.3.1 Transduction of the cell line 
In order to obtain a fast and sensitive method for assessing binding of RAGE and the subsequent 
activation of the NF-κB pathway, R3/1 Control and R3/1 RAGE cells were lentivirally transduced 
with a lentiviral NF-κB-driven reporter encoding for luciferase. Firstly, transduced cells were tested 
for the expression of RAGE (Fig. 1A). This blot shows clearly that R3/1 RAGE transduced cells 
well express the receptor and that there is no expression of RAGE in R3/1 Control cells. Next, 
different clones were produced with two different mode of infections (MOI), 10 and 20. When 
stimulated with IL-1α, a potent inducer of the pro-inflammatory pathway through NF-κB, control 
cells showed negligible luciferase luminescence. By contrast, transduced cells with both MOI 
showed a huge increase in production of luminescence signal, with MOI 20 being superior to MOI 
10. Therefore, experiments were continued with R3/1 cells with NF-κB-Luc MOI 20. Moreover, IL-
1α induced a higher inflammatory response through NF-κB than untreated cells, confirming the 
success of this assay. 
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Figure 1. Luciferase expression in R3/1 clones. A) Expression of RAGE in R3/1 Control or R3/1 RAGE 
(Control or NF-κB-Luc) was determined with a specific antibody against the extracellular domain of 
RAGE. GAPDH detection was used as normalizer. B) Cells were stimulated for 24 hours with and 
without IL-1α in starvation medium. Control cells (no NF-κB-Luc) show no luminescence at all, 
whereas the transfected cells show a clear production of luminescence, increased at higher MOI. 
Shown are mean ± SEM. 
7.3.2 Validating a RAGE-dependent mechanism 
A good cell model was obtained for detecting pro-inflammatory activity, thus the next step was to 
explore the possibility of detecting a RAGE-dependent mechanism of the NF-κB pathway 
activation. To achieve this, ligands of RAGE were used known to activate the NF-κB pathway. 
Established ligands of RAGE are HMGB1 and AGEs, primarily HSA modified with fructose or 
glucose. Cells were treated with different compounds for 24 hours in medium without serum. 
Microscopical analysis was performed to identify cytotoxicity of the compounds, none was 
observed. Then, cells were harvested and lysed, followed by protein concentration determination 
to correct for the measured luciferase luminescence. Figure 2  shows that untreated RAGE cells 
already significantly express a higher basal level of NF-κB-dependent luciferase activity. IL-1α 
works very well as a positive control and the negative control for AGEs, HSA, does not induce a 
cellular response. The AGE, HSA modified with fructose, demonstrated an increased level in 
luminescence, however this is not RAGE dependent. Furthermore, NF-κB activity is increased in 
RAGE cells upon stimulation with HMGB1, nevertheless this is comparable with untreated cells.  
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Figure 2. Treatment with known ligands of RAGE. Cells were treated 24 hours with indicated 
compounds. Results shown were corrected on protein concentration and compared to untreated 
control cells. Mean ± SEM analyzed using two-way ANOVA with Holm-Sidak correction (∗∗∗∗p < 
0.0001 was considered significant, CI 95%) to compare against untreated control cells or an unpaired 
Student’s t-test (#p < 0.05, two-tailed, CI 95%) to compare between control and RAGE cells.  
7.3.3 Effects of AGEs/ALEs on control cells 
An attempt was made to optimize the experiment to gain better results. Different timepoints were 
tested from 2 to 72 hours, various concentrations of AGEs were considered, and cells were 
starved before adding compounds to adopt to medium without serum. It should be taken into 
account that compounds were added in medium without serum considering that FBS contains 
high amount of oxidation products, and most likely also AGEs and/or ALEs. Moreover, different 
AGEs were tested for a RAGE-dependent NF-κB activity, such as HSA modified with fructose, 
glucose or commercially available glycated HSA. Unfortunately, we were unable to detect a 
RAGE-dependent mechanism for assessing NF-κB activity, suggesting that this experimental set-
up is not suitable to identify RAGE ligands. Despite that, we observed that AGEs, as well as ALEs, 
were able to induce pro-inflammatory activity in R3/1 control cells independent of RAGE. 
Representative bar graphs are shown in figure 3. ALEs were produced by incubating HSA with 
different ratios, from 0.1 to 10X of RCS (HNE, ACR and MDA), and were pooled afterwards. Every 
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 compound tested for NF-κB activity was also tested for cytotoxicity using an MTT assay, which 
clearly shows no toxic effect when compared to untreated. On the contrary, when treated, both 
AGEs and ALEs significantly increased cell viability, which can be explained by the fact that these 
compounds can be utilized by cells in absence of serum. NF-κB-dependent luciferase activity is 
also clearly increased when cells were stimulated with different AGEs, with emphasis on glycated 
HSA. Moreover, increasing ratio of RCS versus HSA also showed an increased NF-κB-dependent 
luciferase activity. 
Figure 3. Increased NF-κB activity through different AGEs/ALEs. Cells were stimulated for 6 hours 
with indicated compounds, HSA and AGEs (top) or ALEs (bottom) were added at 500 µg/ml. Followed 
by an MTT assay (A,C) or by a luciferase luminescence measurement (B,D). Compared to untreated, 
mean ± SEM analyzed using ANOVA with Bonferroni correction (∗p < 0.05, ∗p < 0.01 ∗∗∗p < 0.001 and ∗∗∗∗p < 0.0001 were considered significant, CI 95%). 
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 7.3.4 Proliferating effect of ALEs on control cells 
Since both AGEs and ALEs showed an increase in proliferation, we sought to determine the effect 
of AGEs and ALEs on cell proliferation using the RealTime-Glo™ MT Cell Viability Assay from 
Promega. This assay allows us to monitor cell proliferation continuously up to 72 hours. The assay 
is based on the reduction of a substrate into a NanoLuc® substrate by viable cells, which is 
consumed by a NanoLuc® Enzyme to produce a luminescent signal. Non-viable cells are not able 
to produce this substrate and therefore no luminescent signal is produced. Figure 4 shows various 
assays, where AGEs demonstrate to have no effect on cell proliferation. Interestingly, ALEs did 
induce faster cell proliferation correlated to the amount of modification. The value for HSA – 10X 
RCS is out of range due to the high increase of the output of the assay. Figure 4C also shows a 
concentration dependent correlation with HSA modified with 1X RCS. To confirm this data, cells 
were incubated with the same compounds, and manually counted after 70 hours. Surprisingly, this 
data showed no increase in cell number, in contrast with the other assay. It was hypothesized, 
that ALEs do not increase cell proliferation, yet it increases the reduction potential of the cells. For 
example, via the upregulation of reducing enzymes due to activation of the nrf2 pathway. 
 
Figure 4. ALEs increase cell proliferation. A) R3/1 control cells were incubated with 500 µg/ml 
compounds in complete medium. Using RealTime-Glo™ MT Cell Viability Assay, luminescence was 
continuously monitored. Linear regression line was fitted and R square values were calculated. B) 
R3/1 control cells were incubated with 500 µg/ml increasing modified HSA with RCS. Linear 
regression line was fitted and R square values were calculated. C) Different concentrations of HSA 
– 1X RCS were tested for proliferation. Linear regression line was fitted and R square values were 
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 calculated. D) Cells were incubated with the same compounds at 500 µg/ml and counted manually 
after 70 hours. Change in cell viability compared to HSA was plotted, together with the results from 
the RealTime-Glo assay after 70 hours. 
To support the hypothesis of increased reducing potential of cells, an experiment was set-up to 
elaborately increase reducing enzymes in the cells. Bardoxolone is a known activator of the nrf2 
pathway, which is activated to detoxify toxic compounds such as oxidants and RCS partly by the 
upregulation of reducing enzymes like aldo-keto reductases. This enzyme could be capable of 
reducing the cell viability substrate of RealTime-Glo and give a false positive signal in cell 
proliferation. Indeed, low concentrations of bardoxolone were able to increase the luminescence 
signal of the RealTime-Glo assay 5-fold, whereas MTT and cell count showed no increase in cell 
proliferation (Fig. 5). 
 
Figure 5. Bardoxolone increases the production of reducing enzymes. R3/1 control cells were 
incubated with different concentrations of bardoxolone for 24 hours, followed by the assessment of 
three different assays to determine cell proliferation. Compared to untreated of the relative assay, 
shown are mean ± SEM. 
7.4. Discussion 
AGEs are well known ligands of RAGE able to induce pro-inflammatory and pro-fibrotic activity 
through the NF-kB pathway [14-17]. ALEs, having great similarity to AGEs, have also been shown 
to induce pro-inflammatory and pro-fibrotic responses [18]. However, no specific receptor has yet 
been described to this cellular event. Since AGEs and ALEs are produced by similar pathways, 
oxidative degradation of either sugars or lipids forming protein adducts, the involvement of RAGE 
is very likely. Indeed, we have been able to demonstrate already using MS techniques and 
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 molecular modelling studies that a specific set of ALEs can bind RAGE [5]. Therefore, we aimed 
to determine whether ALEs, like AGEs, can bind RAGE and induce a pro-inflammatory and pro-
fibrotic response. To this end, we tried to set-up a cellular model for determining a RAGE-
dependent activation of the NF-kB pathway. Although the cellular model was efficient in evaluating 
activation of the NF-kB pathway, the assay could not distinguish the involvement of RAGE using 
well-known ligands. This could be explained by the fact that the cell line overexpressing RAGE 
already shows a higher basal level of luciferase dependent NF-kB activity, suggesting that the 
cells are more vulnerable. Secondly, experiments were carried out in serum-free medium due to 
the high presence of oxidation products in fetal bovine serum, hence the incubation time was 
relatively short since cells do not respond well in serum-free medium. It is believed that the 
activation of RAGE needs long-term steady-state binding and activation for inducing down-stream 
signaling pathways, making this assay incompatible to study the effects of ALEs on RAGE binding 
and activation. Lastly, since the cells do not express RAGE by itself and had to be lentivirally 
transduced it is plausible to think that some key cellular components in the downstream pathway 
are missing. To circumvent this problem, future studies could instead focus on silencing the gene 
for RAGE in a cell line having basal expression of RAGE, like the human pulmonary epithelial cell 
line A549, to evaluate a RAGE dependent mechanism of NF-kB activation through ALEs [19]. 
Nevertheless, increased NF-kB activity was detected independently of RAGE in the presence of 
different AGEs, either suggesting a role for other receptors or no receptor involvement at all. 
Studies have shown already that the presence of AGEs induce a chronic state of inflammation 
and further studies are necessary to elucidate the mechanisms behind sustained NF-kB activity 
[20]. Proteomic wide studies are necessary to discover which cellular pathways are involved when 
cells are treated with AGEs. ALEs, besides showing an increased NF-kB activity as well, also 
showed an increase in RealTime Glo activity. This assay is originally intended to use for cell 
proliferation/cytotoxicity assays. Nonetheless, we observed an increase in this assay that was not 
related to the increase of cell number when manually counted. Indicating another mechanism 
potentially increasing luciferase dependent RealTime Glo activity. The assay is based on the 
reduction of a substrate by viable cells which is a company secret. The reduced substrate can 
then be converted into a compound producing light by the luciferase enzyme. The increase in 
luciferase activity could therefore be explained by the simple fact that other pathways are activated 
increasing the production of reducing enzymes. One of these pathways is the nrf2 pathway, 
activated under oxidative stress increasing the upregulation of anti-oxidant enzymes able to 
reduce oxidized biomolecules. Bardoxolone is a well-known activator of this pathway [21], and 
indeed showed a huge increase in RealTime Glo activity, confirming the suspicion of increased 
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 reducing potential of the cells instead of actual cell proliferation. ALEs, but not AGEs, showed an 
increase using this assay, suggesting the capability of ALEs to activate the nrf2 pathway. RCS 
are activators of the nrf2 pathway, implying the release of RCS during incubation, via a retro-
Michael mechanism, and sustained activation of the nrf2 pathway. Specific assays are necessary, 
like the nrf2 translocation assay or proteomic studies, to confirm the activation of this pathway. 
In conclusion, due to limitations of the cellular model, a RAGE-dependent activity of AGEs/ALEs 
on the NF-kB pathway could not be determined. However, it can be used for determining pro-
inflammatory activity. Furthermore, ALEs showed activation of the NF-kB pathway, a pro-
inflammatory effect, as well as the nrf2 pathway, an anti-inflammatory effect. This contrary effect 
is likely concentration and/or type of ALEs based. 
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 Chapter VIII: General discussion 
Involvement of AGEs and ALEs in a wide variety of pathologies have been clearly described in 
the past decades and have become an important area of research due to the increasing 
exogenous sources as well as new techniques becoming available providing new information. 
Much focus has therefore been on elucidating the molecular mechanisms behind the formation of 
AGEs/ALEs, and the role they play in particular pathologies. The formation of AGEs/ALEs have 
been extensively described already [1], however this is a just a tip of the iceberg, and many more 
RCS are involved. Combining that with the whole proteome that can be adducted, sensitive, fast 
and reliable methods are necessary to understand what the molecular entities are leading to 
inflammation. Many methods have been set up already in addressing this matter, from MS 
methods to biochemistry and immunological techniques. The most used biochemistry technique 
is the derivatization with DNPH, and subsequent spectrophotometric methods to identify protein 
carbonyls [2]. Immunological techniques include the identification of specific adducts, such as 
protein carbonyls in general or HNE adducts, to give an example, using ELISA or western blotting 
[2-4]. These methods provide a general overview of the protein adducts present, despite that, no 
information can be obtained about the exact nature of the modification and the localization. Hence 
the use of MS methods, by far the most powerful and popular technique to characterize and 
localize protein adducts. Many MS methods have already been set up for in-vitro use for mapping 
adducts of model proteins with certain RCS [5-9]. Although these methods have been contributing 
to the discovery of AGEs/ALEs, very few methods have been able to translate this to physiological 
samples with low abundant AGEs/ALEs. For this purpose, enrichment techniques have been 
explored, including the VC1 pull-down, based on RAGE [10]. RAGE is also a key player in the 
signaling pathways of AGEs and their effect on cells in different pathologies, such as diabetes and 
atherosclerosis [11, 12]. Therefore, the thread of this thesis is to explore RAGE as a stationary 
phase for enriching AGEs/ALEs, to discover the molecular mechanisms of RAGE binding and the 
effect of AGEs/ALEs on cellular signaling pathways through RAGE. 
AGEs and ALEs are very similar compounds, making it plausible to believe that besides AGEs, 
RAGE is also able to bind ALEs. The VC1 pull-down has already been shown to successfully 
capture AGEs, and the first part of the project was therefore focused on elucidating if this 
technique could also be used for capturing ALEs. Indeed, by using an integrated MS and 
computational approach, we discovered that RAGE is able to bind ALEs coming from HSA protein 
adducts with HNE, MDA and ACR. Specifically, those adducts that reduce the basicity of the target 
amino acid and the basic amino acid should be at the center of a set of carboxylic acids which, 
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 once the residue is modified, become available to freely contact the RAGE positive residues. 
Consequently, we revealed a mechanism in which ALEs are able to bind RAGE, making the VC1 
pull-down an even more promising technique in enriching AGEs/ALEs from samples. Apart from 
that, RAGE could also be involved in the signaling pathways that ALEs have been described in 
[13, 14]. 
Since a suitable enrichment strategy was obtained and validated to enrich functionally relevant 
AGEs/ALEs, we aimed to translate this to physiological samples where AGEs/ALEs are present 
in low amounts. We started by oxidizing healthy human plasma in-vitro to obtain a controllable 
model of plasma samples with AGEs/ALEs. AAPH was not suitable for producing AGEs/ALEs, 
although it did increase the presence of protein carbonyls significantly. Suggested is the direct 
oxidation of amino acids that can generate protein carbonyl groups as reviewed by Weber et al 
[15]. We advanced with the direct incubation of plasma with different RCS. HSA protein adduct 
formation was confirmed using intact protein analysis, unfortunately the VC1 pull-down was not 
able to enrich for AGEs/ALEs. This can be due to the interference and higher affinity of other 
proteins in plasma samples, such as prothrombin, which seems to be a strong binder of RAGE 
[unpublished data]. Other explanations could be the involvement of low molecular compounds 
present in plasma masking the molecular entities responsible for binding RAGE. Or the methods 
used for characterization, such as the MS used, are not sensitive enough for identifying low 
abundant AGEs/ALEs. Future studies will explore the possibilities of using the VC1 pull-down in 
tissue samples or cellular extracts. 
The last argument leads us to the next part of the project, which was to improve other variables 
throughout the sample process and characterization. In particular, the use of the newest 
generation MS, the tribrid MS. In combination with the albuminomic approach and stabilizing 
certain adducts by means of reduction, we were able to identify a significant number of 
AGEs/ALEs present in healthy subject and heart failure patients. This is one of the first proofs of 
a huge number of identified AGEs/ALEs in plasma samples without the need of an enrichment 
step, hence very little sample preparation by using a high-resolution MS, Orbitrap Fusion. This 
demonstrates how powerful the tribrid orbitrap MS is when comparing it to other MS instruments, 
making it by far the most sensitive approach for characterizing AGEs/ALEs and perhaps many 
other PTMs. Considering that each and single AGE/ALE identified in heart failure patients and not 
in the control subjects could be a potential biomarker, we aim at setting up a targeted MS method, 
SIM, to validate the use of this approach and for future purposes. 
Having demonstrated that ALEs are binder of RAGE, we also investigated whether ALEs can bind 
RAGE in a cellular model and activate the down-stream signaling pathways. The cellular model 
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 containing a NF-kB gene reporter was successfully set-up, nonetheless the assay could not be 
validated by using well-known ligands of the receptor. Perhaps key cellular components of the 
downstream signaling pathways of RAGE are missing since the cell lines were transduced with 
the receptor. Thus a RAGE dependent NF-kB activation could not be determined, but AGEs/ALEs 
did activate the NF-kB pathway by other means. AGEs have been shown already to activate the 
NF-kB pathway [16], however the molecular mechanisms are still unclear and although one paper 
suggest the inhibition of autophagy resulting in NF-kB activation [17]. Our results also showed an 
increase in NF-kB activity upon stimulation with ALEs, not reported before. On the other hand, 
ALEs also increased the reducing potential of the cells, most likely related to the activation of the 
nrf2 pathway, a protective mechanism. This suggest that ALEs can either have a pro- or anti-
inflammatory effect, most likely depending on the concentration and type of ALE. Proteomic 
studies are vital in understanding the pathways leading up to this. 
In conclusion, besides AGEs, ALEs have been discovered as RAGE binders and the mechanism 
of action was deciphered using a computational approach. However, using RAGE as an 
enrichment technique was not sufficient for identifying low abundant AGEs/ALEs in plasma. 
Regardless, using the newest generation MS, for the first time a high number of AGEs/ALEs were 
identified with little sample preparation in plasma of healthy subjects and heart failure patients. 
Lastly, a RAGE dependent cellular activity could not be determined and more studies are 
necessary to understand the role of AGEs/ALEs on NF-kB activation. 
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 Appendix I: Anti-inflammatory activity 
1. Introduction 
Sustained NF-kB activation has been shown to lead to chronic inflammatory diseases and in 
search of preventive and/or curative medicine, natural compounds could be a key candidate due 
to the presence of many anti-oxidants [1]. Advantages of natural compounds are that they are 
freely available, new compounds can be discovered compared to standard combinatorial 
chemistry and less toxic effects compared to synthesized compounds. Since the NF-κB pathway 
is a good model of evaluating the pro- or anti-inflammatory response, we sought to determine the 
anti-inflammatory effect of natural compounds, known to have a high antioxidant property. Natural 
compounds such as apple, bergamot and artichoke have a very high content of polyphenols and 
have been positively linked in mediating chronic inflammatory diseases [2-5]. Inflammation is often 
accompanied by an increase in ROS which can exceed the anti-oxidant capacity available in the 
body. Therefore, the intake of natural antioxidant sources can prevent or mediate the increase in 
ROS and related inflammatory activity. 
Polyphenols are very diverse compounds containing two or more phenol rings, and aid in the 
protection of plants against pathogens and UV radiation. This group of compounds have been 
researched extensively due to the fact that they contain different chemical properties, however, 
the mechanism of action remains largely unknown and the efficacy is often low. Fractionating 
polyphenol extracts could lead to the discovery of new compounds, and can be tested directly by 
evaluating the anti-inflammatory effect mediated by the NF-κB pathway. Therefore, this part of the 
project was to investigate the anti-inflammatory role of crude or purified extracts of natural 
occurring compounds in preventing sustained inflammation through the activation of the NF-kB 
pathway using the cellular model set-up previously. 
2. Material and Methods 
2.1 Chemicals and reagents 
IL-1α, rosiglitazone and all other chemicals were purchased from Sigma-Aldrich (Milan, Italy). 
ONE-Glo Luciferase Assay System and RealTime-Glo MT Cell Viability Assay were purchased 
from Promega (USA). 
2.2 Cell Culture 
R3/1 control cells containing the NF-kB reporter gene were grown in Dulbecco modified Eagle 
medium (DMEM; Lonza, Verviers, Belgium) supplemented with 10% fetal bovine serum (FBS; 
Gibco). Cells were seeded at 3.000 cells/well in a 96-wells plate for the assessment of anti-
inflammatory activity and incubated overnight before stimulation. 
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 2.3 Preparation of natural extracts 
Both bergamot juice and apple pulp extract were obtained by an enrichment of the phenolic 
fraction by using a polystyrene resin column (Mitsubishi). The elution was carried out by a mild 
KOH solution (pH = 8.5). A cationic resin at acid pH was used to neutralize the extract, that was 
then dried under vacuum. The so obtained extract were then weighed and dissolved in DMSO or 
directly in DMEM for the tests. 
2.4 Stimulation of Cells 
To assess the anti-inflammatory activity, cells were pre-treated with different compounds at 
different concentrations for 18 hours in complete medium, followed by a 6-hour stimulation with 
10 ng/ml IL-1α. Experiments were assayed by NF-κB luciferase activity, RealTime-Glo assay or 
an MTT assay. 
2.5 NF-kB luciferase activity assay 
After treatment, cells were washed twice with cold PBS followed by a freeze-thaw cycle with 
reporter lysis buffer (Promega) for complete cell lysis. After the freeze-thaw cycle, 100 µl ONE-
Glo Luciferase Assay Substrate (Promega) was directly added to the wells, followed by a 
luciferase measurement performed using a luminometer (WALLAC 1420, Multilabel counter, 
Perkin Elmer life and Analytical Sciences). 
2.6 RealTime-Glo assay 
RealTime-Glo assay was performed following manufacturer’s instructions. In brief, for end-point 
measurements, medium containing compounds was removed and replaced with medium 
containing RealTime-Glo reagents, incubated for 30 min. at 37°C and luciferase was measured 
using a luminometer (WALLAC 1420, Multilabel counter, Perkin Elmer life and Analytical 
Sciences). 
2.7 MTT assay 
After stimulation, 10 µl 5 mg/ml MTT reagent was added for 4 hours. Afterwards, medium was 
removed, and cells were lysed and MTT was solubilized by adding 100 µl DMSO. 96-wells plate 
was shaken for 1 minute, followed by an absorbance measurement at 490 nm using a plate reader 
(BioTek's PowerWave HT, USA). Cells incubated with respective concentration of DMSO (<0.1%) 
were used as a control for 100% cell proliferation. Statistical analysis was performed in the 
GraphPad software. Experiments were performed with biological and technical replicates. 
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 3. Results 
3.1 Rosiglitazone as NF-κB inhibitor 
Since an indication was obtained in chapter 7 that bardoxolone is able to increase the reducing 
potential of cells, and potentially providing protection to the cells, we were also interested to see 
if this compound would be able to decrease inflammatory activity. Accordingly, cells were 
incubated for 18 hours with bardoxolone, followed by a 6-hour stimulation with IL-1α. Lower 
concentrations of bardoxolone were used, due to the toxic effects of bardoxolone at higher 
concentrations. Where 10 and 50 nM significantly increased NF-κB dependent luciferase activity, 
100 nM was efficiently in reducing the activity. 
Considering that this assay was able to detect anti-inflammatory activity, an attempt was made to 
optimize this experiment using a compound that is known to possess anti-inflammatory activity 
through NF-κB, rosiglitazone [6]. Without doubt, rosiglitazone can reduce pro-inflammatory activity 
at all concentrations tested and does not show toxicity (Fig. 1). Moreover, we can state that it does 
not increase the reducing potential of the cell. 
3.2 Natural compounds 
Previous experiments with bardoxolone and rosiglitazone have shown that the cellular model can 
be utilized for other purposes than intended. Therefore, our interest was shifted to the identification 
of anti-inflammatory activity of polyphenolic natural compounds, including apple and bergamot 
fruit extracts (Fig. 2). Apple pulp extract demonstrated a significant increase in cell viability using 
the RealTime-Glo assay from 50 µg/ml, but not observed using the MTT assay, suggesting the 
increase in production of reducing enzymes. In fact, at the concentration of 500 µg/ml the MTT 
assay showed a significant toxic effect, while the RealTime-Glo assay is still significantly 
increased. Pulp extract of apple also showed an effect at 50 µg/ml onwards by the inhibition of the 
NF-κB pathway. At the same time, an extract of the bergamot fruit was assayed for the same 
activity. From 250 µg/ml a significant increase in cell viability was observed using the RealTime-
Glo and MTT assay, while a significant decrease is already detected at 1 µg/ml regarding the 
inhibition of the NF-κB pathway. 
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Figure 1. Bardoxolone increases the production of reducing enzymes and rosiglitazone is able to 
reduce NF-κB activity. A) R3/1 control cells were incubated with different concentrations of 
bardoxolone for 24 hours, followed by the assessment of three different assays to determine cell 
proliferation. Compared to untreated of the relative assay, shown are mean ± SEM. B) R3/1 control 
cells were incubated for 18 hours with different concentrations of bardoxolone, followed by a 6 hour 
stimulation with IL-1α. Then NF-κB dependent luciferase activity was measured. Compared to 
control untreated, mean ± SEM are shown. Analyzed using two-way ANOVA with Bonferroni 
correction (compared to control IL-1α, ∗∗p < 0.01, ∗∗∗p < 0.001 and ∗∗∗∗p < 0.0001 were considered 
significant, CI 95%). C) R3/1 control cells were incubated with different concentrations of 
rosiglitazone for 24 hours, followed by the assessment of cell viability using MTT and RealTime-Glo. 
Compared to untreated of the relative assay, shown are mean ± SEM. D) R3/1 control cells were 
incubated for 18 hours with different concentrations of rosiglitazone, followed by a 6 hour 
stimulation with IL-1α. Then NF-κB dependent luciferase activity was measured. Compared to 
control untreated, mean ± SEM are shown. Analyzed using two-way ANOVA with Bonferroni 
correction (compared to control untreated, #p < 0.05 and ###p < 0.001, compared to control IL-1α, ∗∗∗∗p < 0.0001 were considered significant, CI 95%). 
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Figure 2. Polyphenolic compounds are able to increase the reduction potential of R3/1 cells and 
decrease pro-inflammatory activity through the NF-κB pathway. A and C) R3/1 control cells were 
incubated with different concentrations of apple pulp extract (A) or bergamot fruit extract (C) for 24 
hours, followed by the assessment of cell proliferation using MTT and RealTime-Glo. Compared to 
untreated of the relative assay, shown are mean ± SEM. Analyzed using two-way ANOVA with 
Bonferroni correction (compared to untreated RealTime-Glo, ∗∗∗∗p < 0.0001, compared to untreated 
MTT, #p < 0.05, ##p < 0.01 and ###p < 0.001 were considered significant, CI 95%). B and D) R3/1 
control cells were incubated for 18 hours with different concentrations of apple pulp extract (B) or 
bergamot fruit extract (D), followed by a 6 hour stimulation with IL-1α. Then NF-κB dependent 
luciferase activity was measured. Compared to control untreated, mean ± SEM are shown. Analyzed 
using two-way ANOVA with Bonferroni correction (compared to control IL-1α, ∗p < 0.05, ∗∗∗p < 0.001 
and ∗∗∗∗p < 0.0001 were considered significant, CI 95%). 
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 4. Discussion 
Since the activation of the nrf2 pathway is a cellular defense mechanism aiming to reduce 
inflammatory activity, we sought to determine if this cellular model could be utilized for determining 
anti-inflammatory activity through the NF-kB pathway. For this purpose, cells were pre-treated 
with rosiglitazone, to validate the assay since it is known to reduce NF-kB activity [7], and 
subsequently treated with IL-1a, used to induce NF-kB activity. In fact, low concentrations of 
rosiglitazone successfully reduced NF-kB activity in the cells. To link the upregulation of the nrf2 
pathway and reduction in NF-kB activity together, we explored the possibilities of natural 
compounds with high content of polyphenols and anti-oxidant activity. This area of research, using 
natural compounds as medicine, is extensively investigated due to the many advantages 
compared to synthesized compounds. Several natural compounds and extracts were obtained 
and tested for anti-inflammatory activity, as well as for the increase in RealTime Glo activity, most 
likely related to activation of the nrf2 pathway. Apple and bergamot fruits did show the potential of 
using natural compounds for reducing inflammatory activity through the NF-kB pathway, as 
already shown by many different papers [2, 8]. However, the herein described cellular model could 
be utilized as a high-throughput assay able to test the anti-inflammatory activity in a fast and 
sensitive manner, together with the assessment of a possible link with the nrf2 pathway. Further 
studies are necessary to validate the use of this strategy. 
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